


**CUMULATIVE  
SUPPLEMENT 5  
MAY 2022**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**42nd EDITION**

**Department of Health and Human Services**

Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

2022

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**42<sup>nd</sup> EDITION**

**Cumulative Supplement 5  
May 2022**

**CONTENTS**

	<i>PAGE</i>
<b>Contents</b>	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT .....	vi
1.3 APPLICANT NAME CHANGES.....	vii
1.4 LEVOTHYROXINE SODIUM .....	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 <b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Products Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 <b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**42<sup>nd</sup> EDITION**

**CUMULATIVE SUPPLEMENT 5  
MAY 2022**

## **1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## **1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## **1.2 CUMULATIVE SUPPLEMENT CONTENT**

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### **1.3 APPLICANT NAME CHANGES**

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
DAIICHI SANKYO INC (DAIICHI SANKYO)	COSETTE PHARMACEUTICALS INC (COSETTE PHARMS)
DAIICHI SANKYO INC (DAIICHI SANKYO INC)	COSETTE PHARMACEUTICALS INC (COSETTE PHARMS)
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)
LANNETT CO INC (LANNETT)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)

LANNETT CO INC (LANNETT CO INC)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
SANDOZ INC (SANDOZ)	EPIC PHARMA INC (EPIC PHARMA)
TELIGENT OU (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
TELIGENT PHARMA INC (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

---

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The

---

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## **1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST**

### **DESCRIPTION OF REPORT**

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### **DEFINITIONS**

#### **Drug Product**

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### **New Molecular Entity**

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST  
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u>	<u>DEC 2021</u>	<u>MAR 2022</u>	<u>JUN 2022</u>	<u>SEP 2022</u>	<u>DEC 2022</u>
COUNTED					
DRUG PRODUCTS	21133	21339			
LISTED SINGLE SOURCE	2701 (12.8%)	2716 (12.7%)			
MULTISOURCE	18432 (87.2%)	18623 (87.3%)			
THERAPEUTICALLY EQUIVALENT	18298 (86.6%)	18493 (86.7%)			
NOT THERAPEUTICALLY EQUIVALENT	134 (0.6%)	130 (0.6%)			
EXCEPTIONS <sup>4</sup>	54 (0.3%)	53 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	13	11			
NUMBER OF APPLICANTS	1190	1204			

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

---

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET, FOR SUSPENSION;ORAL  
TRIUMEQ PD

+! VIIV HLTHCARE	EQ 60MG BASE;EQ 5MG BASE;30MG	N 215413 001 Mar 30, 2022	Mar NEWA
------------------	-------------------------------	---------------------------	----------

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

>A> AB GLENMARK PHARMS	500MG	A 209227 002 May 19, 2022	May NEWA
YONSA			
+! SUN PHARM	125MG	N 210308 001 May 22, 2018	Feb CAHN

ABROCITINIB

TABLET;ORAL

CIBINQO

+ PFIZER	50MG	N 213871 001 Jan 14, 2022	Jan NEWA
+	100MG	N 213871 002 Jan 14, 2022	Jan NEWA
+!	200MG	N 213871 003 Jan 14, 2022	Jan NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

! AMNEAL PHARM	EQ 200MG BASE	A 075047 001 Dec 30, 1999	Apr CTEC
!	EQ 400MG BASE	A 075047 002 Dec 30, 1999	Apr CTEC
@ MYLAN	EQ 200MG BASE	A 074288 001 Apr 24, 1995	Apr DISC
AB @	EQ 200MG BASE	A 074288 001 Apr 24, 1995	Apr CAHN
AB @	EQ 400MG BASE	A 074288 002 Apr 24, 1995	Apr DISC
AB	EQ 400MG BASE	A 074288 002 Apr 24, 1995	Apr CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP ! SANDOZ INC	1GM/100ML (10MG/ML)	A 204052 001 Mar 22, 2016	Feb CHRS
OFIRMEV			
+ @ MALLINCKRODT HOSP	1GM/100ML (10MG/ML)	N 022450 001 Nov 02, 2010	Feb DISC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

AA ! LARKEN LABS INC	325MG;25MG	A 203484 001 Dec 04, 2015	Apr CTEC
BUTALBITAL AND ACETAMINOPHEN			
AA HAVIX	300MG;50MG	A 214088 001 Apr 07, 2022	Apr NEWA
	325MG;25MG	A 214088 002 Apr 07, 2022	Apr NEWA
AA	325MG;50MG	A 214088 003 Apr 07, 2022	Apr NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA HIKMA	300MG;50MG;40MG	A 215135 001 Mar 25, 2022	Mar NEWA
	325MG;50MG;40MG	A 215135 002 Mar 25, 2022	Mar NEWA
TABLET;ORAL			
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
AA @ NESHER PHARMS	325MG;50MG;40MG	A 211543 001 Jul 17, 2020	Mar DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB HIKMA	300MG;50MG;40MG;30MG	A 215138 002 Jan 26, 2022	Jan NEWA
	325MG;50MG;40MG;30MG	A 215138 001 Jan 26, 2022	Jan NEWA
AB LGM PHARMA	300MG;50MG;40MG;30MG	A 076560 002 Jul 19, 2012	Jan CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA CHARTWELL	120MG/5ML;12MG/5ML	A 089450 001 Oct 27, 1992	Apr CAHN
AA MIKART	120MG/5ML;12MG/5ML	A 089450 001 Oct 27, 1992	Mar CAHN
TABLET;ORAL			
ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA @ CHARTWELL	300MG;15MG	A 089997 001 Dec 28, 1994	Feb CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE  
 @ 300MG;30MG  
 @ 300MG;60MG

A089998 001 Dec 28, 1994 Feb CAHN  
 A089999 001 Dec 28, 1994 Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATESOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ! CHARTWELL 325MG/15ML;7.5MG/15ML  
 AA ! MIKART 300MG/15ML;10MG/15ML  
 AA ! 325MG/15ML;7.5MG/15ML  
 @ TRIS PHARMA INC 300MG/15ML;10MG/15ML  
 @ 325MG/15ML;7.5MG/15ML

A040482 001 Sep 25, 2003 Apr CAHN  
 A040881 001 Feb 25, 2010 Apr CTEC  
 A040482 001 Sep 25, 2003 Mar CAHN  
 A201295 002 Dec 30, 2021 Apr DISC  
 A201295 001 Dec 30, 2021 Apr DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D> AA ! ANDA REPOSITORY 325MG;2.5MG  
 >A> @ 325MG;2.5MG  
 >D> AA ASCENT PHARMS INC 325MG;2.5MG  
 >A> ! 325MG;2.5MG  
 AA ! CHARTWELL 300MG;5MG  
 AA ! 300MG;7.5MG  
 AA ! 300MG;10MG  
 @ 325MG;7.5MG  
 AA 325MG;7.5MG  
 @ 325MG;10MG  
 AA MIKART 325MG;7.5MG

A040846 001 Jun 09, 2010 May DISC  
 A040846 001 Jun 09, 2010 May DISC  
 A211487 001 Nov 07, 2018 May CHRS  
 A211487 001 Nov 07, 2018 May CHRS  
 A040658 001 Jan 19, 2006 Apr CAHN  
 A040658 002 Mar 24, 2006 Apr CAHN  
 A040658 003 Jun 23, 2004 Apr CAHN  
 A040248 001 Apr 28, 2000 Feb CAHN  
 A040432 001 Jan 22, 2003 Apr CAHN  
 A040248 002 Apr 28, 2000 Feb CAHN  
 A040432 001 Jan 22, 2003 Mar CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDESOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

MIKART 300MG/5ML;10MG/5ML

A202142 001 Nov 27, 2018 Mar CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL  
 ACETAZOLAMIDE

>D> AB CADILA 500MG  
 >A> AB ! 500MG  
 >D> AB ! INDICUS PHARMA 500MG  
 >A> @ 500MG

A205301 001 Jan 16, 2019 May CHRS  
 A205301 001 Jan 16, 2019 May CHRS  
 A090779 001 Jul 14, 2011 May DISC  
 A090779 001 Jul 14, 2011 May DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS  
 ACETYLCYSTEINE

AP ASPEN 6GM/30ML (200MG/ML)  
 @ EXELA PHARMA 6GM/30ML (200MG/ML)  
 AP INDOCO 6GM/30ML (200MG/ML)

A213693 001 Feb 03, 2022 Jan NEWA  
 A204797 001 Apr 15, 2021 Feb DISC  
 A215620 001 Feb 23, 2022 Feb NEWA

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION  
 TUDORZA PRESSAIR

+! COVIS 0.4MG/INH

N202450 001 Jul 23, 2012 Apr CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION  
 DUAKLIR PRESSAIR

+! COVIS 0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019 Apr CAHN

ACYCLOVIR

OINTMENT;TOPICAL  
 ACYCLOVIR

@ PRINSTON INC 5%

A212202 001 Nov 15, 2021 Mar DISC

SUSPENSION;ORAL  
 ACYCLOVIR

AB AUROBINDO PHARMA LTD 200MG/5ML

A216331 001 Mar 31, 2022 Mar NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION  
 ACYCLOVIR SODIUM

AP AM INJECTABLES EQ 50MG BASE/ML  
 @ CHARTWELL INJECTABLE EQ 500MG BASE/VIAL  
 @ EQ 1GM BASE/VIAL

A207919 001 Jun 17, 2020 Apr CAHN  
 A074596 002 Apr 22, 1997 Mar CAHN  
 A074596 001 Apr 22, 1997 Mar CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

>A> AB	PADAGIS ISRAEL	0.3%;2.5%	A212464	001	May 31, 2022	May NEWA
>A> AB	ZYDUS PHARMS	0.3%;2.5%	A214553	001	Jun 03, 2022	May NEWA

ALBUTEROL SULFATE

SYRUP;ORAL

ALBUTEROL SULFATE

>D>	@ CHARTWELL RX	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	May CMFD
>A> AA		EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	May CMFD

TABLET;ORAL

ALBUTEROL SULFATE

@ CHARTWELL RX

EQ 4MG BASE

A072151 002 Dec 05, 1989 Feb CMS1

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

@ ATLANTIDE

10MG

A090221 001 Aug 10, 2012 Apr CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLORTIAZIDE

&gt;D&gt; TABLET;ORAL

&gt;D&gt; TEKTURN A HCT

&gt;D&gt; +! NODEN PHARMA

EQ 300MG BASE;12.5MG

N022107 003 Jan 18, 2008 May DISC

&gt;A&gt; + @

EQ 300MG BASE;12.5MG

N022107 003 Jan 18, 2008 May DISC

&gt;D&gt; +!

EQ 300MG BASE;25MG

N022107 004 Jan 18, 2008 May DISC

&gt;A&gt; + @

EQ 300MG BASE;25MG

N022107 004 Jan 18, 2008 May DISC

ALLOPURINOL

INJECTABLE;INJECTION

ALLOPURINOL

AP GLAND PHARMA LTD EQ 500MG BASE/VIAL A212363 001 Jan 26, 2022 Jan NEWA

TABLET;ORAL

ALLOPURINOL

AB ! ACCORD HLTHCARE 300MG A203154 002 May 06, 2013 Apr CHRS

AB HARMAN FINOCHEM 100MG A214443 001 Mar 07, 2022 Feb NEWA

AB 300MG A214443 002 Mar 07, 2022 Feb NEWA

ZYLOPRIM

AB + CASPER PHARMA LLC 300MG N016084 002 Apr CHRS

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALOPRIM

AP +! MYLAN EQ 500MG BASE/VIAL N020298 001 May 17, 1996 Apr CAHN

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSENI

+ @ TAKEDA PHARMS USA

EQ 12.5MG BASE;EQ 15MG BASE

N022426 004 Jan 25, 2013 Mar DISC

+ @

EQ 12.5MG BASE;EQ 45MG BASE

N022426 006 Jan 25, 2013 Mar DISC

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

@ PAR PHARM INC

EQ 0.5MG BASE

A206113 001 Feb 23, 2018 Apr DISC

@

EQ 1MG BASE

A206113 002 Feb 23, 2018 Apr DISC

ALPELISIB

TABLET;ORAL

VIJOICE

+ NOVARTIS

50MG

N215039 001 Apr 05, 2022 Apr NEWA

+

125MG

N215039 002 Apr 05, 2022 Apr NEWA

+!

200MG

N215039 003 Apr 05, 2022 Apr NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB STRIDES PHARMA 100MG A211354 001 Feb 18, 2022 Feb NEWA

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CHARTWELL RX	50MG/5ML	A074028	001	Jun 28, 1993	Mar CAHN
<u>TABLET;ORAL</u>							
			AMANTADINE HYDROCHLORIDE				
>A> AB		EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022	May NEWA
>D> AB		JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	May DISC
>A>	@		100MG	A210403	001	Feb 07, 2018	May DISC

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

>A> AB		APOTEX	5MG	A210701	001	May 19, 2022	May NEWA
>A> AB			10MG	A210701	002	May 19, 2022	May NEWA

AMIFOSTINE

INJECTABLE;INJECTION

AMIFOSTINE

@ EUGIA PHARMA SPECLTS 500MG/VIAL

A204363 001 Jul 17, 2017 Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

>D> AB		USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	May DISC
>A>	@		5MG	A204180	001	Aug 07, 2015	May DISC

AMINO ACIDS

INJECTABLE;INJECTION

NEPHRAMINE 5.4%

@ B BRAUN 5.4% (5.4GM/100ML)

N017766 001 Mar DISC

AMINOCAPROIC ACID

SOLUTION;ORAL

AMINOCAPROIC ACID

AA		AGENIX	0.25GM/ML	A215510	001	Mar 23, 2022	Mar NEWA
----	--	--------	-----------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A> AB		CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	May NEWA
>A> AB			25MG	A216243	002	Jun 06, 2022	May NEWA
>A> AB			50MG	A216243	003	Jun 06, 2022	May NEWA
>A> AB			75MG	A216243	004	Jun 06, 2022	May NEWA
>A> AB			100MG	A216243	005	Jun 06, 2022	May NEWA
>A> AB			150MG	A216243	006	Jun 06, 2022	May NEWA
>D> AB		UPSHER SMITH LABS	10MG	A212654	002	Sep 29, 2021	May DISC
>A>	@		10MG	A212654	002	Sep 29, 2021	May DISC
>D> AB			25MG	A212654	001	Apr 07, 2020	May DISC
>A>	@		25MG	A212654	001	Apr 07, 2020	May DISC
>D> AB			50MG	A212654	003	Sep 29, 2021	May DISC
>A>	@		50MG	A212654	003	Sep 29, 2021	May DISC
>D> AB			75MG	A212654	004	Sep 29, 2021	May DISC
>A>	@		75MG	A212654	004	Sep 29, 2021	May DISC
>D> AB			100MG	A212654	005	Sep 29, 2021	May DISC
>A>	@		100MG	A212654	005	Sep 29, 2021	May DISC
>D> AB			150MG	A212654	006	Sep 29, 2021	May DISC
>A>	@		150MG	A212654	006	Sep 29, 2021	May DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB		MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Jan NEWA
AB			EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Jan NEWA
AB		MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Jan CTEC
AB	!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Jan CTEC
	@	UNITED RES LABS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Apr CAHN
	@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Apr CAHN

AMLODIPINE BESYLATE

SOLUTION;ORAL

NORLIQVA

+! CMP DEV LLC

EQ 1MG BASE/ML

N214439 001 Feb 24, 2022 Feb NEWA

TABLET;ORAL

AMLODIPINE BESYLATE

@ CHARTWELL RX

EQ 2.5MG BASE

A076859 001 Sep 10, 2007 Jan CAHN

@

EQ 5MG BASE

A076859 002 Sep 10, 2007 Jan CAHN

@

EQ 10MG BASE

A076859 003 Sep 10, 2007 Jan CAHN

AB TEVA

EQ 2.5MG BASE

A076846 001 Jun 28, 2007 Mar CMFD

AB

EQ 5MG BASE

A076846 002 Jun 28, 2007 Mar CMFD

AB

EQ 10MG BASE

A076846 003 Jun 28, 2007 Mar CMFD

NORVASC

AB + VIATRIS

EQ 2.5MG BASE

N019787 001 Jul 31, 1992 Jan CAHN

AB +

EQ 5MG BASE

N019787 002 Jul 31, 1992 Jan CAHN

AB +!

EQ 10MG BASE

N019787 003 Jul 31, 1992 Jan CAHN

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

@ TORRENT

EQ 5MG BASE;40MG

A202517 001 Jan 08, 2014 Mar DISC

@

EQ 5MG BASE;80MG

A202517 003 Jan 08, 2014 Mar DISC

@

EQ 10MG BASE;40MG

A202517 002 Jan 08, 2014 Mar DISC

@

EQ 10MG BASE;80MG

A202517 004 Jan 08, 2014 Mar DISC

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PAK

&gt;A&gt; +! PHATHOM 500MG;500MG;EQ 20MG BASE N215152 001 May 03, 2022 May CMS1

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEZNA DUAL PAK

&gt;A&gt; +! PHATHOM 500MG;EQ 20MG BASE N215153 001 May 03, 2022 May CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

&gt;D&gt; AB LANNETT CO INC 1.25MG;1.25MG;1.25MG;1.25MG A214403 001 Nov 26, 2021 May DISC

@

1.25MG;1.25MG;1.25MG;1.25MG

A214403 001 Nov 26, 2021 May DISC

&gt;D&gt; AB

2.5MG;2.5MG;2.5MG;2.5MG

A214403 002 Nov 26, 2021 May DISC

@

2.5MG;2.5MG;2.5MG;2.5MG

A214403 002 Nov 26, 2021 May DISC

&gt;D&gt; AB

3.75MG;3.75MG;3.75MG;3.75MG

A214403 003 Nov 26, 2021 May DISC

@

3.75MG;3.75MG;3.75MG;3.75MG

A214403 003 Nov 26, 2021 May DISC

&gt;D&gt; AB

5MG;5MG;5MG;5MG

A214403 004 Nov 26, 2021 May DISC

@

5MG;5MG;5MG;5MG

A214403 004 Nov 26, 2021 May DISC

&gt;D&gt; AB

6.25MG;6.25MG;6.25MG;6.25MG

A214403 005 Nov 26, 2021 May DISC

@

6.25MG;6.25MG;6.25MG;6.25MG

A214403 005 Nov 26, 2021 May DISC

&gt;D&gt; AB

7.5MG;7.5MG;7.5MG;7.5MG

A214403 006 Nov 26, 2021 May DISC

@

7.5MG;7.5MG;7.5MG;7.5MG

A214403 006 Nov 26, 2021 May DISC

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB TEVA PHARMS USA 3.125MG;3.125MG;3.125MG;3.125MG A210876 001 Jan 31, 2022 Jan NEWA

AB

6.25MG;6.25MG;6.25MG;6.25MG

A210876 002 Jan 31, 2022 Jan NEWA

AB

9.375MG;9.375MG;9.375MG;9.375MG

A210876 003 Jan 31, 2022 Jan NEWA

AB

12.5MG;12.5MG;12.5MG;12.5MG

A210876 004 Jan 31, 2022 Jan NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB ZYDUS PHARMS 1.25MG;1.25MG;1.25MG;1.25MG A207340 001 Oct 31, 2017 Mar CAHN

AB

1.875MG;1.875MG;1.875MG;1.875MG

A207340 002 Oct 31, 2017 Mar CAHN

AB

2.5MG;2.5MG;2.5MG;2.5MG

A207340 003 Oct 31, 2017 Mar CAHN

AB

3.125MG;3.125MG;3.125MG;3.125MG

A207340 004 Oct 31, 2017 Mar CAHN

AB

3.75MG;3.75MG;3.75MG;3.75MG

A207340 005 Oct 31, 2017 Mar CAHN

AB

5MG;5MG;5MG;5MG

A207340 006 Oct 31, 2017 Mar CAHN

AB

7.5MG;7.5MG;7.5MG;7.5MG

A207340 007 Oct 31, 2017 Mar CAHN

AMPHETAMINE SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+ @ AZURITY

2.5MG

N209905 005 Apr 16, 2021 Apr CAHN

+

5MG

N209905 001 Jan 30, 2019 Apr CAHN

+

10MG

N209905 002 Jan 30, 2019 Apr CAHN



INJECTABLE; INTRAVENOUS

M.V.I. ADULT

10MG/VIAL; 0.15MG/VIAL

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ @ HOSPIRA 200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 1 5MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG /5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG /5ML; 10MG/5ML; 0.15MG/5ML

ASENAPINESYSTEM; TRANSDERMAL  
SECUADO

+! HISAMITSU 3.8MG/24HR  
+ 7.6MG/24HR

N212268 001 Oct 11, 2019 Mar CHRS  
N212268 003 Oct 11, 2019 Mar CHRS

ASPIRIN; BUTALBITAL; CAFFEINECAPSULE; ORAL  
BUTALBITAL, ASPIRIN AND CAFFEINE

AA @ LGM PHARMA 500MG; 50MG; 40MG  
NOSTRUM LABS INC 325MG; 50MG; 40MG

A205230 001 Oct 18, 2021 Apr DISC  
A078149 001 Jun 13, 2007 Apr CMFD

AA + ALLERGAN 325MG; 50MG; 40MG  
LANORINAL

N017534 005 Apr 16, 1986 Apr CHRS  
A086996 002 Oct 11, 1985 Apr CHRS

AA ! LANNETT 325MG; 50MG; 40MG  
TABLET; ORAL  
BUTALBITAL, ASPIRIN AND CAFFEINE

A086162 002 Feb 16, 1984 Mar CRLD

+ @ HIKMA INTL PHARMS 325MG; 50MG; 40MG

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATECAPSULE; ORAL  
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>D> AB @ MAYNE PHARMA INC 325MG; 50MG; 40MG; 30MG  
STEVENS J 325MG; 50MG; 40MG; 30MG

A203335 001 Oct 30, 2015 Jan DISC  
A074951 001 Aug 31, 1998 May CHRS

>A> AB ! 325MG; 50MG; 40MG; 30MG  
FIORINAL W/CODEINE

A074951 001 Aug 31, 1998 May CHRS

>D> AB +! ALLERGAN 325MG; 50MG; 40MG; 30MG  
>A> + @ 325MG; 50MG; 40MG; 30MG

N019429 003 Oct 26, 1990 May DISC  
N019429 003 Oct 26, 1990 May DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATETABLET; ORAL  
ORPHEGESIC  
GALT PHARMS 385MG; 30MG; 25MG

A075141 001 May 29, 1998 Mar CMFD

ATAZANAVIR SULFATECAPSULE; ORAL  
ATAZANAVIR SULFATE

AB HETERO LABS LTD III EQ 150MG BASE  
AB EQ 200MG BASE  
AB EQ 300MG BASE

A212278 001 Feb 02, 2022 Jan NEWA  
A212278 002 Feb 02, 2022 Jan NEWA  
A212278 003 Feb 02, 2022 Jan NEWA

REYATAZ  
+ @ BRISTOL MYERS SQUIBB EQ 150MG BASE

N021567 002 Jun 20, 2003 Apr DISC

ATROPOINESOLUTION; INTRAMUSCULAR  
ATROOPEN

>D> +! MERIDIAN MEDCL TECHN EQ 0.25MG SULFATE/0.3ML  
>D> +! EQ 0.5MG SULFATE/0.7ML  
>D> +! EQ 1MG SULFATE/0.7ML  
>D> +! EQ 2MG SULFATE/0.7ML  
>A> +! MMT EQ 0.25MG SULFATE/0.3ML  
>A> +! EQ 0.5MG SULFATE/0.7ML  
>A> +! EQ 1MG SULFATE/0.7ML  
>A> +! EQ 2MG SULFATE/0.7ML

N017106 004 Sep 17, 2004 May CAHN  
N017106 003 Jun 19, 2003 May CAHN  
N017106 002 Jun 19, 2003 May CAHN  
N017106 001 May CAHN  
N017106 004 Sep 17, 2004 May CAHN  
N017106 003 Jun 19, 2003 May CAHN  
N017106 002 Jun 19, 2003 May CAHN  
N017106 001 May CAHN

ATROPOINE SULFATESOLUTION; INTRAVENOUS  
ATROPINE SULFATE

>D> +! ACCORD HLTHCARE 0.4MG/ML (0.4MG/ML)  
>A> AP +! 0.4MG/ML (0.4MG/ML)  
>D> +! 1MG/ML (1MG/ML)  
>A> AP +! 1MG/ML (1MG/ML)

N214652 001 Sep 29, 2020 May CFTG  
N214652 001 Sep 29, 2020 May CFTG  
N214652 002 Sep 29, 2020 May CFTG  
N214652 002 Sep 29, 2020 May CFTG

SOLUTION; INTRAVENOUS  
ATROPINE SULFATE

>A> AP	AM REGENT	0.4MG/ML (0.4MG/ML)	A216120	001	May 26, 2022	May NFTG
>A> AP		1MG/ML (1MG/ML)	A216120	002	May 26, 2022	May NFTG
AP	AMNEAL	0.5MG/5ML (0.1MG/ML)	A215342	001	Jan 26, 2022	Jan NEWA
AP	+! HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jan CMFD

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE  
@ MAYNE PHARMA INC 0.025MG;2.5MG

A210789	001	Jun 03, 2020	Jan DISC
---------	-----	--------------	----------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR  
DUODOTE  
+! MMT 2.1MG/0.7ML;600MG/2ML

N021983	001	Sep 28, 2006	Jan CAHN
---------	-----	--------------	----------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS  
AZACITIDINE

AP	AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Jan NEWA
----	--------	------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL  
AZELASTINE HYDROCHLORIDE

>D> AB	APOTEX INC	0.2055MG/SPRAY	A201846	001	Aug 31, 2012	May DISC
>A>	@	0.2055MG/SPRAY	A201846	001	Aug 31, 2012	May DISC
>D> AB	AUROBINDO PHARMA LTD	0.2055MG/SPRAY	A212775	001	Nov 12, 2020	May DISC
>A>	@	0.2055MG/SPRAY	A212775	001	Nov 12, 2020	May DISC
>D> AB	HIKMA	0.2055MG/SPRAY	A207243	001	Sep 22, 2017	May DISC
>A>	@	0.2055MG/SPRAY	A207243	001	Sep 22, 2017	May DISC

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL  
EDARBI  
+ AZURITY EQ 40MG MEDOXOMIL  
+! EQ 80MG MEDOXOMIL

N200796	001	Feb 25, 2011	Mar CAHN
N200796	002	Feb 25, 2011	Mar CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL  
EDARBYCLOR  
+ AZURITY EQ 40MG MEDOXOMIL;12.5MG  
+! EQ 40MG MEDOXOMIL;25MG

N202331	001	Dec 20, 2011	Mar CAHN
N202331	002	Dec 20, 2011	Mar CAHN

AZITHROMYCIN

SOLUTION/DROPS; OPHTHALMIC  
AZASITE

+! THEA PHARMA	1%	N050810	001	Apr 27, 2007	Apr CAHN
----------------	----	---------	-----	--------------	----------

TABLET; ORAL  
AZITHROMYCIN

AB	ATLANTIDE	EQ 250MG BASE	A065404	001	Feb 11, 2008	Apr CAHN
AB		EQ 500MG BASE	A065405	001	Feb 11, 2008	Apr CAHN
AB		EQ 600MG BASE	A065302	003	Feb 11, 2008	Apr CAHN

BACLOFEN

GRANULES; ORAL  
LYVISPAH  
+ AMNEAL 5MG/PACKET  
+ 10MG/PACKET  
+! 20MG/PACKET

N215422	001	Nov 22, 2021	Feb CAHN
N215422	002	Nov 22, 2021	Feb CAHN
N215422	003	Nov 22, 2021	Feb CAHN

INJECTABLE; INTRATHECAL  
LIORESAL

AP	+! AMNEAL	0.05MG/ML	N020075	003	Nov 07, 1996	Feb CAHN
AP	+!	0.5MG/ML	N020075	001	Jun 17, 1992	Feb CAHN
AP	+!	2MG/ML	N020075	002	Jun 17, 1992	Feb CAHN

SUSPENSION; ORAL  
FLEQSUVY

+! AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Feb NEWA
------------	----------	---------	-----	--------------	----------

TABLET; ORAL

BACLOFEN

AB	MANKIND PHARMA	5MG	A215885	001	Jan 25, 2022	Jan NEWA
----	----------------	-----	---------	-----	--------------	----------

TABLET;ORAL  
BACLOFEN

AB		10MG	A215885	002	Jan 25, 2022	Jan NEWA
AB		20MG	A215885	003	Jan 25, 2022	Jan NEWA

BARICITINIB

TABLET;ORAL  
OLUMIANT

>A>	+	ELI LILLY AND CO	4MG	N207924	003	May 10, 2022	May NEWA
-----	---	------------------	-----	---------	-----	--------------	----------

BENZONATATE

CAPSULE;ORAL  
BENZONATATE

AA	ACELLA	100MG	A091310	001	Jan 16, 2015	Jan CAHN
AA		200MG	A091310	002	Jan 16, 2015	Jan CAHN
>D> AA	MIKART	100MG	A040851	001	Nov 09, 2009	May DISC
>A>	@	100MG	A040851	001	Nov 09, 2009	May DISC
>D> AA		150MG	A040851	002	Nov 09, 2009	May DISC
>A>	@	150MG	A040851	002	Nov 09, 2009	May DISC
>D> AA		200MG	A040851	003	Nov 09, 2009	May DISC
>A>	@	200MG	A040851	003	Nov 09, 2009	May DISC
AA	! THEPHARMANETWORK LLC	100MG	A040627	002	Mar 30, 2007	Jan CMS1
AA	! SOL GEL TECHNOLOGIES	150MG	A040627	003	Sep 24, 2014	Jan CMS1
AA	!	200MG	A040627	002	Jul 25, 2007	Mar CMS1

BENZOYL PEROXIDE

CREAM;TOPICAL  
EPSOLAY

+!	SOL GEL TECHNOLOGIES	5%	N214510	001	Apr 22, 2022	Apr NEWA
----	----------------------	----	---------	-----	--------------	----------

BENZOYL PEROXIDE: TRETINOIN

CREAM;TOPICAL  
TWYNEO

+!	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	Mar CMFD
+ @		3%;0.1%	N214902	001	Jul 26, 2021	Feb CAHN
+ @	SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021	Jan DISC

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL  
BENZPHETAMINE HYDROCHLORIDE

AA	CHARTWELL	25MG	A090473	001	Sep 15, 2010	Apr CAHN
		50MG	A090473	002	Sep 15, 2010	Apr CAHN
AA	MIKART	25MG	A090473	001	Sep 15, 2010	Mar CAHN
		50MG	A090473	002	Sep 15, 2010	Mar CAHN

BENZTROPINE MESYLATE

INJECTABLE;INJECTION  
BENZTROPINE MESYLATE

AP	! HIKMA FARMACEUTICA COGENTIN	1MG/ML	A090287	001	Aug 31, 2009	Mar CHRS
+ @	AKORN	1MG/ML	N012015	001		Mar DISC

BETAINE

FOR SOLUTION;ORAL  
BETAINE

AB	LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Jan NEWA
----	--------------------	--------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPOIONATE

OINTMENT;TOPICAL  
BETAMETHASONE DIPROPOIONATE

AB	PADAGIS ISRAEL	EQ 0.05% BASE	A215847	001	Apr 12, 2022	Apr NEWA
AB	TASMAN PHARMA	EQ 0.05% BASE	A215186	001	Feb 18, 2022	Feb NEWA

BEXAROTENE

GEL;TOPICAL  
BEXAROTENE

AB	AMNEAL TARGRETIN	1%	A215398	001	Apr 27, 2022	Apr NFTG
AB	+! BAUSCH	1%	N021056	001	Jun 28, 2000	Apr CFTG

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	UNITED RES LABS	5MG	A075474	001	Oct 25, 2002	Apr CAHN
AB		10MG	A075474	002	Oct 25, 2002	Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS LTD	2.5MG; 6.25MG	A215995	001	Jan 26, 2022	Jan NEWA
AB		5MG; 6.25MG	A215995	002	Jan 26, 2022	Jan NEWA
AB		10MG; 6.25MG	A215995	003	Jan 26, 2022	Jan NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

AP	MEITHEAL	250MG/VIAL	A091602	001	Jul 16, 2018	Apr CAHN
----	----------	------------	---------	-----	--------------	----------

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP	APOTEX	3.5MG/VIAL	A205533	001	May 02, 2022	Apr NFTG
AP	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	Apr NFTG
AP	EUGIA PHARMA	3.5MG/VIAL	A212825	001	May 02, 2022	Apr NFTG
AP	FRESENIUS KABI USA	3.5MG/VIAL	A209659	001	May 02, 2022	Apr NFTG
AP	PHARMASCIENCE INC	3.5MG/VIAL	A208392	001	May 02, 2022	Apr NFTG
AP	QILU PHARM HAINAN	3.5MG/VIAL	A210824	001	May 02, 2022	Apr NFTG
AP	TEVA PHARMS USA	3.5MG/VIAL	A205857	001	May 02, 2022	Apr NFTG
AP	ZYDUS PHARMS	3.5MG/VIAL	A210204	001	May 02, 2022	Apr NFTG
	VELCADE					
AP	+! TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003	Apr CFTG
	POWDER;INTRAVENOUS, SUBCUTANEOUS					
	BORTEZOMIB					
>A>	+! HOSPIRA INC	1MG/VIAL	N209191	001	May 02, 2022	May NEWA
>A>	+!	2.5MG/VIAL	N209191	002	May 02, 2022	May NEWA

BOSENTAN

TABLET;ORAL

BOSENTAN

@	CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020	Mar CAHN
@		125MG	A210342	002	Jan 03, 2020	Mar CAHN

BRIMONIDINE TARTRATE

GEL;TOPICAL

BRIMONIDINE TARTRATE

@	PADAGIS ISRAEL MIRVASO	EQ 0.33% BASE	A209158	001	Sep 23, 2021	Apr DISC
---	------------------------	---------------	---------	-----	--------------	----------

+!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Apr CTEC
----	------------------	---------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AT	APOTEX	0.15%	A078479	001	Jan 31, 2022	Jan NEWA
----	--------	-------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB	APOTEX INC	0.2%;EQ 0.5% BASE	A091442	001	Apr 20, 2022	Apr NEWA
AB	SANDOZ INC	0.2%;EQ 0.5% BASE	A091087	001	Apr 04, 2022	Mar NFTG
AB	COMBIGAN					

AB	+! ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007	Mar CFTG
----	-------------	-------------------	---------	-----	--------------	----------

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

AB	BAUSCH AND LOMB	1%	A204884	001	Aug 18, 2021	Mar CAHN
----	-----------------	----	---------	-----	--------------	----------

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2	@ CHARTWELL RX	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Apr CAHN
	EUGIA PHARMA	EQ 0.09% ACID	A204813	001	Mar 18, 2022	Mar NEWA
	@ VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Feb CAHN

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

	@ NATCO	3MG	A206724	001	Nov 23, 2016	Jan CAHN
--	---------	-----	---------	-----	--------------	----------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

AB	MYLAN	0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Mar NFTG
AB		0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Mar NFTG
	SYMBICORT					
AB	+! ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Mar CFTG
AB	+!	0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Mar CFTG

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
>A> AP	GLAND PHARMA LTD	0.25MG/ML	A216434	001	May 26, 2022	May NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

POSIMIR

>D>	+ @ DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CAHN
>A>	+! INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

@ CIVICA	0.5%	A211096	001	Feb 19, 2019	Apr CAHN
@ NOVOCOL PHARM	0.5%	A211096	001	Feb 19, 2019	Mar CAHN
@ STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
@	0.5%	A091503	002	Oct 18, 2011	Feb CAHN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
@ STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Feb CAHN
@	0.5%	A091487	001	Oct 18, 2011	Feb CAHN
@	0.75%	A091487	003	Oct 18, 2011	Feb CAHN

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

ZYNRELEF KIT

+ @ HERON THERAPS INC	60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML	N211988	001	May 12, 2021	Apr DISC
+ @	300MG/10.5ML (29.25MG/ML);9MG/10.5ML	N211988	003	May 12, 2021	Apr DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

>A> AB	ALVOGEN	5MCG/HR	A207490	001	May 17, 2022	May CAHN
>A> AB		10MCG/HR	A207490	002	May 17, 2022	May CAHN
>A> AB		15MCG/HR	A207490	003	May 17, 2022	May CAHN
>A> AB		20MCG/HR	A207490	004	May 17, 2022	May CAHN

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CTEC
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CTEC
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CTEC
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CTEC
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CTEC
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CTEC
+		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CTEC

FILM;BUCCAL

## BUPRENORPHINE HYDROCHLORIDE

@ ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jan DISC
@	EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jan DISC
@	EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jan DISC
@	EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jan DISC
@	EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jan DISC
@	EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jan DISC
@	EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jan DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

## FILM;BUCCAL, SUBLINGUAL

## BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A> AB	AVEVA	EQ 8MG BASE;EQ 2MG BASE	A212756	001	Jun 02, 2022	May NEWA
>A> AB		EQ 12MG BASE;EQ 3MG BASE	A212756	002	Jun 02, 2022	May NEWA

BUPROPION HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## BUPROPION HYDROCHLORIDE

AB3	GRANULES	150MG	A215568	001	Feb 02, 2022	Jan NEWA
AB3		300MG	A215568	002	Feb 02, 2022	Jan NEWA
AB3	WOCKHARDT LTD	300MG	A202189	002	Jan 28, 2022	Feb NEWA

BUSPIRONE HYDROCHLORIDE

## TABLET;ORAL

## BUSPIRONE HYDROCHLORIDE

AB	! ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Feb CHRS
	@ MYLAN	7.5MG	A075467	002	Mar 28, 2001	Feb DISC
AB	TEVA	15MG	A075022	003	Feb 28, 2002	Feb CHRS

BUSULFAN

## TABLET;ORAL

## MYLERAN

+!	WOODWARD SPECI	2MG
----	----------------	-----

N 009386 001

Apr CAHN

CABERGOLINE

## TABLET;ORAL

## CABERGOLINE

AB	STRIDES PHARMA	0.5MG	A076310	001	Dec 29, 2005	Mar CMFD
----	----------------	-------	---------	-----	--------------	----------

CAFFEINE CITRATE

## SOLUTION;ORAL

## CAF'CIT

+ @ HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N 020793	002	Apr 12, 2000	Jan DISC
AA ! EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 077304	001	Sep 21, 2006	Jan CHRS

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE;INJECTION

## DEXTROSE 5% AND LACTATED RINGER'S

AP	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;60 0MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	Mar NEWA
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ FRESENIUS KABI USA	20MG/100ML;5GM/100ML;179MG/100ML;6 00MG/100ML;310MG/100ML	A211428	001	Nov 09, 2021	Apr DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## SOLUTION;PERFUSION, CARDIAC

## CARDIOPLEGIC IN PLASTIC CONTAINER

AT	FRESENIUS KABI USA	17.6MG/100ML;325.3MG/100ML;119.3MG /100ML;643MG/100ML	A214623	001	Feb 18, 2022	Feb NEWA
----	--------------------	---	---------	-----	--------------	----------

CAPTOPRII

## TABLET;ORAL

## CAPTOPRIL

AB	ATLANTIDE	12.5MG	A 074532	001	Mar 28, 1997	Mar CAHN
AB		25MG	A 074532	002	Mar 28, 1997	Mar CAHN
AB		50MG	A 074532	003	Mar 28, 1997	Mar CAHN
AB		100MG	A 074532	004	Mar 28, 1997	Mar CAHN

CARBAMAZEPINE

TABLET;ORAL

CARBAMAZEPINE

@ VGYAAN

200MG

A214328 001 Aug 16, 2021 Feb DISC

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB ZHEJIANG JIUZHOU 100MG

A215591 001 Mar 31, 2022

Mar NEWA

AB 200MG

A215591 002 Mar 31, 2022

Mar NEWA

AB 400MG

A215591 003 Mar 31, 2022

Mar NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB RISING 12.5MG;200MG;50MG

A213212 001 Jan 25, 2022

Jan NEWA

AB 18.75MG;200MG;75MG

A213212 002 Jan 25, 2022

Jan NEWA

AB 25MG;200MG;100MG

A213212 003 Jan 25, 2022

Jan NEWA

AB 31.25MG;200MG;125MG

A213212 004 Jan 25, 2022

Jan NEWA

AB 37.5MG;200MG;150MG

A213212 005 Jan 25, 2022

Jan NEWA

AB 50MG;200MG;200MG

A213212 006 Jan 25, 2022

Jan NEWA

STALEVO 125

AB + ORION PHARMA 31.25MG;200MG;125MG

N021485 006 Aug 29, 2008

Jan CTEC

STALEVO 200

AB +! ORION PHARMA 50MG;200MG;200MG

N021485 004 Aug 02, 2007

Jan CTEC

STALEVO 50

AB +! ORION PHARMA 12.5MG;200MG;50MG

N021485 001 Jun 11, 2003

Jan CTEC

STALEVO 75

AB + ORION PHARMA 18.75MG;200MG;75MG

N021485 005 Aug 29, 2008

Jan CTEC

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

AP TEYRO LABS 50MG/5ML (10MG/ML)

A077861 001 Jan 18, 2007

Apr CAHN

AP 150MG/15ML (10MG/ML)

A077861 002 Jan 18, 2007

Apr CAHN

AP 450MG/45ML (10MG/ML)

A077861 003 Jan 18, 2007

Apr CAHN

AP 600MG/60ML (10MG/ML)

A077861 004 Jan 18, 2007

Apr CAHN

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP AMNEAL EQ 0.25MG BASE/ML

A215337 001 Jan 27, 2022

Jan NEWA

CARMUSTINE

&gt;A&gt; POWDER; INTRAVENOUS

CARMUSTINE

&gt;A&gt; +! ACCORD HLTHCARE 50MG/VIAL

N215000 001 May 16, 2022

May NEWA

&gt;A&gt; +! 300MG/VIAL

N215000 002 May 16, 2022

May NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

@ ORCHID HLTHCARE FOR SUSPENSION;ORAL

CEFADROXIL

@ ORCHID HLTHCARE EQ 250MG BASE/5ML

A065307 002 Oct 16, 2006

Mar DISC

@ EQ 500MG BASE/5ML

A065307 003 Oct 16, 2006

Mar DISC

TABLET;ORAL

CEFADROXIL

@ ORCHID HLTHCARE EQ 1GM BASE

A065301 001 Sep 18, 2006

Mar DISC

AB ! TEVA PHARMS EQ 1GM BASE

A062774 001 Apr 08, 1987

Mar CTEC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

QILU

EQ 2GM BASE/VIAL

A203661 002 Mar 11, 2022

Mar NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION  
CEFEPIME HYDROCHLORIDE

AP	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Jan CMFD
AP		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Jan CMFD

CEFOTETAN DISODIUM

INJECTABLE; INJECTION  
CEFOTAN IN PLASTIC CONTAINER  
© PAI HOLDINGS PHARM EQ 20MG BASE/ML  
© EQ 40MG BASE/ML

N050694	002	Jul 30, 1993	Apr CAHN
N050694	001	Jul 30, 1993	Apr CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL  
CEFPODOXIME PROXETIL

>A> AB	ALKEM LABS LTD	EQ 100MG BASE	A210568	001	May 18, 2022	May NEWA
>A> AB		EQ 200MG BASE	A210568	002	May 18, 2022	May NEWA

CEFPROZIL

FOR SUSPENSION; ORAL  
CEFPROZIL

© CHARTWELL RX	125MG/5ML	A065236	001	Dec 08, 2005	Mar CAHN
©	250MG/5ML	A065236	002	Dec 08, 2005	Mar CAHN
© ORCHID HLTHCARE	125MG/5ML	A065284	002	Dec 30, 2005	Mar DISC
©	250MG/5ML	A065284	001	Dec 30, 2005	Mar DISC

TABLET; ORAL  
CEFPROZIL

© ORCHID HLTHCARE	250MG	A065267	001	Dec 19, 2005	Mar DISC
©	500MG	A065267	002	Dec 19, 2005	Mar DISC

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS  
CEFTAROLINE FOSAMIL

© APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Mar DISC
©	600MG/VIAL	A208075	002	Sep 21, 2021	Mar DISC
TEFLARO					
+! ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Mar CTEC
+!	600MG/VIAL	N200327	002	Oct 29, 2010	Mar CTEC

CEFTRIAKONE SODIUM

INJECTABLE; INJECTION  
CEFTRIAKONE

AP	ATLANTIDE	EQ 1GM BASE/VIAL	A065180	001	May 12, 2006	Apr CAHN
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS	CEFTRIAKONE				
AP	ATLANTIDE	EQ 250MG BASE/VIAL	A065391	001	Apr 12, 2007	Apr CAHN
AP		EQ 500MG BASE/VIAL	A065391	002	Apr 12, 2007	Apr CAHN
AP		EQ 2GM BASE/VIAL	A065391	003	Apr 12, 2007	Apr CAHN
>D> AP	LUPIN	EQ 250MG BASE/VIAL	A065125	001	Sep 30, 2003	May DISC
>A>	©	EQ 250MG BASE/VIAL	A065125	001	Sep 30, 2003	May DISC
>D> AP		EQ 500MG BASE/VIAL	A065125	002	Sep 30, 2003	May DISC
>A>	©	EQ 500MG BASE/VIAL	A065125	002	Sep 30, 2003	May DISC
>D> AP		EQ 1GM BASE/VIAL	A065125	003	Sep 30, 2003	May DISC
>A>	©	EQ 1GM BASE/VIAL	A065125	003	Sep 30, 2003	May DISC
>D> AP		EQ 2GM BASE/VIAL	A065125	004	Sep 30, 2003	May DISC
>A>	©	EQ 2GM BASE/VIAL	A065125	004	Sep 30, 2003	May DISC

CEFUROXIME AXETIL

TABLET; ORAL  
CEFUROXIME AXETIL

AB	ATLANTIDE	EQ 125MG BASE	A065166	001	Jul 29, 2005	Mar CAHN
AB		EQ 250MG BASE	A065166	002	Jul 29, 2005	Mar CAHN
AB		EQ 500MG BASE	A065166	003	Jul 29, 2005	Mar CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION  
ZINACEF

AP	+! PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
AP	+!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ZINACEF

AB +! PAI HOLDINGS PHARM EQ 750MG BASE/VIAL N 050558 002 Oct 19, 1983 Feb CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB

@ UNICHEM	50MG	A 213301	001	Jan 12, 2021	Feb DISC
@	100MG	A 213301	002	Jan 12, 2021	Feb DISC
@	200MG	A 213301	003	Jan 12, 2021	Feb DISC
@	400MG	A 213301	004	Jan 12, 2021	Feb DISC

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

@ ORCHID HLTHCARE	EQ 125MG BASE/5ML	A 065326	001	Jul 10, 2006	Mar DISC
@	EQ 250MG BASE/5ML	A 065326	002	Jul 10, 2006	Mar DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>D>	@ ATLANTIDE	5MG/5ML	A 078757	001	Aug 28, 2009	Apr CAHN
>A > AA	@ TORRENT	5MG/5ML	A 078870	001	Apr 27, 2009	May CMFD
		5MG/5ML	A 078870	001	Apr 27, 2009	May CMFD

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+! WOODWARD SPECL 2MG

N 010669 002 Apr CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM

AB	+ VALEANT PHARM INTL	5MG	A 085461	001	Jan CRLD
AB	+	10MG	A 085472	001	Jan CRLD

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIOGARD

@ COLGATE PALMOLIVE CO	0.12%	A 073695	001	Jan 14, 1994	Apr DISC
------------------------	-------	----------	-----	--------------	----------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

@ ECR PHARMA	EQ 4MG MALEATE; EQ 5MG BITARTRATE	A 077273	002	Sep 24, 2007	Feb DISC
@	EQ 8MG MALEATE; EQ 10MG BITARTRATE	A 077273	001	Sep 24, 2007	Feb DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ APPCO	10MG	A 213590	001	Aug 31, 2020	Mar CAHN	
@	25MG	A 213590	002	Aug 31, 2020	Mar CAHN	
@	50MG	A 213590	003	Aug 31, 2020	Mar CAHN	
@	100MG	A 213590	004	Aug 31, 2020	Mar CAHN	
@	200MG	A 213590	005	Aug 31, 2020	Mar CAHN	
AB	MSN	25MG	A 214827	001	Jan 27, 2022	Jan NEWA
AB		50MG	A 214827	002	Jan 27, 2022	Jan NEWA
AB		100MG	A 214827	003	Jan 27, 2022	Jan NEWA
AB		200MG	A 214827	004	Jan 27, 2022	Jan NEWA

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	CHARTWELL RX	25MG	A 211063	001	Feb 26, 2019	Jan CAHN
AB		50MG	A 211063	002	Feb 26, 2019	Jan CAHN
AB	INVENTIA	25MG	A 211320	001	Feb 09, 2022	Jan NEWA
AB		50MG	A 211320	002	Feb 09, 2022	Jan NEWA
>D> AB	SUNNY	25MG	A 209068	001	Jan 25, 2022	May DISC
>A > AB	@	25MG	A 209068	001	Jan 25, 2022	May DISC
AB		25MG	A 209068	001	Jan 25, 2022	Jan NEWA
>D> AB		50MG	A 209068	002	Jan 25, 2022	May DISC
>A > AB	@	50MG	A 209068	002	Jan 25, 2022	May DISC

TABLET;ORAL  
CHLORTHALIDONE

AB		50MG	A209068	002	Jan 25, 2022	Jan NEWA
AB	TAGI	25MG	A212878	001	Feb 24, 2022	Feb NEWA
AB		50MG	A212875	001	Feb 24, 2022	Feb NEWA

CHLORZOXAZONE

TABLET;ORAL  
CHLORZOXAZONE

AB	RISING	375MG	A213126	001	Apr 05, 2022	Mar NEWA
AB		500MG	A213126	002	Apr 05, 2022	Mar NEWA
AB		750MG	A213126	003	Apr 05, 2022	Mar NEWA

CHOLESTYRAMINE

POWDER;ORAL  
CHOLESTYRAMINE

AB	@ UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Mar DISC
		EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jan NEWA
	@	EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Mar DISC
AB		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jan NEWA

CICLOPIROX

SHAMPOO;TOPICAL  
CICLOPIROX

AT	PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	Mar CAHN
	SOLUTION;TOPICAL					
	CICLOPIROX					
AT	CHARTWELL RX	8%	A078046	001	Sep 18, 2007	Mar CAHN

CIMETIDINE

TABLET;ORAL  
CIMETIDINE

	@ CHARTWELL RX	200MG	A074100	001	Jan 31, 1995	Jan CAHN
	@	300MG	A074100	002	Jan 31, 1995	Jan CAHN
	@	400MG	A074100	003	Jan 31, 1995	Jan CAHN
	@	800MG	A074100	004	Jan 31, 1995	Jan CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL  
CINACALCET HYDROCHLORIDE

	@ AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Feb DISC
	@	60MG	A204364	002	Dec 02, 2021	Feb DISC
	@	90MG	A204364	003	Dec 02, 2021	Feb DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL  
CIPROFLOXACIN HYDROCHLORIDE

	@ AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN
	@	EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN
	@	EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION  
CISATRACURIUM BESYLATE

>A> AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	001	May 24, 2022	May NEWA
>A> AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	May NEWA
AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Mar NEWA
AP		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Mar NEWA
AP	SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Mar CMFD

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL  
CITALOPRAM HYDROBROMIDE

+! ALMATICHA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Jan NEWA
--------------	--------------	---------	-----	--------------	----------

CLARITHROMYCIN

TABLET;ORAL  
CLARITHROMYCIN

AB	ALEMBIC PHARMS LTD	250MG	A210459	001	Jan 31, 2022	Jan NEWA
AB		500MG	A210459	002	Jan 31, 2022	Jan NEWA

CLINDAMYCIN PHOSPHATE

LOTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AB	ENCUBE	EQ 1% BASE	A215607	001	Jan 18, 2022	Jan NEWA
	SOLUTION;TOPICAL					
	CLINDAMYCIN PHOSPHATE					

AT PAI HOLDINGS PHARM EQ 1% BASE A206945 001 Dec 30, 2016 Mar CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB1	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Feb CTEC
AB2	SOLARIS PHARMA CORP	1.2%;0.025%	A212845	001	Feb 10, 2022	Feb NFTG
	VELTIN					
AB2	+! ALMIRALL ZIANA	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CFTG
AB1	+! BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006	Feb CTEC

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

AB	AUROBINDO PHARMA LTD	2.5MG/ML	A214404	001	Mar 24, 2022	Mar NEWA
	TABLET;ORAL					
	CLOBAZAM					

AB MSN 10MG A213404 001 May 11, 2021 Feb CMFD

AB 20MG A213404 002 May 11, 2021 Feb CMFD

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A215838	001	Apr 21, 2022	Apr NEWA
	GEL;TOPICAL					
	CLOBETASOL PROPIONATE					
AB	PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017	Mar CAHN
	LOTION;TOPICAL					
	CLOBETASOL PROPIONATE					
AB	PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016	Mar CAHN
	OINTMENT;TOPICAL					
	CLOBETASOL PROPIONATE					
AB	PAI HOLDINGS PHARM	0.05%	A208589	001	Jan 23, 2019	Mar CAHN
	SOLUTION;TOPICAL					
	CLOBETASOL PROPIONATE					
AT	SOLARIS PHARMA CORP	0.05%	A211240	001	Feb 17, 2022	Feb NEWA
	@ TOILMAR	0.05%	A076977	001	Aug 05, 2005	Feb DISC

CLONIDINE

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

ATHENA EQ 0.17MG BASE

@ EQ 0.17MG BASE

@ EQ 0.26MG BASE

N022500 001 Dec 03, 2009 Feb CMFD

N022500 001 Dec 03, 2009 Jan CAHN

N022500 002 Dec 03, 2009 Jan CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

>D>	@ AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May CMFD
>A> AB		0.1MG	A070886	002	Aug 31, 1988	May CMFD
>D>	@	0.2MG	A070886	001	Aug 31, 1988	May CMFD
>A> AB		0.2MG	A070886	001	Aug 31, 1988	May CMFD
>D>	@	0.3MG	A070886	003	Aug 31, 1988	May CMFD
>A> AB		0.3MG	A070886	003	Aug 31, 1988	May CMFD
AB	URL LABS	0.1MG	A070923	003	Sep 04, 1987	Apr CAHN
AB		0.2MG	A070923	002	Sep 04, 1987	Apr CAHN
AB		0.3MG	A070923	001	Sep 04, 1987	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

@ MAYNE PHARMA INC 0.1MG

A210680 001 Apr 30, 2018 Feb DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB DR REDDYS EQ 75MG BASE A076273 001 Jan 14, 2008 Apr CAHN

COLCHICINE

TABLET;ORAL

COLCHICINE

AB @ PAR PHARM INC 0.6MG A203976 001 Aug 12, 2021 Feb DISC  
STRIDES PHARMA 0.6MG A209173 001 Mar 10, 2022 Mar NEWACOLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

>D> AB LUPIN LTD 625MG A201354 001 Dec 17, 2020 May DISC  
>A> @ 625MG A201354 001 Dec 17, 2020 May DISC  
AB SPH 625MG A213456 001 Jan 21, 2022 Jan NEWACOlestipol HYDROCHLORIDE

TABLET;ORAL

COlestipol

AB + PFIZER 1GM N020222 001 Jul 19, 1994 Apr CHRS  
COlestipol HYDROCHLORIDE  
AB ! IMPAX LABS 1GM A077510 001 Oct 24, 2006 Apr CHRS  
AB ZYDUS PHARMS 1GM A215223 001 Mar 10, 2022 Feb NEWACROMOLYN SODIUM

SOLUTION;INHALATION

CROMOLYN SODIUM

AN FERA PHARMS LLC 10MG/ML A075437 001 Apr 21, 2000 Mar CMFD  
AN MICRO LABS 10MG/ML A213658 001 Apr 29, 2022 Apr NEWACUPRIC SULFATE

INJECTABLE;INJECTION

CUPRIC SULFATE

+ @ ABRAXIS PHARM EQ 0.4MG COPPER/ML N019350 001 May 05, 1987 Apr DISC

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

AP WELDING 1MG/ML A215417 001 Apr 15, 2022 Apr NEWA  
AP ZYDUS PHARMS 1MG/ML A214655 001 Apr 15, 2022 Apr NEWA  
DODEX  
>D> ACCORD HLTHCARE 1MG/ML A083022 001 May CTEC  
>A> AP 1MG/ML A083022 001 May CTEC  
1MG/ML A083022 001 Apr CMFDCYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

>D> AB ANI PHARMS 25MG A207014 001 Mar 19, 2018 May DISC  
>A> @ 25MG A207014 001 Mar 19, 2018 May DISC  
@ 50MG A207014 002 Mar 19, 2018 Apr DISCCYCLOSPORINE

EMULSION;OPHTHALMIC

CYCLOSPORINE

AB MYLAN 0.05% A205894 001 Feb 02, 2022 Jan NFTG  
RESTASIS  
AB +! ALLERGAN 0.05% N050790 001 Dec 23, 2002 Jan CFTG  
SOLUTION;ORAL  
CYCLOSPORINE  
@ MAYNE PHARMA 100MG/ML A065054 001 Dec 18, 2001 Feb DISCCYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

@ TRIS PHARMA INC 2MG/5ML A205431 001 Dec 21, 2021 Apr DISC

CYSTEAMINE BITARTRATE

GRANULE, DELAYED RELEASE;ORAL  
PROCYSB1

>A>	+	HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	May CAHN
>A>	+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	May CAHN
>D>	+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	May CAHN
>D>	+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	May CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
CYSTEINE HYDROCHLORIDE

AP		ETON	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Apr NFTG
AP	+!	ELCYS EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr CFTG

CYTARABINE

INJECTABLE;INJECTION  
CYTARABINE

AP		HONG KONG	20MG/ML	A208485	001	Feb 28, 2022	Feb NEWA
----	--	-----------	---------	---------	-----	--------------	----------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL  
DALFAMPRIDINE

>D> AB		HIKMA	10MG	A206646	001	Oct 24, 2018	May DISC
>A>	@		10MG	A206646	001	Oct 24, 2018	May DISC

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS  
FRAGMIN

+	Pfizer	10,000IU/4ML (2,500IU/ML)
---	--------	---------------------------

N020287 012 Mar 15, 2022 Mar NEWA

DANTROLENE SODIUM

INJECTABLE;INJECTION  
DANTROLENE SODIUM  
@ EUGIA PHARMA SPECLTS

20MG/VIAL

A205239 001 Feb 18, 2016 Mar CAHN

DAPAGLIFLOZIN

TABLET;ORAL  
DAPAGLIFLOZIN

AB		ZYDUS PHARMS	5MG	A211582	001	Feb 22, 2022	Feb NFTG
AB			10MG	A211582	002	Feb 22, 2022	Feb NFTG
		FARXIGA					
AB	+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb CFTG
AB	+!		10MG	N202293	002	Jan 08, 2014	Feb CFTG

DAPSONE

GEL;TOPICAL  
DAPSONE

AB		MYLAN	7.5%	A213847	001	Feb 04, 2022	Jan NEWA
AB		SEEGPHARM SA	5%	A210178	001	Mar 31, 2022	Mar NEWA
AB		TORRENT	7.5%	A214722	001	Feb 10, 2022	Feb NEWA
		TABLET;ORAL					
		DAPSONE					
	@	VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Jan DISC
	@		100MG	A204074	002	May 10, 2016	Jan DISC

DAPTOMYCIN

POWDER;INTRAVENOUS  
DAPZURA RT  
+! BAXTER HLTHCARE CORP

500MG/VIAL

N213645 001 Jan 25, 2022 Jan NEWA

DARIDOREXANT HYDROCHLORIDE

TABLET;ORAL  
QUVIVIQ

+	IDORSIA	EQ 25MG BASE	N214985	001	Apr 07, 2022	Apr NEWA
+	!	EQ 50MG BASE	N214985	002	Apr 07, 2022	Apr NEWA

DASATINIB

TABLET;ORAL

>D>	DASATINIB						
>D> AB	APOTEX	80MG	A203180	001	Nov 23, 2021	May	DISC
>A>	@	80MG	A203180	001	Nov 23, 2021	May	DISC
>D> AB		140MG	A203180	002	Nov 23, 2021	May	DISC
>A>	@	140MG	A203180	002	Nov 23, 2021	May	DISC
	SPRYCEL						
>D> AB	+ BRISTOL MYERS SQUIBB	80MG	N021986	005	Oct 28, 2010	May	CTEC
>A>	+	80MG	N021986	005	Oct 28, 2010	May	CTEC
>D> AB	+	140MG	N021986	006	Oct 28, 2010	May	CTEC
>A>	+	140MG	N021986	006	Oct 28, 2010	May	CTEC

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

AP	JIANGSU HANSOH PHARM	50MG/VIAL	A213472	001	Apr 15, 2022	Apr	NEWA
----	----------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

	@ AMNEAL	90MG	A214194	003	Aug 02, 2021	Mar	DISC
AB	CIPLA	90MG	A215026	001	Feb 23, 2022	Feb	NEWA
AB		180MG	A215026	002	Feb 23, 2022	Feb	NEWA
AB		360MG	A215026	003	Feb 23, 2022	Feb	NEWA
AB	MSN	90MG	A214650	003	Apr 20, 2022	Apr	NEWA
	TABLET;ORAL						
	DEFERASIROX						
	@ AMNEAL	180MG	A210727	003	Jun 15, 2020	Apr	DISC

DEFERIPRONE

TABLET;ORAL

DEFERIPRONE

AB	HIKMA	1GM	A213239	002	Feb 08, 2022	Jan	NFTG
AB	FERRIPROX						
AB	+ CHIESI	1GM	N021825	002	Jul 25, 2019	Jan	CFTG

DESOGESTREL; ETHINYLN ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYLN ESTRADIOOL

@ MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Jan	DISC
@	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Jan	DISC

MG, 0.025MG

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

AB	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Mar	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

+ @ SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb	CAHN
+ @	EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb	CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB	LUPIN LTD	EQ 25MG BASE	A204172	003	Apr 13, 2022	Apr	NEWA
----	-----------	--------------	---------	-----	--------------	-----	------

DEXAMETHASONE

SOLUTION;ORAL

DEXAMETHASONE

+! HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983	Mar	CRLD
----------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

DEXAMETHASONE

BP + HIKMA	0.5MG	A084611	001		Jan	CRLD
AB PRASCO	4MG	A080399	002	Apr 20, 2022	Apr	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP +! FRESENIUS KABI USA EQ 4MG PHOSPHATE/ML A084916 001 Feb CRLD

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

AB PADAGIS US 0.1%; 0.3% A212715 001 Feb 11, 2022 Feb NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

AA +! PAI HOLDINGS PHARM 2MG/5ML A088251 001 Mar 23, 1984 Apr CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

FILM; Buccal, Sublingual

IGALMI

+! BIOXCEL EQ 0.12MG BASE N215390 001 Apr 05, 2022 Apr NEWA  
+! EQ 0.18MG BASE N215390 002 Apr 05, 2022 Apr NEWA

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP MEITHEAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204843 001 Jan 18, 2019 Apr CAHN

@ PIRAMAL CRITICAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A214794 001 Sep 03, 2021 Feb DISC

DEXTROAMPHETAMINE

SYSTEM; TRANSDERMAL

XELSTRYM

+ NOVEN PHARMS INC 4.5MG/9HR N215401 001 Mar 22, 2022 Mar NEWA  
+ 9MG/9HR N215401 002 Mar 22, 2022 Mar NEWA  
+ 13.5MG/9HR N215401 003 Mar 22, 2022 Mar NEWA  
+! 18MG/9HR N215401 004 Mar 22, 2022 Mar NEWADEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

@ MAYNE PHARMA 5MG A076137 001 Jan 18, 2002 Feb DISC  
@ 10MG A076137 002 Jan 18, 2002 Feb DISC  
@ 15MG A076137 003 Jan 18, 2002 Feb DISC  
@ NESHER PHARMS 5MG A209111 001 Jun 27, 2017 Mar DISC  
@ 10MG A209111 002 Jun 27, 2017 Mar DISC  
@ 15MG A209111 003 Jun 27, 2017 Mar DISC

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

ARBOR PHARMS LLC 2.5MG A090533 001 Oct 25, 2011 Jan CTEC  
7.5MG A090533 003 Oct 25, 2011 Jan CTEC  
15MG A090533 005 Oct 25, 2011 Jan CTEC  
20MG A090533 006 Oct 25, 2011 Jan CTEC  
30MG A090533 007 Oct 25, 2011 Jan CTEC  
@ NESHER PHARMS 5MG A206588 001 Mar 28, 2016 Mar DISC  
@ 10MG A206588 002 Mar 28, 2016 Mar DISC  
@ WINDER LABS LLC 2.5MG A212160 001 Jun 07, 2021 Jan DISC  
@ 5MG A212160 002 Jun 07, 2021 Jan DISC  
@ 7.5MG A212160 003 Jun 07, 2021 Jan DISC  
@ 10MG A212160 004 Jun 07, 2021 Jan DISC  
@ 15MG A212160 005 Jun 07, 2021 Jan DISC  
@ 20MG A212160 006 Jun 07, 2021 Jan DISC  
@ 30MG A212160 007 Jun 07, 2021 Jan DISCDIAZEPAM

GEL; RECTAL

DIASTAT

>D> + BAUSCH 2.5MG/0.5ML (5MG/ML) N020648 001 Jul 29, 1997 May CHRS  
>A> +! 2.5MG/0.5ML (5MG/ML) N020648 001 Jul 29, 1997 May CHRS

DIASTAT ACUDIAL

>D> + BAUSCH 10MG/2ML (5MG/ML) N020648 007 Sep 15, 2005 May CHRS  
>A> +! 10MG/2ML (5MG/ML) N020648 007 Sep 15, 2005 May CHRS

TABLET;ORAL  
VALIUM

AB	+ WAYLIS THERAP	2MG	N 013263	002	Mar CAHN
AB	+	5MG	N 013263	004	Mar CAHN
AB	+!	10MG	N 013263	006	Mar CAHN

DICLOFENAC POTASSIUM

CAPSULE;ORAL  
DICLOFENAC POTASSIUM

AB	STRIDES PHARMA	25MG	A 210078	001	Dec 03, 2019	Apr CMFD
AB	FOR SOLUTION;ORAL DICLOFENAC POTASSIUM					
AB	ANNORA PHARMA	50MG	A 215375	001	Mar 04, 2022	Feb NEWA
AB	TABLET;ORAL DICLOFENAC POTASSIUM					
AB	UMEDICA LABS PVT LTD	50MG	A 215750	001	May 11, 2022	Apr NEWA

DICLOFENAC SODIUM

GEL;TOPICAL  
DICLOFENAC SODIUM

	CIPLA	1%	A 209903	001	Aug 03, 2018	Mar CTEC
AB	SOLUTION;TOPICAL DICLOFENAC SODIUM					
AB	APOTEX	2%	A 207714	001	May 06, 2022	Apr NFTG
	@ TWI PHARMS	1.5%	A 202393	001	Nov 24, 2014	Mar DISC
AB	PENNSAID					
AB	+! HORIZON	2%	N 204623	001	Jan 16, 2014	Apr CFTG

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
DICYCLOMINE HYDROCHLORIDE  
@ GENE YORK PHARMS

10MG/ML

A 212058 001 Apr 26, 2019 Feb DISC

DIGOXIN

ELIXIR;ORAL  
DIGOXIN

AA	AMICI	0.05MG/ML	A 215209	001	Mar 11, 2022	Mar NEWA
	TABLET;ORAL DIGOXIN					
AB	AUROBINDO PHARMA LTD	0.0625MG	A 214982	001	Feb 08, 2022	Jan NFTG
AB		0.125MG	A 214982	002	Feb 08, 2022	Jan NEWA
AB		0.25MG	A 214982	003	Feb 08, 2022	Jan NEWA
	LANOXIN					
AB	+ CONCORDIA	0.0625MG	N 020405	001	Sep 30, 1997	Jan CFTG

DITHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL  
TRUDHESA

>D>	+! IMPEL NEUROPHARMA	0.725MG/SPRAY	N 213436	001	Sep 02, 2021	May CAHN
>A>	+! IMPEL PHARMS	0.725MG/SPRAY	N 213436	001	Sep 02, 2021	May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
DILTIAZEM HYDROCHLORIDE

AB1	MAYNE PHARMA INTL	60MG	A 215775	001	May 05, 2022	Apr NEWA
AB1		90MG	A 215775	002	May 05, 2022	Apr NEWA
AB1		120MG	A 215775	003	May 05, 2022	Apr NEWA

SOLUTION;INTRAVENOUS  
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

+ @ EXELA PHARMA	125MG/125ML (1MG/ML)	N 215252	001	Oct 28, 2021	Feb DISC
+ @	250MG/250ML (1MG/ML)	N 215252	002	Oct 28, 2021	Feb DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL  
DIMETHYL FUMARATE

@ PHARMATHEN	120MG	A 210436	001	Mar 26, 2021	Apr DISC
@	240MG	A 210436	002	Mar 26, 2021	Apr DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ HOSPIRA 50MG/ML

A040140 001 Nov 20, 1998 Mar DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP ! CHARTWELL INJECTABLE 5MG/ML  
@ EUGIA PHARMA SPECIALISTS 5MG/MLA074939 001 Apr 13, 1998 Mar CAHN  
A075769 001 Nov 27, 2002 Mar CAHNDISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

AB MAYNE PHARMA EQ 100MG BASE  
AB EQ 150MG BASEA070173 001 May 31, 1985 Feb CMFD  
A070173 002 May 31, 1985 Feb CMFDDIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB UNICHEM EQ 250MG VALPROIC ACID  
AB EQ 500MG VALPROIC ACIDA214643 001 Feb 25, 2022 Feb NEWA  
A214643 002 Feb 25, 2022 Feb NEWADOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP MEITHEAL 20MG/2ML (10MG/ML)  
AP 80MG/8ML (10MG/ML)  
AP 160MG/16ML (10MG/ML)A209634 001 Aug 24, 2018 Apr CAHN  
A209634 002 Aug 24, 2018 Apr CAHN  
A209634 003 Aug 24, 2018 Apr CAHNDOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB TEVA PHARMS USA 0.125MG  
AB 0.25MG  
AB 0.5MGA210018 001 Apr 15, 2022 Apr NEWA  
A210018 002 Apr 15, 2022 Apr NEWA  
A210018 003 Apr 15, 2022 Apr NEWA

TABLET; ORAL

DOFETILIDE

AB VGYAAN 0.125MG  
AB 0.25MG  
AB 0.5MGA215323 001 Apr 14, 2022 Apr NEWA  
A215323 002 Apr 14, 2022 Apr NEWA  
A215323 003 Apr 14, 2022 Apr NEWADONEPEZIL HYDROCHLORIDE

SYSTEM; TRANSDERMAL

ADILARITY

+ CORIUM 5MG/DAY  
+! 10MG/DAYN212304 001 Mar 11, 2022 Mar NEWA  
N212304 002 Mar 11, 2022 Mar NEWA

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB CHARTWELL RX 5MG  
AB 10MGA090425 001 May 31, 2011 Mar CAHN  
A090425 002 May 31, 2011 Mar CAHNDORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT GLAND PHARMA LTD EQ 2% BASE  
>D> AT MICRO LABS EQ 2% BASE  
>A> AT ! EQ 2% BASE  
>D> TRUSOPT  
>D> AT +! MERCK EQ 2% BASE  
>A> + @ EQ 2% BASEA215660 001 Jan 27, 2022 Jan NEWA  
A204778 001 Nov 08, 2019 May CHRS  
A204778 001 Nov 08, 2019 May CHRS  
N020408 001 Dec 09, 1994 May DISC  
N020408 001 Dec 09, 1994 May DISCDORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

AT +! THEA PHARMA EQ 2% BASE; EQ 0.5% BASE  
AT +! THEA PHARMA EQ 2% BASE; EQ 0.5% BASE  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE  
AT MICRO LABS EQ 2% BASE; EQ 0.5% BASEN020869 001 Apr 07, 1998 Apr CAHN  
N202667 001 Feb 01, 2012 Apr CAHN  
A215936 001 Jan 25, 2022 Jan NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

AP CHARTWELL INJECTABLE 20MG/ML A076266 001 Jan 10, 2003 Mar CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

AB +! VIATRIS EQ 1MG BASE N019668 001 Nov 02, 1990 Jan CAHN

AB + EQ 2MG BASE N019668 002 Nov 02, 1990 Jan CAHN

AB + EQ 4MG BASE N019668 003 Nov 02, 1990 Jan CAHN

AB + EQ 8MG BASE N019668 004 Nov 02, 1990 Jan CAHN

DOXAZOSIN MESYLATE

@ CHARTWELL RX

EQ 1MG BASE

A075646 001 Oct 18, 2000 Jan CAHN

@ EQ 2MG BASE

A075646 002 Oct 18, 2000 Jan CAHN

@ EQ 4MG BASE

A075646 003 Oct 18, 2000 Jan CAHN

@ EQ 8MG BASE

A075646 004 Oct 18, 2000 Jan CAHN

AB METHOD EQ 1MG BASE A212727 001 Mar 15, 2022 Mar NEWA

AB EQ 2MG BASE A212727 002 Mar 15, 2022 Mar NEWA

AB EQ 4MG BASE A212727 003 Mar 15, 2022 Mar NEWA

AB EQ 8MG BASE A212727 004 Mar 15, 2022 Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

+ VIATRIS

EQ 4MG BASE

N021269 001 Feb 22, 2005 Jan CAHN

+!

EQ 8MG BASE

N021269 002 Feb 22, 2005 Jan CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB EDENBRIDGE PHARMS EQ 150MG BASE A213796 001 Apr 19, 2022 Apr NEWA

AB EPIC PHARMA LLC EQ 50MG BASE A210675 004 Mar 03, 2022 Feb NEWA

AB EQ 75MG BASE A210675 005 Mar 03, 2022 Feb NEWA

AB JUBILANT CADISTA EQ 10MG BASE A215483 001 Mar 14, 2022 Mar NEWA

AB EQ 25MG BASE A215483 002 Mar 14, 2022 Mar NEWA

AB EQ 50MG BASE A215483 003 Mar 14, 2022 Mar NEWA

AB EQ 75MG BASE A215483 004 Mar 14, 2022 Mar NEWA

AB EQ 100MG BASE A215483 005 Mar 14, 2022 Mar NEWA

AB MANKIND PHARMA EQ 10MG BASE A215710 001 Feb 09, 2022 Jan NEWA

AB EQ 25MG BASE A215710 002 Feb 09, 2022 Jan NEWA

AB EQ 50MG BASE A215710 003 Feb 09, 2022 Jan NEWA

AB EQ 75MG BASE A215710 004 Feb 09, 2022 Jan NEWA

AB EQ 100MG BASE A215710 005 Feb 09, 2022 Jan NEWA

AB ! PAR PHARM EQ 150MG BASE A071422 006 Nov 09, 1987 Apr CTEC

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP EUGIA PHARMA 2MCG/ML (2MCG/ML) A213717 001 Jan 24, 2022 Jan NEWA

AP 4MCG/2ML (2MCG/ML) A213717 002 Jan 24, 2022 Jan NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

@ IMPAX LABS INC

EQ 150MG BASE

A200065 001 Feb 17, 2011 Mar DISC

MONODOX

AB + CHARTWELL RX EQ 150MG BASE N050641 004 Feb 17, 2022 Feb NEWA

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

&gt;A&gt; AB CADILA EQ 50MG BASE A207774 001 May 31, 2018 May CAHN

&gt;A&gt; AB EQ 100MG BASE A207774 002 May 31, 2018 May CAHN

@ NESHER PHARMS

EQ 50MG BASE

A208263 001 Nov 22, 2021 Mar DISC

@

EQ 100MG BASE

A208263 002 Nov 22, 2021 Mar DISC

&gt;D&gt; AB ZYDUS PHARMS EQ 50MG BASE A207774 001 May 31, 2018 May CAHN

&gt;D&gt; AB EQ 100MG BASE A207774 002 May 31, 2018 May CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

@ EMCURE PHARMS LTD

EQ 100MG BASE

A209969 001 Nov 09, 2018 Jan DISC

AB PRAXGEN EQ 100MG BASE A212487 001 Mar 30, 2022 Mar NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

AB +! DUCHESNAY 20MG;20MG  
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE  
AB ACTAVIS LABS FL INC 20MG;20MG

N209661 001 Nov 07, 2016 Feb CFTG  
A212472 001 Mar 01, 2022 Feb NFTG

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB	CELLTRION	100MG	A214217	001	May 05, 2022	Apr NEWA
AB		200MG	A214217	002	May 05, 2022	Apr NEWA
AB		300MG	A214217	003	May 05, 2022	Apr NEWA
>D>	AB SLATE	100MG	A215265	001	Nov 01, 2021	May DISC
>A>	@	100MG	A215265	001	Nov 01, 2021	May DISC
>D>	AB	200MG	A215265	002	Nov 01, 2021	May DISC
>A>	@	200MG	A215265	002	Nov 01, 2021	May DISC
>D>	AB	300MG	A215265	003	Nov 01, 2021	May DISC
>A>	@	300MG	A215265	003	Nov 01, 2021	May DISC

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL  
DRIZALMA SPRINKLE

+ SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Feb CAHN
+	EQ 30MG BASE	N212516	002	Jul 19, 2019	Feb CAHN
+	EQ 40MG BASE	N212516	003	Jul 19, 2019	Feb CAHN
+!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Feb CAHN

DUVELISIBCAPSULE;ORAL  
COPIKTRA

>D>	+ @ SECURA	15MG	N211155	001	Sep 24, 2018	May CMFD
>A>	+	15MG	N211155	001	Sep 24, 2018	May CMFD
	+	15MG	N211155	001	Sep 24, 2018	Apr DISC
>D>	+	25MG	N211155	002	Sep 24, 2018	May CMFD
>A>	+	25MG	N211155	002	Sep 24, 2018	May CMFD
	+	25MG	N211155	002	Sep 24, 2018	Apr DISC

EDARAVONE

>A>	SUSPENSION;ORAL					
>A>	RADICAVA ORS					
>A>	+! MITSUBISHI TANABE	105MG/5ML	N215446	001	May 12, 2022	May NEWA

EFAVIRENZTABLET;ORAL  
EFAVIRENZ  
@ AUROBINDO PHARMA LTD 600MG

A205322 001 Aug 30, 2018 Apr DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB HETERO LABS LTD V 600MG;200MG;300MG A203053 001 Jan 24, 2022 Jan NEWA

EFINAConazoleSOLUTION;TOPICAL  
EFINAConazole

>D>	AB LUPIN LTD	10%	A212169	001	Mar 02, 2022	May DISC
>A>	@	10%	A212169	001	Mar 02, 2022	May DISC
AB		10%	A212169	001	Mar 02, 2022	Feb NEWA

EFLORNITHINE HYDROCHLORIDECREAM;TOPICAL  
VANIQA  
+ @ SKINMEDICA

13.9%

N021145 001 Jul 27, 2000 Feb DISC

ELIGLUSTAT TARTRATECAPSULE;ORAL  
ELIGLUSTAT TARTRATE

AB AIZANT EQ 84MG BASE A212463 001 Sep 08, 2021 Feb CAHN

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

DESCOVY

+ GILEAD SCIENCES INC 120MG;EQ 15MG BASE

N208215 002 Jan 07, 2022 Jan NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB	ALKEM LABS LTD	1MG/ML	A213714	001	Mar 30, 2022	Mar NEWA
AB	ANNORA PHARMA	1MG/ML	A214467	001	Feb 24, 2022	Feb NEWA

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jan CHRS
AP	CHARTWELL INJECTABLE	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN
AP	! HIKMA FARMACEUTICA	1.25MG/ML	A078687	001	Dec 23, 2008	Jan CHRS
AP	HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Jan CHRS

ENTECAVIR

TABLET;ORAL

ENTECAVIR

@ ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Apr DISC
@	1MG	A205824	002	Aug 25, 2017	Apr DISC
>D> AB YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	May DISC
>A> @	0.5MG	A208195	001	Nov 10, 2021	May DISC
>D> AB	1MG	A208195	002	Nov 10, 2021	May DISC
>A> @	1MG	A208195	002	Nov 10, 2021	May DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

@ ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	Feb DISC
AB APOTEX	40MG	A209645	001	Apr 22, 2022	Apr NEWA
XTANDI					
AB +! ASTELLAS	40MG	N203415	001	Aug 31, 2012	Apr CTEC
+!	40MG	N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

AP AGGREGA	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Apr NEWA
>A> +! ENDO VENTURES	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	May NEWA
+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CMFD
AP GLAND PHARMA LTD	50MG/ML (50MG/ML)	A216146	001	Feb 25, 2022	Feb NEWA
AP MANKIND PHARMA	50MG/ML (50MG/ML)	A216129	001	Apr 14, 2022	Apr NEWA

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

+! BELCHER	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Mar NEWA
SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS					
EPINEPHRINE					
+! BELCHER	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014	Mar CDFR

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE

+! DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985	Feb CRLD
LIGNOSPAN STANDARD					
+! DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985	Jan CRLD

EPLERENONE

TABLET;ORAL

EPLERENONE

AB KARTHA	25MG	A214663	001	Mar 23, 2022	Mar NEWA
AB	50MG	A214663	002	Mar 23, 2022	Mar NEWA

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AP SHUANGCHENG 75MG/100ML A213081 002 Apr 20, 2022 Apr NEWA

ERYTHROMYCIN

TABLET, COATED PARTICLES; ORAL

PCE

>D>	+ @ ARBOR PHARMS LLC	333MG	N050611 001 Sep 09, 1986	May CAHN
>D>	+ @	500MG	N050611 002 Aug 22, 1990	May CAHN
>A>	+ @ AZURITY	333MG	N050611 001 Sep 09, 1986	May CAHN
>A>	+ @	500MG	N050611 002 Aug 22, 1990	May CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

>D> AB	+ ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207 001	May CAHN
>A> AB	+ AZURITY	EQ 200MG BASE/5ML	N050207 001	May CAHN
ERYPED				
>D> AB	+ ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207 003 Mar 30, 1987	May CAHN
>D> AB	+!	EQ 400MG BASE/5ML	N050207 002	May CAHN
>A> AB	+ AZURITY	EQ 200MG BASE/5ML	N050207 003 Mar 30, 1987	May CAHN
>A> AB	+!	EQ 400MG BASE/5ML	N050207 002	May CAHN
TABLET, CHEWABLE; ORAL				
E.E.S.				
>D>	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297 002	May CAHN
>A>	@ AZURITY	EQ 200MG BASE	N050297 002	May CAHN
ERYPED				
>D>	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297 003 Jul 05, 1988	May CAHN
>A>	@ AZURITY	EQ 200MG BASE	N050297 003 Jul 05, 1988	May CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN LACTOBIONATE

AP NEXUS PHARMS EQ 500MG BASE/VIAL A215290 001 Feb 14, 2022 Feb NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HYDROCHLORIDE

AP	EUGIA PHARMA	10MG/ML	A216244 001 Mar 21, 2022	Mar NEWA
AP		20MG/ML	A216244 002 Mar 21, 2022	Mar NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	HAINAN POLY	EQ 40MG BASE/VIAL	A215732 001 Feb 10, 2022	Feb NEWA
	@ MYLAN	EQ 20MG BASE/VIAL	A202686 001 May 17, 2017	Apr CAHN
	@	EQ 40MG BASE/VIAL	A202686 002 May 17, 2017	Apr CAHN
	@ MYLAN LABS LTD	EQ 40MG BASE/VIAL	A202686 002 May 17, 2017	Apr DISC
	@ SUN PHARM	EQ 20MG BASE/VIAL	A200882 001 Mar 18, 2013	Feb CAHN
AP		EQ 40MG BASE/VIAL	A200882 002 Mar 18, 2013	Feb CAHN

ESTRADIOL

TABLET; ORAL

ESTRADIOL

>A>	@ LANNETT CO INC	0.5MG	A040138 001 Jan 30, 1998	May CAHN
>A>	@	1MG	A040138 002 Jan 30, 1998	May CAHN
>A>	@	2MG	A040138 003 Jan 30, 1998	May CAHN
>D>	@ LANNETT HOLDINGS INC	0.5MG	A040138 001 Jan 30, 1998	May CAHN
>D>	@	1MG	A040138 002 Jan 30, 1998	May CAHN
>D>	@	2MG	A040138 003 Jan 30, 1998	May CAHN
	@ MAYNE PHARMA	0.5MG	A040114 003 Mar 14, 1996	Feb DISC
	@	1MG	A040114 001 Mar 14, 1996	Feb DISC
	@	2MG	A040114 002 Mar 14, 1996	Feb DISC

ESTRADIOL; PROGESTERONE

CAPSULE; ORAL

BIJUVA

>D>	+ @ THERAPEUTICSMD INC	0.5MG;100MG	N210132 002 Dec 28, 2021	Apr DISC
	+!	1MG;100MG	N210132 001 Oct 28, 2018	May CTEC
>A>	+!	1MG;100MG	N210132 001 Oct 28, 2018	May CTEC

CAPSULE;ORAL ESTRADIOL AND PROGESTERONE >A> @ AMNEAL PHARMS 1MG;100MG		A214293 001 May 16, 2022 May DISC
<u>ESZOPICLONE</u>		
TABLET;ORAL ESZOPICLONE & CHARTWELL RX 1MG	A091165 001 Jul 14, 2011 Jan CAHN	
& 2MG	A091165 002 Jul 14, 2011 Jan CAHN	
& 3MG	A091165 003 Jul 14, 2011 Jan CAHN	
<u>ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE</u>		
TABLET;ORAL-28 ZOVIA 1/35E-28 & MAYNE PHARMA 0.035MG;1MG	A072721 001 Dec 30, 1991 Jan DISC	
<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>		
TABLET;ORAL-28 LEVONORGESTREL AND ETHINYL ESTRADIOL AB1 NAARI PTE LTD 0.02MG;0.1MG	A207065 001 Aug 17, 2020 Apr CTEC	
<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>		
>A> TABLET;ORAL >A> FEMCON FE >A> + @ APIL 0.035MG;0.4MG >A> NEXESTA FE >A> AB AUROBINDO PHARMA LTD 0.035MG;0.4MG >A> NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE >A> AB AMNEAL PHARMS 0.035MG;0.4MG >A> AB BARR 0.035MG;0.4MG >A> AB LUPIN LTD 0.035MG;0.4MG >A> AB ! MYLAN LABS LTD 0.035MG;0.4MG >A> AB NAARI PTE LTD 0.035MG;0.4MG	N021490 001 Nov 14, 2003 May CDFR A207535 001 Feb 02, 2017 May CDFR A078892 001 Sep 26, 2011 May CDFR A078965 001 Aug 05, 2010 May CDFR A091332 001 Mar 23, 2016 May CDFR A202086 001 Apr 01, 2015 May CDFR A207066 001 Mar 29, 2017 May CDFR	
TABLET;ORAL-28 NORETHINDRONE AND ETHINYL ESTRADIOL & MAYNE PHARMA 0.035MG;0.5MG	A070686 001 Jan 29, 1987 Jan DISC	
>D> TABLET, CHEWABLE;ORAL >D> FEMCON FE >D> + @ APIL 0.035MG;0.4MG >D> NEXESTA FE >D> AB AUROBINDO PHARMA LTD 0.035MG;0.4MG >D> NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE >D> AB AMNEAL PHARMS 0.035MG;0.4MG >D> AB BARR 0.035MG;0.4MG >D> AB LUPIN LTD 0.035MG;0.4MG >D> AB ! MYLAN LABS LTD 0.035MG;0.4MG >D> AB NAARI PTE LTD 0.035MG;0.4MG	N021490 001 Nov 14, 2003 May CDFR A207535 001 Feb 02, 2017 May CDFR A078892 001 Sep 26, 2011 May CDFR A078965 001 Aug 05, 2010 May CDFR A091332 001 Mar 23, 2016 May CDFR A202086 001 Apr 01, 2015 May CDFR A207066 001 Mar 29, 2017 May CDFR	
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>		
CAPSULE;ORAL NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE AB MAYNE PHARMA 0.02MG;1MG	A213901 001 Apr 28, 2022 Apr NEWA	
>A> TABLET;ORAL >A> FINZALA >A> AB TEVA PHARMS USA INC 0.02MG;1MG	A210087 001 Apr 07, 2020 May CDFR	
>A> MIBELAS 24 FE >A> AB LUPIN 0.02MG;1MG	A206287 001 May 24, 2016 May CDFR	
>A> MINASTRIN 24 FE >A> AB +! APIL 0.02MG;1MG	N203667 001 May 08, 2013 May CDFR	
>A> NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE >A> @ AMNEAL PHARMS 0.02MG;1MG	A207514 001 Sep 11, 2017 May CDFR	
>A> AB GLENMARK PHARMS LTD 0.02MG;1MG	A210369 001 Dec 26, 2017 May CDFR	
>A> @ MYLAN LABS LTD 0.02MG;1MG	A206120 001 Sep 12, 2017 May CDFR	
>A> AB XIROMED 0.02MG;1MG	A209609 001 Jul 16, 2018 May CDFR	
TABLET;ORAL-21 MICROGESTIN 1.5/30 & MAYNE PHARMA 0.03MG;1.5MG	A075548 002 Jul 30, 2003 Jan DISC	
MICROGESTIN 1/20 & MAYNE PHARMA 0.02MG;1MG	A075647 002 Jul 30, 2003 Jan DISC	

TABLET;ORAL-28

MICROGESTIN FE 1.5/30	@ MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Jan DISC
MICROGESTIN FE 1/20	@ MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Jan DISC
NORETHINDRONE ACETATE AND ETHINYLN STRADIOL	@ MAYNE PHARMA	0.02MG, 0.03MG, 0.035MG;1MG, 1MG, 1MG	A076629	001	Mar 18, 2010	Jan DISC
AB MYLAN		0.02MG, 0.03MG, 0.035MG;1MG, 1MG, 1MG	A205069	001	Jun 22, 2018	Feb CMFD
AB		0.02MG, 0.03MG, 0.035MG;1MG, 1MG, 1MG	A205069	001	Jun 22, 2018	Feb CAHN
>D>	TABLET, CHEWABLE;ORAL					
>D>	FINZALA					
>D> AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	May CDFR
AB		0.02MG;1MG	A210087	001	Apr 07, 2020	Jan CMFD
>D>	MIBELAS 24 FE					
>D> AB	LUPIN	0.02MG;1MG	A206287	001	May 24, 2016	May CDFR
>D>	MINASTRIN 24 FE					
>D> AB	+! APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CDFR
>D>	NORETHINDRONE ACETATE AND ETHINYLN STRADIOL AND FERROUS FUMARATE					
>D>	@ AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	May CDFR
	@	0.02MG;1MG	A207514	001	Sep 11, 2017	Jan DISC
>D> AB	GLENMARK PHARMS LTD	0.02MG;1MG	A210369	001	Dec 26, 2017	May CDFR
>D>	@ MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	May CDFR
>D> AB	XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	May CDFR

ETHINYLN STRADIOL; NORGESTREL

TABLET;ORAL-21						
LO/OVRAL						
+ @ CADENCE HEALTH		0.03MG;0.3MG	N017612	001		Apr CRLD
TABLET;ORAL-28						
CRYSELLE						
AB ! DURAMED PHARMS BARR		0.03MG;0.3MG	A075840	002	Nov 30, 2001	Apr CHRS
LO/OVRAL-28						
+ @ WYETH PHARMS		0.03MG;0.3MG	N017802	001		Apr CRLD

ETONOGESTREL

IMPLANT; IMPLANTATION						
IMPLANON						
@ ORGANON		68MG/IMPLANT	N021529	001	Jul 17, 2006	Jan CAHN
NEXPLANON						
+! ORGANON		68MG/IMPLANT	N021529	002	May 31, 2011	Jan CAHN

ETRAVIRINE

TABLET;ORAL						
ETRAVIRINE						
AB CARNEGIE		100MG	A215402	001	Apr 13, 2022	Apr NEWA
AB		200MG	A215402	002	Apr 13, 2022	Apr NEWA

EXEMESTANE

TABLET;ORAL						
EXEMESTANE						

>A> AB EUGIA PHARMA 25MG A216454 001 May 20, 2022 May NEWA

EZETIMIBE

TABLET;ORAL						
EZETIMIBE						
@ APOTEX		10MG	A208332	001	Jun 12, 2017	Apr DISC

FAMCICLOVIR

TABLET;ORAL						
FAMCICLOVIR						
@ CIPLA		125MG	A078278	001	Mar 21, 2011	Mar DISC
@		250MG	A078278	002	Mar 21, 2011	Mar DISC
@		500MG	A078278	003	Mar 21, 2011	Mar DISC

FAMOTIDINE

INJECTABLE;INJECTION						
FAMOTIDINE PRESERVATIVE FREE						
@ AKORN		10MG/ML	A076324	001	Nov 27, 2002	Feb CAHN
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
@ AKORN		10MG/ML	A076322	001	Nov 27, 2002	Feb CAHN

TABLET;ORAL  
FAMOTIDINE

>A> AB	ZYDUS PHARMS	20MG	A216441	001	Jun 03, 2022	May NEWA
>A> AB		40MG	A216441	002	Jun 03, 2022	May NEWA

FEBUXOSTAT

TABLET;ORAL  
FEBUXOSTAT

AB	PRINSTON INC	40MG	A206266	001	Mar 28, 2022	Mar NEWA
AB		80MG	A206266	002	Mar 28, 2022	Mar NEWA

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL  
FELODIPINE

@ ATLANTIDE	2.5MG	A091484	001	Aug 15, 2012	Apr CAHN
@	5MG	A091484	002	Aug 15, 2012	Apr CAHN
@	10MG	A091484	003	Aug 15, 2012	Apr CAHN

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS  
INJECTAFER

+! AM REGENT	100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022	Feb NEWA
--------------	-------------------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
FESOTERODINE FUMARATE

>D>	@ ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	May CMFD
>A> AB		4MG	A204827	001	Dec 10, 2015	May CMFD
>D>	@	8MG	A204827	002	Dec 10, 2015	May CMFD
>A> AB		8MG	A204827	002	Dec 10, 2015	May CMFD

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL  
ALLEGRA

@ CHATTEM SANOFI	60MG	N020625	001	Jul 25, 1996	Jan CAHN
@	60MG	N020625	001	Jul 25, 1996	Jan CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL  
FINGOLIMOD HYDROCHLORIDE

@ MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb DISC
AB	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb CAHN

FLECAINIDE ACETATE

TABLET;ORAL  
FLECAINIDE ACETATE

@ CHARTWELL	50MG	A079164	001	Jul 09, 2009	Feb CAHN
@	100MG	A079164	002	Jul 09, 2009	Feb CAHN
@	150MG	A079164	003	Jul 09, 2009	Feb CAHN

FLUCYTOSINE

CAPSULE;ORAL  
FLUCYTOSINE

AB	STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Feb CMFD
AB		500MG	A212632	002	Apr 17, 2020	Feb CMFD

FLUDROCORTISONE ACETATE

TABLET;ORAL  
FLUDROCORTISONE ACETATE

>A> AB	NOVITIUM PHARMA	0.1MG	A215279	001	May 31, 2022	May NEWA
--------	-----------------	-------	---------	-----	--------------	----------

FLUNISOLIDE

SPRAY, METERED;NASAL  
FLUNISOLIDE

>D>	! APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	May DISC
>A>	@	0.029MG/SPRAY	A077436	001	Aug 09, 2007	May DISC

FLUOCINOLONE ACETONIDE

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

@ PAI HOLDINGS PHARM 0.01%

A088312 001 Jan 27, 1984 Apr CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

@ EUGIA PHARMA SPECILTS 500MG/10ML (50MG/ML)  
@ 1GM/20ML (50MG/ML)  
@ 2.5GM/50ML (50MG/ML)  
@ 5GM/100ML (50MG/ML)A202668 001 Jul 17, 2012 Mar CAHN  
A202668 002 Jul 17, 2012 Mar CAHN  
A202669 001 Jul 17, 2012 Mar CAHN  
A202669 002 Jul 17, 2012 Mar CAHNFLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1 MICRO LABS EQ 10MG BASE  
AB1 EQ 20MG BASE  
AB EQ 40MG BASEA216232 001 Mar 29, 2022 Mar NEWA  
A216232 002 Mar 29, 2022 Mar NEWA  
A216232 003 Mar 29, 2022 Mar NEWAFLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB TARO PHARM INDS LTD 1MG  
AB 2.5MG  
AB 5MG  
AB 10MG  
AB TWI PHARMS 2.5MG  
AB 5MG  
AB 10MGA215674 001 Apr 14, 2022 Apr NEWA  
A215674 002 Apr 14, 2022 Apr NEWA  
A215674 003 Apr 14, 2022 Apr NEWA  
A215674 004 Apr 14, 2022 Apr NEWA  
A215848 001 Apr 01, 2022 Mar NEWA  
A215848 002 Apr 01, 2022 Mar NEWA  
A215848 003 Apr 01, 2022 Mar NEWAFLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

+! ALMIRALL 0.05%  
FLURANDRENOLIDE  
@ CINTEX SVCS 0.05%  
LOTION;TOPICAL  
FLURANDRENOLIDE  
@ CINTEX SVCS 0.05%N012806 002 Feb CTEC  
A205342 001 Apr 13, 2016 Feb DISC  
A205343 001 Dec 22, 2016 Feb DISCFLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

RISING 15MG  
! 30MGA070345 002 Nov 27, 1985 Apr CAHN  
A070345 001 Nov 27, 1985 Apr CAHNFLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

@ CHARTWELL RX 125MG

A075818 001 Sep 18, 2001 Jan CAHN

FLUTICASONE PROPIONATE

LOTION;TOPICAL

CUTIVATE

AB + @ FOUGERA PHARMS 0.05%  
+ 0.05%  
FLUTICASONE PROPIONATE  
AB ! GLENMARK GENERICS 0.05%  
POWDER;INHALATION  
ARMONAIR DIGITALER  
+ @ TEVA PHARM 0.03MG/INHN021152 001 Mar 31, 2005 Mar DISC  
N021152 001 Mar 31, 2005 Mar CHRS  
A090759 001 May 02, 2011 Mar CHRS  
N208798 008 Apr 08, 2022 Apr NEWAFLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB BIONPHARMA INC 100MG

A212182 002 Sep 16, 2020 Feb CMFD

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

@ ARTHUR GRP	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Mar CAHN
@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Mar CAHN
@ PRAZGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Feb DISC
@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Feb DISC

FOSDENOPTERIN HYDROBROMIDE

POWDER; INTRAVENOUS

NULIBRY

+! SENTYNL THERAPS INC EQ 9.5MG BASE/VIAL

N214018 001 Feb 26, 2021 Mar CAHN

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE

AA CIPLA EQ 3GM BASE/PACKET A211881 001 Jan 26, 2022 Jan NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP ATLANTIDE EQ 50MG PHENYTOIN NA/ML A078137 001 Aug 06, 2007 Apr CAHN

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

>A> AB RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	May CAHN
>D> AB ZENARA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	May CAHN
AB	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Mar NEWA

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FULVESTRANT

AO @ APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jan DISC
AO JIANGSU HANSOH PHARM	50MG/ML	A214682	001	Feb 10, 2022	Feb NEWA
AO ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Feb CMFD

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP HONG KONG	10MG/ML	A212803	001	Jan 27, 2022	Jan NEWA
AP MEITHEAL	10MG/ML	A212803	001	Jan 27, 2022	Mar CAHN

SOLUTION; ORAL

FUROSEMIDE

>D> AA ! HIKMA	10MG/ML	A070434	001	Apr 22, 1987	May CTEC
>A> !	10MG/ML	A070434	001	Apr 22, 1987	May CTEC
>D> AA WOCKHARDT BIO AG	10MG/ML	A070655	001	Oct 02, 1987	May DISC
>A> @	10MG/ML	A070655	001	Oct 02, 1987	May DISC

TABLET; ORAL

FUROSEMIDE

@ EPIC PHARMA LLC 40MG

N018750 002 Jul 30, 1984 Mar CAHN

GABAPENTIN

CAPSULE; ORAL

NEURONTIN

AB + VIATRIS	100MG	N020235	001	Dec 30, 1993	Feb CAHN
AB +	300MG	N020235	002	Dec 30, 1993	Feb CAHN
AB +!	400MG	N020235	003	Dec 30, 1993	Feb CAHN

SOLUTION; ORAL

GABAPENTIN

@ PAI HOLDINGS PHARM 250MG/5ML

A211330 001 Dec 03, 2019 Feb CAHN

@ VISTAPHARM 250MG/5ML

A211330 001 Dec 03, 2019 Feb CAHN

NEURONTIN

AA +! VIATRIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb CAHN
---------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

NEURONTIN

AB + VIATRIS	600MG	N020882	001	Oct 09, 1998	Feb CAHN
AB +!	800MG	N020882	002	Oct 09, 1998	Feb CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL  
HORIZANT  
+ AZURITY 300MG N022399 002 Dec 13, 2011 Mar CAHN  
+! 600MG N022399 001 Apr 06, 2011 Mar CAHN

GALLIUM GA-68 GOZETOTIDE

POWDER;INTRAVENOUS  
ILLUCCIX  
+! TELIX N/A N214032 001 Dec 17, 2021 Mar CPOT  
LOCAMETZ  
+! AAA USA NOVARTIS N/A N215841 001 Mar 23, 2022 Mar NEWA

GANCICLOVIR SODIUM

INJECTABLE;INJECTION  
GANCICLOVIR SODIUM  
@ STERISCIENCE EQ 500MG BASE/VIAL A204560 001 Nov 17, 2017 Feb CAHN

GANIRELIX ACETATE

INJECTABLE;INJECTION  
>A> FYREMADEL  
>A> AP SUN PHARM 250MCG/0.5ML A204246 001 Nov 30, 2018 May CTNA  
GANIRELIX ACETATE  
AP AMPHASSTAR PHARMS INC 250MCG/0.5ML A212613 001 Apr 07, 2022 Apr NEWA  
>A> AP HONG KONG 250MCG/0.5ML A214996 001 Jun 06, 2022 May NEWA  
>D> AP SUN PHARM 250MCG/0.5ML A204246 001 Nov 30, 2018 May CTNA

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION  
GEMCITABINE HYDROCHLORIDE  
AP TEYRO LABS EQ 200MG BASE/VIAL A078759 001 Jul 25, 2011 Apr CAHN  
AP EQ 1GM BASE/VIAL A078759 002 Jul 25, 2011 Apr CAHN

GEMFIBROZIL

TABLET;ORAL  
GEMFIBROZIL  
@ CHARTWELL RX 600MG A074615 001 Sep 29, 1995 Feb CAHN

GEMIFLOXACIN MESYLATE

TABLET;ORAL  
FACTIVE  
+ @ LG CHEM LTD EQ 320MG BASE N021158 001 Apr 04, 2003 Jan DISC  
GEMIFLOXACIN MESYLATE  
@ ORBION PHARMS EQ 320MG BASE A090466 001 Jun 15, 2015 Jan DISC

GLIPIZIDE

TABLET;ORAL  
GLIPIZIDE  
>D> AB APOTEX 10MG A075795 002 Jun 13, 2001 May CHRS  
>A> AB ! 10MG A075795 002 Jun 13, 2001 May CHRS  
AB AUROBINDO PHARMA USA 5MG A074226 001 May 10, 1994 Feb CAHN  
AB 10MG A074226 002 May 10, 1994 Feb CAHN  
GLUCOTROL  
>D> AB + PFIZER 5MG N017783 001 May 08, 1984 May DISC  
>A> + @ 5MG N017783 001 May 08, 1984 May DISC  
>D> AB +! 10MG N017783 002 May 08, 1984 May DISC  
>A> + @ 10MG N017783 002 May 08, 1984 May DISC

GLYBURIDE

TABLET;ORAL  
GLYBURIDE  
@ SUNNY 1.25MG A203581 001 Apr 14, 2016 Mar DISC  
@ 2.5MG A203581 002 Apr 14, 2016 Mar DISC  
@ 5MG A203581 003 Apr 14, 2016 Mar DISC  
GLYBURIDE (MICRONIZED)  
@ CHARTWELL RX 1.5MG A075174 001 Jun 22, 1998 Feb CAHN  
@ 3MG A075174 002 Jun 22, 1998 Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>D>	AP	ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021	May DISC
>A>		@	0.2MG/ML	A214213	001	Nov 09, 2021	May DISC
		SOLUTION; INTRAMUSCULAR, INTRAVENOUS					
		GLYCOPYRROLATE					

+! FRESENIUS KABI USA

0.6MG/3ML (0.2MG/ML)

N214919 001 Apr 21, 2022 Apr NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	AMNEAL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May CAHN
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May CAHN
>D>	AP	PUNISKA	EQ 0.1IMG BASE/ML (EQ 0.1IMG BASE/ML)	A078262	001	Dec 31, 2007	May CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

>A>	AB	TWI PHARMS	EQ 1MG BASE	A216399	001	Jun 08, 2022	May NEWA
>A>	AB		EQ 2MG BASE	A216399	002	Jun 08, 2022	May NEWA
		TABLET, EXTENDED RELEASE; ORAL					
		GUANFACINE HYDROCHLORIDE					
>D>		@ YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May CMFD
>A>	AB		EQ 1MG BASE	A213428	001	Nov 25, 2020	May CMFD
>D>		@	EQ 2MG BASE	A213428	002	Nov 25, 2020	May CMFD
>A>	AB		EQ 2MG BASE	A213428	002	Nov 25, 2020	May CMFD
>D>		@	EQ 3MG BASE	A213428	003	Nov 25, 2020	May CMFD
>A>	AB		EQ 3MG BASE	A213428	003	Nov 25, 2020	May CMFD
>D>		@	EQ 4MG BASE	A213428	004	Nov 25, 2020	May CMFD
>A>	AB		EQ 4MG BASE	A213428	004	Nov 25, 2020	May CMFD

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB		SANDOZ	0.5MG	A071209	002	Nov 17, 1986	Mar CMS1
AB			1MG	A071209	003	Nov 17, 1986	Mar CMS1
		@	2MG	A071209	004	Nov 17, 1986	Mar CMS1

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

+!	B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992	Mar CTEC
	@ HOSPIRA	4,000 UNITS/100ML	N019805	001	Jan 25, 1989	Mar DISC
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ HOSPIRA	5,000 UNITS/100ML	N019805	002	Jan 25, 1989	Mar DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

AB	+!	AZURITY	37.5MG;20MG	N020727	001	Jun 23, 2005	Mar CFTG
	+!		37.5MG;20MG	N020727	001	Jun 23, 2005	Mar CAHN
		ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE					
AB		RICONPHARMA LLC	37.5MG;20MG	A215586	001	Apr 06, 2022	Mar NFTG

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	CHARTWELL RX	25MG	A087565	001	Mar 09, 1982	Feb CAHN
@		50MG	A084912	001		Feb CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

## TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ CHARTWELL RX 25MG; 40MG  
@ 25MG; 80MGA071060 001 Aug 26, 1987 Feb CAHN  
A071061 001 Aug 26, 1987 Jan CAHNHYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

## TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

>A>	@ LUPIN	12.5MG; EQ 10MG BASE	A076374	001	Mar 31, 2004	May DISC
>A>	@	12.5MG; EQ 20MG BASE	A076374	002	Mar 31, 2004	May DISC
>A>	@	25MG; EQ 20MG BASE	A076374	003	Mar 31, 2004	May DISC
QUINARETIC						
>D> AB	LUPIN	12.5MG; EQ 10MG BASE	A076374	001	Mar 31, 2004	May DISC
>D> AB		12.5MG; EQ 20MG BASE	A076374	002	Mar 31, 2004	May DISC
>D> AB		25MG; EQ 20MG BASE	A076374	003	Mar 31, 2004	May DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

## TABLET; ORAL

MAXZIDE

AB	+! AUROBINDO PHARMA USA	50MG; 75MG	N019129	001	Oct 22, 1984	Feb CAHN
	MAXZIDE-25					
AB	+ AUROBINDO PHARMA USA	25MG; 37.5MG	N019129	003	May 13, 1988	Feb CAHN
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
AB	RUBICON	25MG; 37.5MG	A216211	001	Feb 23, 2022	Feb NEWA
AB		50MG; 75MG	A216211	002	Feb 23, 2022	Feb NEWA

HYDROCODONE BITARTRATE

## TABLET, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

>A> AB	ALVOGEN	20MG	A208269	001	Mar 01, 2021	May CAHN
>A> AB		30MG	A208269	002	Mar 01, 2021	May CAHN
>A> AB		40MG	A208269	003	Mar 01, 2021	May CAHN
>A> AB		60MG	A208269	004	Mar 01, 2021	May CAHN
>A> AB		80MG	A208269	005	Mar 01, 2021	May CAHN
>A> AB		100MG	A208269	006	Mar 01, 2021	May CAHN
>A> AB		120MG	A208269	007	Mar 01, 2021	May CAHN
>D> AB	ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	May CAHN
>D> AB		30MG	A208269	002	Mar 01, 2021	May CAHN
>D> AB		40MG	A208269	003	Mar 01, 2021	May CAHN
>D> AB		60MG	A208269	004	Mar 01, 2021	May CAHN
>D> AB		80MG	A208269	005	Mar 01, 2021	May CAHN
>D> AB		100MG	A208269	006	Mar 01, 2021	May CAHN
>D> AB		120MG	A208269	007	Mar 01, 2021	May CAHN

HYDROXOCOBALAMIN

## INJECTABLE; INJECTION

CYANOKIT

@ BTG INTL 2.5GM/VIAL (5GM/KIT)  
+! 5GM/VIAL (5GM/KIT)N022041 002 Dec 15, 2006 Mar CAHN  
N022041 001 Apr 08, 2011 Mar CAHNHYDROXYCHLOROQUINE SULFATE

## TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

!	ACCORD HLTHCARE	400MG	A213342	004	Aug 18, 2021	Jan CHRS
!		400MG	A213342	004	Aug 18, 2021	Jan CHRS
>A> AB	AUROBINDO PHARMA USA	200MG	A040274	001	May 29, 1998	May CAHN
>D> AB	MYLAN	200MG	A040274	001	May 29, 1998	May CAHN
	+ NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022	Jan NEWA
	+!	300MG	N214581	002	Jan 14, 2022	Jan NEWA

HYDROXYZINE HYDROCHLORIDE

## SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM 10MG/5ML

A040391 001 Apr 10, 2002 Jan CAHN

## TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	@ AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May CMFD
>A> AB		10MG	A087871	002	Dec 20, 1982	May CMFD
>D>	@	25MG	A087871	003	Dec 20, 1982	May CMFD
>A> AB		25MG	A087871	003	Dec 20, 1982	May CMFD

TABLET;ORAL  
HYDROXYZINE HYDROCHLORIDE

>D>	@	50MG	A087871	001	Dec 20, 1982	May CMFD
>A> AB		50MG	A087871	001	Dec 20, 1982	May CMFD

IBUPROFEN

SUSPENSION;ORAL  
IBUPROFEN

>D>	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	May CTEC
>A> AB		100MG/5ML	A209178	001	Feb 16, 2018	May CTEC
>A> AB	STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	May NEWA

TABLET;ORAL  
IBUPROFEN

	@ SUNSHINE	400MG	A204062	001	Sep 10, 2018	Mar CAHN
	@	600MG	A204062	002	Sep 10, 2018	Mar CAHN
	@	800MG	A204062	003	Sep 10, 2018	Mar CAHN
AB	YICHANG HUMANWELL	400MG	A215318	001	Mar 30, 2022	Mar NEWA
AB		600MG	A215318	002	Mar 30, 2022	Mar NEWA
AB		800MG	A215318	003	Mar 30, 2022	Mar NEWA

ILOPERIDONE

TABLET;ORAL  
FANAPT

AB	+! VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Apr CTEC
AB	+	2MG	N022192	002	May 06, 2009	Apr CTEC
AB	+	4MG	N022192	003	May 06, 2009	Apr CTEC
AB	+	6MG	N022192	004	May 06, 2009	Apr CTEC
AB	+	8MG	N022192	005	May 06, 2009	Apr CTEC
AB	+	10MG	N022192	006	May 06, 2009	Apr CTEC
AB	+	12MG	N022192	007	May 06, 2009	Apr CTEC

## ILOPERIDONE

AB	LUPIN LTD	1MG	A206890	001	May 05, 2022	Apr NEWA
AB		2MG	A206890	002	May 05, 2022	Apr NEWA
AB		4MG	A206890	003	May 05, 2022	Apr NEWA
AB		6MG	A206890	004	May 05, 2022	Apr NEWA
AB		8MG	A206890	005	May 05, 2022	Apr NEWA
AB		10MG	A206890	006	May 05, 2022	Apr NEWA
AB		12MG	A206890	007	May 05, 2022	Apr NEWA

INDAPAMIDE

TABLET;ORAL  
INDAPAMIDE

	@ CHARTWELL RX	1.25MG	A074594	001	May 23, 1996	Feb CAHN
	@	2.5MG	A074594	002	May 23, 1996	Feb CAHN

IODIXANOL

## INJECTABLE;INJECTION

>A>	IODIXANOL					
>A> AP	HENGRIU PHARMA	55%	A214271	001	May 19, 2022	May NFTG
>A> AP		65.2%	A214271	002	May 19, 2022	May NFTG
	VISIPAQUE 270					
>D>	+! GE HEALTHCARE	55%	N020351	001	Mar 22, 1996	May CFTG
>A> AP	+!	55%	N020351	001	Mar 22, 1996	May CFTG
	VISIPAQUE 320					
>D>	+! GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996	May CFTG
>A> AP	+!	65.2%	N020351	002	Mar 22, 1996	May CFTG

IOFLUPANE I-123

SOLUTION;INTRAVENOUS  
DATSCAN

AP	+! GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011	Mar CFTG
	IOFLUPANE I-123					
AP	CURIUM	5mCi/2.5ML (2mCi/ML)	A213792	001	Mar 30, 2022	Mar NFTG

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION  
IRINOTECAN HYDROCHLORIDE

AP	EUGIA PHARMA	500MG/25ML (20MG/ML)	A213278	004	Apr 11, 2022	Apr NEWA
----	--------------	----------------------	---------	-----	--------------	----------

ISONIAZID

SYRUP;ORAL							
ISONIAZID							
@ CHARTWELL RX	50MG/5ML			A081118	001	Jul 21, 1997	Mar CAHN
TABLET;ORAL							
ISONIAZID							
AA MIKART	100MG			A040090	001	Jun 26, 1997	Mar CAHN
AA	300MG			A040090	002	Jun 26, 1997	Mar CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL							
ISOSORBIDE MONONITRATE							
AB SHANDONG	120MG			A214115	001	Apr 29, 2022	Apr NEWA
AB ZYDUS PHARMS	30MG			A075395	001	Mar 16, 2000	Mar CAHN
AB	60MG			A075395	002	Mar 16, 2000	Mar CAHN
AB	120MG			A075395	003	Mar 16, 2000	Mar CAHN

ITRACONAZOLE

CAPSULE;ORAL							
ITRACONAZOLE							
>D> AB JUBILANT GENERICS	100MG			A203445	001	Feb 23, 2017	May DISC
>A> @	100MG			A203445	001	Feb 23, 2017	May DISC

IVABRADINE HYDROCHLORIDE

TABLET;ORAL							
CORLANOR							
+ AMGEN INC	EQ 5MG BASE			N206143	001	Apr 15, 2015	Jan CTEC
+!	EQ 7.5MG BASE			N206143	002	Apr 15, 2015	Jan CTEC
IVABRADINE HYDROCHLORIDE							
@ CENTAUR PHARMS PVT	EQ 5MG BASE			A214051	001	Dec 30, 2021	Jan DISC
@	EQ 7.5MG BASE			A214051	002	Dec 30, 2021	Jan DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION							
KETOROLAC TROMETHAMINE							
@ STERISCIENCE	15MG/ML			A078299	001	Jul 16, 2007	Feb CAHN
@	15MG/ML			A201155	001	Aug 04, 2014	Feb CAHN
@	30MG/ML			A078299	002	Jul 16, 2007	Feb CAHN
@	30MG/ML			A201155	002	Aug 04, 2014	Feb CAHN
TABLET;ORAL							
KETOROLAC TROMETHAMINE							
AB HAVIX	10MG			A215788	001	Mar 23, 2022	Mar NEWA
AB SENORES PHARMS	10MG			A215788	001	Mar 23, 2022	Mar CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION							
OMIDRIA							
AT +! RAYNER SURGICAL	EQ 0.3% BASE;EQ 1% BASE			N205388	001	May 30, 2014	Feb CAHN

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS;OPHTHALMIC							
ACUVUE THERAVISION WITH KETOTIFEN							
+! JOHNSON JOHNSON VISN	EQ 19MCG BASE			N022388	001	Feb 25, 2022	Feb NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION							
LABETALOL HYDROCHLORIDE							
@ STERISCIENCE	5MG/ML			A079134	001	Feb 03, 2010	Feb CAHN

LACOSAMIDE

SOLUTION;INTRAVENOUS							
LACOSAMIDE							
AP FRESENIUS KABI USA	200MG/20ML (10MG/ML)			A214677	001	May 03, 2022	Apr NEWA
AP INDOCO	200MG/20ML (10MG/ML)			A214301	001	Apr 07, 2022	Apr NFTG
AP VIMPAT							
AP +! UCB INC	200MG/20ML (10MG/ML)			N022254	001	Oct 28, 2008	Apr CFTG
AP SOLUTION;ORAL							
>A> LACOSAMIDE							
>A> AA ALKEM LABS LTD	10MG/ML			A214672	001	May 19, 2022	May NFTG
>A> AA HETERO LABS LTD III	10MG/ML			A209301	001	May 31, 2022	May NEWA

	SOLUTION;ORAL VIMPAT							
>D>	+! UCB INC	10MG/ML	N 022255	001	Apr 20,	2010	May	CFTG
>A> AA	+!	10MG/ML	N 022255	001	Apr 20,	2010	May	CFTG
	TABLET;ORAL LACOSAMIDE							
AB	ALEMBIC PHARMS LTD	50MG	A 204974	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 204974	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 204974	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 204974	004	Mar 17,	2022	Mar	NFTG
AB	ALKEM LABS LTD	50MG	A 214695	001	Mar 31,	2022	Mar	NEWA
AB		100MG	A 214695	002	Mar 31,	2022	Mar	NEWA
AB		150MG	A 214695	003	Mar 31,	2022	Mar	NEWA
AB		200MG	A 214695	004	Mar 31,	2022	Mar	NEWA
AB	AMNEAL PHARMS	50MG	A 204857	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 204857	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 204857	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 204857	004	Mar 17,	2022	Mar	NFTG
AB	GLENMARK PHARMS LTD	50MG	A 205006	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 205006	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 205006	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 205006	004	Mar 17,	2022	Mar	NFTG
AB	HETERO LABS LTD V	50MG	A 204787	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 204787	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 204787	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 204787	004	Mar 17,	2022	Mar	NFTG
AB	INDOCO	50MG	A 208308	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 208308	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 208308	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 208308	004	Mar 17,	2022	Mar	NFTG
AB	MSN LABS PVT LTD	50MG	A 204921	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 204921	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 204921	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 204921	004	Mar 17,	2022	Mar	NFTG
AB	SCIEGEN PHARMS INC	50MG	A 205237	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 205237	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 205237	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 205237	004	Mar 17,	2022	Mar	NFTG
AB	SUN PHARM	50MG	A 205031	001	Mar 17,	2022	Mar	NFTG
AB		100MG	A 205031	002	Mar 17,	2022	Mar	NFTG
AB		150MG	A 205031	003	Mar 17,	2022	Mar	NFTG
AB		200MG	A 205031	004	Mar 17,	2022	Mar	NFTG
	VIMPAT							
AB	+ UCB INC	50MG	N 022253	001	Oct 28,	2008	Mar	CFTG
AB	+	100MG	N 022253	002	Oct 28,	2008	Mar	CFTG
AB	+	150MG	N 022253	003	Oct 28,	2008	Mar	CFTG
AB	+!	200MG	N 022253	004	Oct 28,	2008	Mar	CFTG

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL  
LAMIVUDINE AND ZIDOVUDINE  
© CHARTWELL RX 150MG;300MG A 079081 001 May 25, 2011 Mar CAHN

LAMOTRIGINE

TABLET, FOR SUSPENSION;ORAL  
LAMICTAL CD

AB	+ GLAXOSMITHKLINE LLC	2MG	N 020764	004	Sep 08,	2000	Jan	CDFR
AB	+	5MG	N 020764	001	Aug 24,	1998	Jan	CDFR
AB	+!	25MG	N 020764	002	Aug 24,	1998	Jan	CDFR
	@	100MG	N 020764	003	Aug 24,	1998	Jan	CDFR
	LAMOTRIGINE							
AB	ALEMBIC PHARMS LTD	5MG	A 201168	001	Jun 12,	2014	Jan	CDFR
AB		25MG	A 201168	002	Jun 12,	2014	Jan	CDFR
AB	AUROBINDO PHARMA	5MG	A 090401	002	Nov 04,	2009	Jan	CDFR
AB		25MG	A 090401	003	Nov 04,	2009	Jan	CDFR
AB	DR REDDYS LABS LTD	5MG	A 076701	001	Jan 22,	2009	Jan	CDFR
AB		25MG	A 076701	002	Jan 22,	2009	Jan	CDFR
AB	GLENMARK PHARMS LTD	5MG	A 079099	001	Feb 19,	2009	Jan	CDFR
AB		25MG	A 079099	002	Feb 19,	2009	Jan	CDFR
	@ JUBILANT GENERICS	5MG	A 200220	001	Feb 28,	2011	Jan	CDFR
	@	25MG	A 200220	002	Feb 28,	2011	Jan	CDFR
	@ MYLAN	5MG	A 076630	001	Jan 22,	2009	Jan	CDFR
	@	25MG	A 076630	002	Jan 22,	2009	Jan	CDFR

## TABLET, FOR SUSPENSION;ORAL

## LAMOTRIGINE

	@ SANDOZ	5MG	A078409	002	Jan 22, 2009	Jan CDFR
	@	25MG	A078409	003	Jan 22, 2009	Jan CDFR
AB	TARO	5MG	A079204	001	Feb 04, 2009	Jan CDFR
AB		25MG	A079204	002	Feb 04, 2009	Jan CDFR
	@ TEVA	5MG	A076420	001	Jun 21, 2006	Jan CDFR
	@	25MG	A076420	002	Jun 21, 2006	Jan CDFR
AB	WATSON LABS	2MG	A076928	001	Jan 22, 2009	Jan CDFR
AB		5MG	A076928	002	Jan 22, 2009	Jan CDFR
AB		25MG	A076928	003	Jan 22, 2009	Jan CDFR
AB	ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009	Jan CDFR
AB		25MG	A078009	003	Jan 22, 2009	Jan CDFR

## TABLET, ORALLY DISINTEGRATING;ORAL

## LAMOTRIGINE

AB	AMRING PHARMS	25MG	A214124	001	Feb 03, 2022	Jan NEWA
AB		50MG	A214124	002	Feb 03, 2022	Jan NEWA
AB		100MG	A214124	003	Feb 03, 2022	Jan NEWA
AB		200MG	A214124	004	Feb 03, 2022	Jan NEWA

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL  
LANSOPRAZOLE

AB	ATLANTIDE	15MG	A202176	001	Sep 14, 2012	Apr CAHN
AB		30MG	A202176	002	Sep 14, 2012	Apr CAHN

LANTHANUM CARBONATETABLET, CHEWABLE;ORAL  
LANTHANUM CARBONATE

AB	BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan NEWA
AB		EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan NEWA
AB		EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan NEWA
AB	INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan NEWA
AB		EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan NEWA
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan NEWA

LEFLUNOMIDETABLET;ORAL  
LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan CMFD
AB		20MG	A213497	002	May 10, 2021	Jan CMFD

LEUPROLIDE ACETATEFOR SUSPENSION;INTRAMUSCULAR  
LUTRATE DEPOT KIT

>D>	+ @ GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	May CMFD
>A>	+!	22.5MG/VIAL	N205054	001	Aug 28, 2018	May CMFD
	INJECTABLE;INJECTION LEUPROLIDE ACETATE					

>A> AP	EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	May NEWA
--------	--------------	-----------	---------	-----	--------------	----------

LEUPROLIDE MESYLATEEMULSION;SUBCUTANEOUS  
CAMCEVI KIT  
+! ACCORD

EQ 42MG BASE

N211488 001 May 25, 2021 Jan CAHN

LEVETIRACETAMINJECTABLE;INTRAVENOUS  
LEVETIRACETAM

AP	PRINSTON INC	500MG/5ML (100MG/ML)	A209474	001	Mar 28, 2022	Mar NEWA

## SOLUTION;ORAL

## LEVETIRACETAM

	@ WOCKHARDT BIO AG	100MG/ML	A090028	001	Mar 03, 2010	Apr DISC

## TABLET;ORAL

## LEVETIRACETAM

	ALKEM LABS LTD	250MG	A216375	001	May 27, 2022	May NEWA

## 500MG

		750MG	A216375	003	May 27, 2022	May NEWA

## 1GM

	LOTUS PHARM CO LTD	500MG	A090906	001	Nov 05, 2010	Apr DISC

## @ LOTUS PHARM CO LTD

	SCIEGEN PHARMS INC	250MG	A215069	003	May 27, 2022	May NEWA

## 500MG

		500MG	A215069	004	May 27, 2022	May NEWA
--	--	-------	---------	-----	--------------	----------

TABLET;ORAL

LEVETIRACETAM

@ SECAN PHARMS

500MG

A205102 004 Dec 16, 2015

Jan DISC

@

1GM

A205102 003 Dec 16, 2015

Jan DISC

AB STALLION LABS

250MG

A079042 001 Jan 15, 2009

Mar CAHN

AB

500MG

A079042 002 Jan 15, 2009

Mar CAHN

AB

750MG

A079042 003 Jan 15, 2009

Mar CAHN

AB

1GM

A079042 004 Jan 15, 2009

Mar CAHN

LEVOSETIRIZINE DIHYDROCHLORIDESOLUTION;ORAL

XYZAL

+ @ CHATTEM SANOFI

2.5MG/5ML

N022157 001 Jan 28, 2008

Jan CAHN

TABLET;ORAL

XYZAL

+ @ CHATTEM SANOFI

5MG

N022064 001 May 25, 2007

Jan CAHN

LEVOFLOXACINTABLET;ORAL

LEVOFLOXACIN

AB CHARTWELL MOLECULAR

250MG

A076890 001 Mar 30, 2012

Mar CAHN

AB

500MG

A076890 002 Mar 30, 2012

Mar CAHN

AB

750MG

A076890 003 Mar 30, 2012

Mar CAHN

LEVOLEUCOVORIN CALCIUMSOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

@ PRAXGEN

EQ 175MG BASE/17.5ML (EQ 10MG  
BASE/ML)

A213797 001 Nov 02, 2021

Feb DISC

LEVONORGESTRELTABLET;ORAL

LEVONORGESTREL

&gt;D&gt; ! L PERRIGO CO

0.75MG

A090740 001 Dec 30, 2010

May DISC

&gt;A&gt;

0.75MG

A090740 001 Dec 30, 2010

May DISC

LEVOOTHYROXINE SODIUMCAPSULE;ORAL

LEVOOTHYROXINE SODIUM

@ TEVA PHARMS USA INC

0.112MG

A211369 003 Apr 16, 2021

Jan DISC

TIROSINT

+ INSTITUT BIOCHIMIQUE

0.112MG

N021924 008 Oct 02, 2009

Jan CTEC

SOLUTION;ORAL

ERMEZA

+! MYLAN

150MCG/5ML

N215809 001 Apr 29, 2022

Apr NEWA

LEVOOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

AB1, GENUS LIFESCIENCES

0.025MG

N021137 001 Jun 06, 2003

Jan CMFD

AB3,

0.05MG

N021137 002 Jun 06, 2003

Jan CMFD

AB4

0.075MG

N021137 003 Jun 06, 2003

Jan CMFD

AB1,

0.088MG

N021137 004 Jun 06, 2003

Jan CMFD

AB3,

0.1MG

N021137 005 Jun 06, 2003

Jan CMFD

AB4

0.112MG

N021137 006 Jun 06, 2003

Jan CMFD

AB1,

0.125MG

N021137 007 Jun 06, 2003

Jan CMFD

AB3,

0.137MG

N021137 008 Jun 06, 2003

Jan CMFD

AB4

0.15MG

N021137 009 Jun 06, 2003

Jan CMFD

AB1,

TABLET;ORAL LEVOLET					
AB3, AB4	0.175MG	N 021137	010	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.2MG	N 021137	011	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.3MG	N 021137	012	Jun 06, 2003	Jan CMFD
AB4					
LEVOTHYROXINE SODIUM					
AB1, WATSON LABS TEVA	0.025MG	A 207588	001	May 10, 2022	Apr NEWA
AB2	0.05MG	A 207588	002	May 10, 2022	Apr NEWA
AB1, AB2	0.075MG	A 207588	003	May 10, 2022	Apr NEWA
AB1, AB2	0.088MG	A 207588	004	May 10, 2022	Apr NEWA
AB1, AB2	0.1MG	A 207588	005	May 10, 2022	Apr NEWA
AB1, AB2	0.112MG	A 207588	006	May 10, 2022	Apr NEWA
AB1, AB2	0.125MG	A 207588	007	May 10, 2022	Apr NEWA
AB1, AB2	0.137MG	A 207588	008	May 10, 2022	Apr NEWA
AB1, AB2	0.15MG	A 207588	009	May 10, 2022	Apr NEWA
AB1, AB2	0.175MG	A 207588	010	May 10, 2022	Apr NEWA
AB1, AB2	0.2MG	A 207588	011	May 10, 2022	Apr NEWA
AB1, AB2	0.3MG	A 207588	012	May 10, 2022	Apr NEWA
AB2					
THYRO-TABS					
AB1, + ALVOGEN	0.025MG	N 021116	001	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.05MG	N 021116	002	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.075MG	N 021116	003	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.088MG	N 021116	010	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.1MG	N 021116	004	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.112MG	N 021116	011	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.125MG	N 021116	005	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.137MG	N 021116	012	Dec 07, 2004	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.15MG	N 021116	006	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.175MG	N 021116	007	Oct 24, 2002	Apr CTEC
AB2,					
AB3,					
AB4					
AB1, +	0.2MG	N 021116	008	Oct 24, 2002	Apr CTEC
AB2,					

TABLET;ORAL  
THYRO-TABS

AB3,					
AB4					
AB1, +	0.3MG		N 021116	009	Oct 24, 2002
AB2,					Apr CTEC
AB3,					
AB4					

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC					
AKTEN					
+! THEA PHARMA	3.5%		N 022221	001	Oct 07, 2008
INJECTABLE;INJECTION					Apr CAHN
LIDOCAINE HYDROCHLORIDE					
AP SINTETICA SA	4%		A 214269	001	May 05, 2022
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					Apr NEWA
AP ! HOSPIRA	4%		A 088295	001	May 17, 1984
SOLUTION;TOPICAL					Apr CTEC
LIDOCAINE HYDROCHLORIDE					
AT NOVITIUM PHARMA	4%		A 216250	001	Mar 23, 2022
					Mar NEWA

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL					
LIDOCAINE AND PRILOCAINE					
@ ACRUX DDS PTY	2.5%;2.5%		A 212482	001	Jul 27, 2021
ALEOR DERMACEUTICALS	2.5%;2.5%		A 213923	001	Apr 08, 2022
					Jan DISC
					Apr NEWA

LINEZOLID

SOLUTION;INTRAVENOUS					
LINEZOLID					
>D> AP HOSPIRA INC	600MG/300ML (2MG/ML)		A 205442	001	Jul 07, 2015
>A>	@ 600MG/300ML (2MG/ML)		A 205442	001	Jul 07, 2015
					May DISC
					May DISC

LISINOPRIL

TABLET;ORAL					
LISINOPRIL					
@ GRAVITI PHARMS	2.5MG		A 075999	001	Jul 01, 2002
@	5MG		A 075999	002	Jul 01, 2002
@	10MG		A 075999	003	Jul 01, 2002
@	20MG		A 075999	004	Jul 01, 2002
@	30MG		A 075999	005	Jul 01, 2002
@	40MG		A 075999	006	Jul 01, 2002
@ STRIDES PHARMA	2.5MG		A 076071	001	Jul 01, 2002
@	5MG		A 076071	002	Jul 01, 2002
@	10MG		A 076071	003	Jul 01, 2002
@	20MG		A 076071	004	Jul 01, 2002
@	30MG		A 076071	005	Jul 01, 2002
@	40MG		A 076071	006	Jul 01, 2002
PRINIVIL					
@ MERCK	5MG		N 019558	001	Dec 29, 1987
@	40MG		N 019558	004	Oct 25, 1988
					Mar DISC
					Mar DISC

LITHIUM CITRATE

SYRUP;ORAL					
LITHIUM CITRATE					
+ @ HIKMA	EQ 300MG CARBONATE/5ML		N 018421	001	
! PAJ HOLDINGS PHARM	EQ 300MG CARBONATE/5ML		A 070755	001	May 21, 1986
! WOCKHARDT BIO AG	EQ 300MG CARBONATE/5ML		A 070755	001	May 21, 1986
AA !	EQ 300MG CARBONATE/5ML		A 070755	001	May 21, 1986
					Apr CTEC
					Apr CHRS

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL					
LOPERAMIDE HYDROCHLORIDE					
@ CHARTWELL RX	2MG		A 072993	001	Aug 28, 1992
					Mar CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL					
LOPINAVIR AND RITONAVIR					
AB LAURUS	100MG;25MG		A 213857	001	Mar 21, 2022
AB	200MG;50MG		A 213857	002	Mar 21, 2022
					Mar NEWA
					Mar NEWA

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL  
LOREEV XR  
+ ALMATICHA 1.5MG N214826 004 Feb 16, 2022 Feb NEWA

LUBIPROSTONE

CAPSULE;ORAL  
LUBIPROSTONE  
>D> AB AMNEAL 8MCG A209450 001 Nov 30, 2021 May DISC  
>A> @ 8MCG A209450 001 Nov 30, 2021 May DISC  
>D> AB 24MCG A209450 002 Nov 30, 2021 May DISC  
>A> @ 24MCG A209450 002 Nov 30, 2021 May DISC  
AB DR REDDYS 8MCG A206994 001 Feb 08, 2022 Jan NEWA  
AB 24MCG A206994 002 Feb 08, 2022 Jan NEWA  
AB TEVA PHARMS USA INC 8MCG A209920 001 Jan 18, 2022 Jan NEWA  
AB 24MCG A209920 002 Jan 18, 2022 Jan NEWA

LUMATEPERONE TOSYLATE

CAPSULE;ORAL  
CAPLYTA  
>A> + INTRA-CELLULAR EQ 10.5MG BASE N209500 002 Apr 22, 2022 May NEWA  
>A> + EQ 21MG BASE N209500 003 Apr 22, 2022 May NEWA

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

SOLUTION;INTRAVENOUS  
PLUVICTO  
+! AAA USA NOVARTIS 27mCi/ML N215833 001 Mar 23, 2022 Mar NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL  
MAFENIDE ACETATE  
AT ! PAR FORM 5% A201511 001 Feb 12, 2013 Feb CHRS  
SULFAMYLYON  
+ @ MYLAN INSTITUTIONAL 5% N019832 003 Jun 05, 1998 Feb DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION  
>A> KABILYTE  
>A> AP FRESENIUS KABI USA 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML A215371 001 Jun 08, 2022 May NFTG  
PLASMA-LYTE A IN PLASTIC CONTAINER  
>D> +! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N017378 002 Nov 22, 1982 May CFTG  
>A> AP +! 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N017378 002 Nov 22, 1982 May CFTG

MARAVIROC

TABLET;ORAL  
MARAVIROC  
AB HETERO LABS LTD III 150MG A203347 001 Feb 07, 2022 Jan NFTG  
AB 300MG A203347 002 Feb 07, 2022 Jan NFTG  
SELZENTRY  
AB + VIIV HLTHCARE 150MG N022128 001 Aug 06, 2007 Jan CFTG  
AB +! 300MG N022128 002 Aug 06, 2007 Jan CFTG

MAVACAMTEN

CAPSULE;ORAL  
CAMZYOS  
+ MYOKARDIA 2.5MG N214998 001 Apr 28, 2022 Apr NEWA  
+ 5MG N214998 002 Apr 28, 2022 Apr NEWA  
+ 10MG N214998 003 Apr 28, 2022 Apr NEWA  
+! 15MG N214998 004 Apr 28, 2022 Apr NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL  
MECLIZINE HYDROCHLORIDE  
AA APNAR PHARMA LP 12.5MG A087128 002 Apr CAHN  
AA 25MG A087128 001 Apr CAHN  
AA INVAGEN PHARMS 12.5MG A200432 001 Feb 17, 2022 Feb NEWA  
AA 25MG A200432 002 Feb 17, 2022 Feb NEWA  
AA 50MG A200432 003 Feb 17, 2022 Feb NEWA

	TABLET, CHEWABLE;ORAL MECLIZINE HYDROCHLORIDE				
AA	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022
	<u>MELOXICAM</u>				Feb NEWA
	CAPSULE;ORAL VIVLODEX				
	+ @ ICEUTICA OPERATIONS	5MG	N207233	001	Oct 22, 2015
	+ @	10MG	N207233	002	Oct 22, 2015
	SUSPENSION;ORAL MELOXICAM				Mar CAHN
>A>	+! AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004
>D>	MOBIC				May CTNA
>D>	+ @ AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004
	<u>MELPHALAN HYDROCHLORIDE</u>				May CTNA
	INJECTABLE;INJECTION MELPHALAN HYDROCHLORIDE				
	@ NANJING	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019
	<u>MEMANTINE HYDROCHLORIDE</u>				Apr CAHN
	CAPSULE, EXTENDED RELEASE;ORAL MEMANTINE HYDROCHLORIDE				
	@ ANI PHARMS	14MG	A205365	002	Feb 28, 2020
	TABLET;ORAL MEMANTINE HYDROCHLORIDE				Apr DISC
AB	ALLIED	5MG	A209527	001	May 07, 2018
AB		10MG	A209527	002	May 07, 2018
	@ RISING	5MG	A079225	001	Jan 30, 2015
	@	10MG	A079225	002	Jan 30, 2015
	<u>MEPERIDINE HYDROCHLORIDE</u>				Jan CAHN
	TABLET;ORAL MEPERIDINE HYDROCHLORIDE				
	@ GENUS	50MG	A040893	001	Jun 24, 2009
	@	75MG	A040893	002	Jun 24, 2009
	@	100MG	A040893	003	Jun 24, 2009
	@	150MG	A040893	004	Jun 24, 2009
	@ MIKART	50MG	A040893	001	Jun 24, 2009
	@	75MG	A040893	002	Jun 24, 2009
	@	100MG	A040893	003	Jun 24, 2009
	@	150MG	A040893	004	Jun 24, 2009
	<u>MESALAMINE</u>				Mar CAHN
	CAPSULE, EXTENDED RELEASE;ORAL MESALAMINE				
AB	SUN PHARM	500MG	A214585	001	May 11, 2022
AB	TEVA PHARMS USA	375MG	A209970	001	May 06, 2022
	PENTASA				Apr NEWA
AB	+! TAKEDA PHARMS USA	500MG	N020049	002	Jul 08, 2004
	TABLET, DELAYED RELEASE;ORAL ASACOL HD				Apr CFTG
>D>	+! APIL	800MG	N021830	001	May 29, 2008
>D> AB	+ @	800MG	N021830	001	May 29, 2008
>A>	MESALAMINE				May DISC
>D> AB	ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017
>A>	!	800MG	A203286	001	Jul 21, 2017
	<u>METFORMIN HYDROCHLORIDE</u>				May CTEC
	TABLET, EXTENDED RELEASE;ORAL METFORMIN HYDROCHLORIDE				
AB1	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008
AB		750MG	A078596	002	Jan 03, 2008
	@ AMTA	500MG	A213394	001	Aug 03, 2021
	@	1GM	A213394	002	Aug 03, 2021
AB2	SCIEGEN PHARMS INC	500MG	A214629	001	Feb 22, 2022
AB2		1GM	A214629	002	Feb 22, 2022

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

>D>	AB	+ TAKEDA PHARMS USA	500MG; EQ 15MG BASE	N021842	001	Aug 29, 2005	May DISC
>A>		+ @	500MG; EQ 15MG BASE	N021842	001	Aug 29, 2005	May DISC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

@	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Feb DISC
@		10MG	A210484	002	Aug 02, 2018	Feb DISC

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB		BAUSCH AND LOMB INC	25MG	A207438	001	Oct 05, 2018	Apr CAHN
AB			50MG	A207438	002	Oct 05, 2018	Apr CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

AB		+ VALIDUS PHARMS	1GM	N017681	001		Apr CMFD
----	--	------------------	-----	---------	-----	--	----------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE LPF

+ @	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan CRLD
+ @	HOSPIRA	METHOTREXATE PRESERVATIVE FREE				
+ @	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan CRLD
+ @		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan CRLD
	METHOTREXATE SODIUM					
+ @	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan CRLD
+ @		EQ 20MG BASE/VIAL	N011719	001		Jan CRLD
+ @		EQ 25MG BASE/ML	N011719	005		Jan CRLD
+ @		EQ 50MG BASE/VIAL	N011719	003		Jan CRLD
+ @		EQ 100MG BASE/VIAL	N011719	006		Jan CRLD
	METHOTREXATE SODIUM PRESERVATIVE FREE					
@	EUGIA PHARMA SPEC LTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar CAHN
@		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar CAHN
@		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar CAHN
@		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar CAHN
AP	HIKMA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jan CHRS
+ @	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988	Jan CRLD
+ @	MEXATE-AQ					
+ @	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan CRLD

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

AB		+ NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar CFTG
AB		+	15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar CFTG
AB		+	20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar CFTG
AB		+ !	30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar CFTG
	METHYLPHENIDATE						
AB		MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	A206497	001	Mar 14, 2022	Mar NFTG
AB			15MG/9HR (1.6MG/HR)	A206497	002	Mar 14, 2022	Mar NFTG
AB			20MG/9HR (2.2MG/HR)	A206497	003	Mar 14, 2022	Mar NFTG
AB			30MG/9HR (3.3MG/HR)	A206497	004	Mar 14, 2022	Mar NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

>A>	AB2	+ AYTU BIOPHARMA	10MG	N021259	003	May 27, 2003	May CAHN
>A>	AB2	+	20MG	N021259	001	Apr 03, 2001	May CAHN
>A>	AB2	+	30MG	N021259	002	Jun 19, 2003	May CAHN
>A>	AB2	+	40MG	N021259	004	Feb 19, 2006	May CAHN
>A>	AB2	+	50MG	N021259	005	Feb 19, 2006	May CAHN

CAPSULE, EXTENDED RELEASE;ORAL  
METADATE CD

>A> AB2	+!	60MG	N 021259	006	Feb 19, 2006	May CAHN
>D> AB2	+	LANNETT CO INC 10MG	N 021259	003	May 27, 2003	May CAHN
>D> AB2	+	20MG	N 021259	001	Apr 03, 2001	May CAHN
>D> AB2	+	30MG	N 021259	002	Jun 19, 2003	May CAHN
>D> AB2	+	40MG	N 021259	004	Feb 19, 2006	May CAHN
>D> AB2	+	50MG	N 021259	005	Feb 19, 2006	May CAHN
>D> AB2	+!	60MG	N 021259	006	Feb 19, 2006	May CAHN

TABLET, EXTENDED RELEASE;ORAL  
METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL	72MG	A 076655	002	Feb 28, 2022	Feb NEWA
AB	! OSMOTICA	72MG	A 205327	005	Jul 28, 2017	Feb CTEC
>A> AB	RHODES PHARMS	18MG	A 214111	001	May 31, 2022	May NEWA
>A> AB		27MG	A 214111	002	May 31, 2022	May NEWA
>A> AB		36MG	A 214111	003	May 31, 2022	May NEWA
>A> AB		54MG	A 214111	004	May 31, 2022	May NEWA

METHYLPREDNISOLONE

TABLET;ORAL  
METHYLPREDNISOLONE

@ AMNEAL	4MG	A 207481	001	Sep 21, 2021	Mar DISC
@	8MG	A 207481	002	Sep 21, 2021	Mar DISC
@	16MG	A 207481	003	Sep 21, 2021	Mar DISC
@	32MG	A 207481	004	Sep 21, 2021	Mar DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION  
METHYLPREDNISOLONE ACETATE

AB	PAR STERILE PRODUCTS	40MG/ML	A 214297	001	Jan 21, 2022	Jan NEWA
AB		80MG/ML	A 214297	002	Jan 21, 2022	Jan NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION  
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A 212396	001	Apr 20, 2021	Jan CMFD
AP		EQ 125MG BASE/VIAL	A 212396	002	Apr 20, 2021	Jan CMFD
AP		EQ 500MG BASE/VIAL	A 212396	003	Apr 20, 2021	Jan CMFD
AP		EQ 1GM BASE/VIAL	A 212396	004	Apr 20, 2021	Jan CMFD
AP		EQ 2GM BASE/VIAL	A 212396	005	Apr 20, 2021	Jan CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL  
METHYLTESTOSTERONE

AB	! IMPAX LABS INC	10MG	A 204851	001	Sep 21, 2015	Feb CTEC
AB	NOVITIUM PHARMA	10MG	A 215270	001	Feb 18, 2022	Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION  
REGLAN

+ @ HIKMA	EQ 5MG BASE/ML	N 017862	001		Jan CRLD
-----------	----------------	----------	-----	--	----------

TABLET;ORAL  
METOCLOPRAMIDE HYDROCHLORIDE

@ CHARTWELL RX	EQ 5MG BASE	A 074478	001	Oct 05, 1995	Mar CAHN
@	EQ 10MG BASE	A 072215	001	Jan 30, 1990	Mar CAHN
@	EQ 10MG BASE	A 074478	002	Oct 05, 1995	Mar CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION  
METOPROLOL TARTRATE

@ STERISCIENCE	1MG/ML	A 090317	001	Apr 19, 2010	Feb CAHN
----------------	--------	----------	-----	--------------	----------

TABLET;ORAL  
METOPROLOL TARTRATE

@ CHARTWELL RX	50MG	A 073288	001	Mar 25, 1994	Mar CAHN
@	100MG	A 073289	001	Mar 25, 1994	Mar CAHN

METRONIDAZOLE

GEL;VAGINAL  
METRONIDAZOLE

AB	GLENMARK PHARMS LTD	0.75%	A 215794	001	Jan 27, 2022	Jan NEWA
----	---------------------	-------	----------	-----	--------------	----------

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER  
@ RISING 500MG/100ML

A205531 001 May 09, 2017 Jan CAHN

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@ STERISCIENCE EQ 1MG BASE/ML  
@ EQ 5MG BASE/ML

A090315 001 Nov 29, 2010 Jan CAHN  
A090315 002 Nov 29, 2010 Jan CAHN

MIDOZALAM HYDROCHLORIDE

@ STERISCIENCE EQ 1MG BASE/ML  
@ EQ 5MG BASE/ML

A090316 001 May 04, 2011 Feb CAHN  
A090316 002 May 04, 2011 Feb CAHN

SOLUTION; INTRAMUSCULAR

SEIZALAM

>D> +! MERIDIAN MEDCL TECHN EQ 50MG BASE/10ML (EQ 5MG BASE/ML) N209566 001 Sep 14, 2018 May CAHN  
>A> +! MMT EQ 50MG BASE/10ML (EQ 5MG BASE/ML) N209566 001 Sep 14, 2018 May CAHN

MIGLUSTATCAPSULE; ORAL

MIGLUSTAT

AB BRECKENRIDGE 100MG A209325 001 Feb 03, 2022 Jan NEWA

MINOCYCLINE HYDROCHLORIDEAEROSOL, FOAM; TOPICAL

AMZEEQ

+! JOURNEY EQ 4% BASE

N212379 001 Oct 18, 2019 Jan CAHN

ZILXI

+! JOURNEY EQ 1.5% BASE

N213690 001 May 28, 2020 Jan CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

>A> AB BEXIMCO PHARMS USA EQ 50MG BASE A215466 001 May 27, 2022 May NEWA  
>A> AB EQ 75MG BASE A215466 002 May 27, 2022 May NEWA  
>A> AB EQ 100MG BASE A215466 003 May 27, 2022 May NEWA

MIRTAZAPINETABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB SQUARE PHARMS 15MG A205798 001 Jun 01, 2017 Jan CAHN  
AB 30MG A205798 002 Jun 01, 2017 Jan CAHN  
AB 45MG A205798 003 Jun 01, 2017 Jan CAHN

MISOPROSTOLTABLET; ORAL

CYTOTEC

AB + PFIZER 0.1MG N019268 003 Sep 21, 1990 Mar CTEC  
AB +! 0.2MG N019268 001 Dec 27, 1988 Mar CTEC  
MISOPROSTOL  
AB ANI PHARMS 0.1MG A076095 001 Jul 10, 2002 Mar CMFD  
AB 0.2MG A076095 002 Jul 10, 2002 Mar CMFD

MITAPIVAT SULFATETABLET; ORAL

PYRUKYND

+ AGIOS PHARMS INC EQ 5MG BASE N216196 001 Feb 17, 2022 Feb NEWA  
+ EQ 20MG BASE N216196 002 Feb 17, 2022 Feb NEWA  
+! EQ 50MG BASE N216196 003 Feb 17, 2022 Feb NEWA

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDESPRAY, METERED; NASAL

RYALTRIS

+! GLENMARK SPECIALTY

0.025MG/SPRAY; 0.665MG/SPRAY

N211746 001 Jan 13, 2022 Jan NEWA

MONTELUKAST SODIUMGRANULE; ORAL

SINGULAIR

AB +! ORGANON EQ 4MG BASE/PACKET N021409 001 Jul 26, 2002 Mar CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

@ NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jan DISC
@	30MG	A203158	002	Aug 04, 2021	Jan DISC
@	50MG	A203158	003	Aug 04, 2021	Jan DISC
@	60MG	A203158	004	Aug 04, 2021	Jan DISC
@	80MG	A203158	005	Aug 04, 2021	Jan DISC
@	100MG	A203158	006	Aug 04, 2021	Jan DISC

INJECTABLE; INJECTION  
MORPHINE SULFATE

>D>	+ @ HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	May CMFD
>A>	+!	50MG/ML	N202515	006	Apr 29, 2021	May CMFD
	+ @	50MG/ML	N202515	006	Apr 29, 2021	Jan DISC
	INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Jan CMFD

TABLET;ORAL  
MORPHINE SULFATE

AB	@ RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Feb DISC
		15MG	A215584	001	Feb 07, 2022	Jan NEWA
AB	@	30MG	A215584	002	Feb 07, 2022	Feb DISC
		30MG	A215584	002	Feb 07, 2022	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

	@ NESHER PHARMS	30MG	A076720	002	Dec 23, 2005	Mar DISC
	@	60MG	A076720	001	May 19, 2004	Mar DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT1	INDOCO	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Apr CAHN
-----	--------	--------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL  
MYCOPHENOLATE MOFETIL

AB	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan NEWA
----	-----------------	----------	---------	-----	--------------	----------

NAFCILLIN SODIUM

INJECTABLE;INJECTION  
NAFCILLIN SODIUM

@ STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Feb CAHN
@	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Feb CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION  
REVEX

+ @ EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CPOT
+ @	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CPOT

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
NALMEFENE HYDROCHLORIDE

! PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jan NEWA
REVEX					
+ @ EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CDFR
+ @	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CDFR

NALOXONE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS  
NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

>D>	+! KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	May DISC
>A>	+ @	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	May DISC
	+!	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	Feb NEWA

NANDROLONE DECANOATE

INJECTABLE;INJECTION  
DECA-DURABOLIN

@ WOODWARD SPECL	50MG/ML	N013132	001	Jun 12, 1986	Apr CAHN
@	100MG/ML	N013132	002	Jun 12, 1986	Apr CAHN
+ @	200MG/ML	N013132	003	Jun 12, 1986	Apr CAHN

NAPROXEN

SUSPENSION;ORAL

NAPROXEN

&gt;A&gt; AB HETERO LABS LTD III 25MG/ML

A215776 001 Jun 07, 2022 May NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Mar NEWA
AB		EQ 5MG BASE	A213349	002	Mar 31, 2022	Mar NEWA
AB		EQ 10MG BASE	A213349	003	Mar 31, 2022	Mar NEWA
AB		EQ 20MG BASE	A213349	004	Mar 31, 2022	Mar NEWA
AB	PRINSTON INC	EQ 2.5MG BASE	A212682	001	Apr 07, 2022	Apr NEWA
AB		EQ 5MG BASE	A212682	002	Apr 07, 2022	Apr NEWA
AB		EQ 10MG BASE	A212682	003	Apr 07, 2022	Apr NEWA
AB		EQ 20MG BASE	A212682	004	Apr 07, 2022	Apr NEWA
>D> AB	REYOUNG	EQ 2.5MG BASE	A212917	001	Dec 17, 2021	May CAHN
>A> AB		EQ 2.5MG BASE	A212917	001	Dec 17, 2021	May CAHN
>D> AB		EQ 5MG BASE	A212917	002	Dec 17, 2021	May CAHN
>A> AB		EQ 5MG BASE	A212917	002	Dec 17, 2021	May CAHN
>D> AB		EQ 10MG BASE	A212917	003	Dec 17, 2021	May CAHN
>A> AB		EQ 10MG BASE	A212917	003	Dec 17, 2021	May CAHN
>D> AB		EQ 20MG BASE	A212917	004	Dec 17, 2021	May CAHN
>A> AB		EQ 20MG BASE	A212917	004	Dec 17, 2021	May CAHN
AB	UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Mar NEWA
AB		EQ 5MG BASE	A213830	002	Mar 15, 2022	Mar NEWA
AB		EQ 10MG BASE	A213830	003	Mar 15, 2022	Mar NEWA
AB		EQ 20MG BASE	A213830	004	Mar 15, 2022	Mar NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

@ AM REGENT 5MG/10ML (0.5MG/ML)  
@ 10MG/10ML (1MG/ML)A209182 001 May 04, 2018 Apr DISC  
A209182 002 May 04, 2018 Apr DISCNIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

>D> AB	BEIJING	500MG	A214428	001	Nov 22, 2021	May DISC
>A>	@	500MG	A214428	001	Nov 22, 2021	May DISC
>D> AB		1GM	A214428	002	Nov 22, 2021	May DISC
>A>	@	1GM	A214428	002	Nov 22, 2021	May DISC
AB	MACLEODS PHARMS LTD	500MG	A204934	001	Mar 03, 2022	Feb NEWA
AB		1GM	A204934	002	Mar 03, 2022	Feb NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

+! HIKMA INTL PHARMS 25MG/10ML (2.5MG/ML)

N022276 001 Jul 24, 2008 Apr CAHN

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+! HIKMA INTL PHARMS 20MG/200ML (0.1MG/ML)

N022276 002 Apr 07, 2016 Apr CAHN

+! 40MG/200ML (0.2MG/ML)

N022276 003 Apr 07, 2016 Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2	ALKEM LABS LTD	30MG	A216067	001	Mar 29, 2022	Mar NEWA
AB2		60MG	A216067	002	Mar 29, 2022	Mar NEWA
AB2		90MG	A216067	003	Mar 29, 2022	Mar NEWA

NIMODIPINE

SOLUTION;ORAL

NYMALIZE

+ @ AZURITY 3MG/ML

N203340 001 May 10, 2013 Mar CAHN

+! 6MG/ML

N203340 002 Apr 08, 2020 Mar CAHN

NITISINONE

CAPSULE;ORAL						
NITISINONE						
>A> AB	DIPHARMA	2MG	A212390	001	May 26, 2022	May NEWA
>A> AB		5MG	A212390	002	May 26, 2022	May NEWA
>A> AB		10MG	A212390	003	May 26, 2022	May NEWA

NITRIC OXIDE

GAS; INHALATION						
NOXIVENT						
AA	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr CAHN
		800PPM	A207141	002	Oct 02, 2018	Apr CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL						
NITROFURANTOIN						
AB	@ AUROBINDO PHARMA USA	100MG	A077025	001	Aug 18, 2004	Apr CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL						
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)						
AB	INVENTIA	75MG;25MG	A211013	001	Feb 18, 2022	Feb NEWA

NITROGLYCERIN

TABLET; SUBLINGUAL						
NITROGLYCERIN						
AB	ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022	Feb NEWA
AB		0.4MG	A210153	002	Mar 08, 2022	Feb NEWA
AB		0.6MG	A210153	003	Mar 08, 2022	Feb NEWA
NITROSTAT						
AB	VIATRIS	0.3MG	N021134	001	May 01, 2000	Jan CAHN
AB	+	0.4MG	N021134	002	May 01, 2000	Jan CAHN
AB	+!	0.6MG	N021134	003	May 01, 2000	Jan CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL						
NORTRIPTYLINE HYDROCHLORIDE						
AB	@ AUROBINDO PHARMA LTD	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
AB	@	EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
AB	@	EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
AB	@	EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN

NYSTATIN

SUSPENSION;ORAL						
NILSTAT						
+	@ GLENMARK PHARMS LTD	100,000 UNITS/ML	N050299	001		Apr CAHN
NYSTATIN						
AA	MEDLEY PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Feb NEWA
>A> AA	VISTAPHARM	100,000 UNITS/ML	A064142	002	Mar 07, 2011	May CMS1

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL						
NYSTATIN AND TRIAMCINOLONE ACETONIDE						
AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214186	001	Mar 04, 2022	Feb NEWA

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL						
MYCAPSSA						
+! AMRYT		EQ 20MG BASE	N208232	001	Jun 26, 2020	Jan CAHN
INJECTABLE;INJECTION						
OCTREOTIDE ACETATE						
AP	HERITAGE PHARMS	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr CMFD
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr CMFD
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Apr CMFD
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr CMFD
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Apr CMFD

OFLOXACIN

SOLUTION/DROPS;OTIC

OFLOXACIN

AT FDC LTD 0.3% A215038 001 Jan 19, 2022 Jan NEWA

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	CHARTWELL MOLECULAR	2.5MG	A203333	001	Mar 15, 2016	Mar CAHN
AB		5MG	A203333	002	Mar 15, 2016	Mar CAHN
AB		7.5MG	A203333	003	Mar 15, 2016	Mar CAHN
AB		10MG	A203333	004	Mar 15, 2016	Mar CAHN
AB		15MG	A203333	005	Mar 15, 2016	Mar CAHN
AB		20MG	A203333	006	Mar 15, 2016	Mar CAHN
TABLET, ORALLY DISINTEGRATING;ORAL						
OLANZAPINE						
AB	CHARTWELL MOLECULAR	5MG	A203456	001	Mar 16, 2016	Mar CAHN
AB		10MG	A203456	002	Mar 16, 2016	Mar CAHN
AB		15MG	A203456	003	Mar 16, 2016	Mar CAHN
AB		20MG	A203456	004	Mar 16, 2016	Mar CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

@ STRIDES PHARMA	10MG	A075876	001	May 29, 2003	Jan CAHN
@	20MG	A075876	002	May 29, 2003	Jan CAHN
@	40MG	A075876	003	Jan 21, 2009	Jan CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006	Apr CMFD
AB		8MG	A077406	004	Dec 26, 2006	Apr CMFD
		16MG	A077406	001	Dec 26, 2006	Apr CMFD
		24MG	A077406	002	Dec 26, 2006	Apr CMFD

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	ATLANTIDE	EQ 2MG BASE/ML	A077577	001	Dec 26, 2006	Mar CAHN
	@ STERISCIENCE	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Feb CAHN
AP	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	ATLANTIDE	EQ 2MG BASE/ML	A077716	001	Dec 26, 2006	Mar CAHN
	@ STERISCIENCE	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Feb CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@ AUROBINDO PHARMA	EQ 24MG BASE	A078539	003	Jul 31, 2007	Feb DISC
@ CASI PHARMS INC	EQ 24MG BASE	A077517	003	Jun 25, 2007	Feb DISC
>D> @ CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25, 2007	May CMFD
>A> AB	EQ 4MG BASE	A077303	001	Jun 25, 2007	May CMFD
>D> @	EQ 8MG BASE	A077303	002	Jun 25, 2007	May CMFD
>A> AB	EQ 8MG BASE	A077303	002	Jun 25, 2007	May CMFD
>D> @	EQ 24MG BASE	A077303	004	Jun 25, 2007	May CMFD
>A> AB !	EQ 24MG BASE	A077303	004	Jun 25, 2007	May CMFD
>D> AB !	EQ 16MG BASE	A076183	004	Dec 26, 2006	Mar DISC
>A> AB !	EQ 24MG BASE	A076183	001	Dec 26, 2006	Feb DISC
>D> AB ! GLENMARK GENERICS	EQ 8MG BASE	A077535	002	Jun 25, 2007	May CHRS
>A> AB !	EQ 8MG BASE	A077535	002	Jun 25, 2007	May CHRS
AB !	EQ 8MG BASE	A077535	002	Jun 25, 2007	Feb CHRS
@	EQ 24MG BASE	A077535	003	Jun 25, 2007	Feb DISC
@ TEVA	EQ 4MG BASE	A076252	001	Jun 25, 2007	Feb DISC
@	EQ 8MG BASE	A076252	002	Jun 25, 2007	Feb DISC
@	EQ 24MG BASE	A076252	003	Jun 25, 2007	Feb DISC
ZOFRAN					
+ @ NOVARTIS	EQ 4MG BASE	N020103	001	Dec 31, 1992	Feb DISC
+ @	EQ 8MG BASE	N020103	002	Dec 31, 1992	Feb DISC
+ @	EQ 24MG BASE	N020103	003	Aug 27, 1999	Feb DISC

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

>A>	AB	ALVOGEN	EQ 6MG BASE/ML	A208823	001	Oct 31, 2017	May CAHN
>D>	AB	ALVOGEN PINE BROOK	EQ 6MG BASE/ML	A208823	001	Oct 31, 2017	May CAHN
	@	APTAPHARMA INC	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Mar DISC
AB		HETERO LABS LTD V	EQ 6MG BASE/ML	A209590	001	Mar 28, 2022	Mar NEWA
AB		LEADING PHARMA LLC	EQ 6MG BASE/ML	A214949	001	Feb 28, 2022	Feb NEWA
AB		MSN	EQ 6MG BASE/ML	A215313	001	May 02, 2022	Apr NEWA
AB		STRIDES PHARMA	EQ 6MG BASE/ML	A211894	001	Jan 13, 2022	Jan NEWA

OTESECONAZOLE

CAPSULE;ORAL

VIVJOA

+! MYCOVIA PHARMS

150MG

N215888

001 Apr 26, 2022

Apr NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

@ STERISCIENCE

@

EQ 1GM BASE/VIAL

A091486

001 Aug 25, 2014

Feb CAHN

EQ 2GM BASE/VIAL

A091486

002 Aug 25, 2014

Feb CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

@ CHARTWELL MOLECULAR

@

50MG/10ML (5MG/ML)

A208523

001 Feb 10, 2017

Mar CAHN

100MG/20ML (5MG/ML)

A208523

002 Feb 10, 2017

Mar CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB UNITED RES LABS

10MG

A071026

002 Aug 10, 1987

Apr CAHN

AB

15MG

A071026

003 Aug 10, 1987

Apr CAHN

AB

30MG

A071026

001 Aug 10, 1987

Apr CAHN

SERAX

+ @ ALPHARMA US PHARMS

10MG

N015539

002

Jan CRLD

+ @

15MG

N015539

004

Jan CRLD

+ @

30MG

N015539

006

Jan CRLD

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

@ CHARTWELL RX

5MG/5ML

A075039

001 Jan 29, 1999

Mar CAHN

AA

! LANNETT CO INC

5MG/5ML

A074520

001 Mar 29, 1996

Mar CHRS

@ WOCKHARDT BIO AG

5MG/5ML

A074868

001 Feb 12, 1997

Mar DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@ NOVEL LABS INC

100MG/5ML

A204603

001 Apr 29, 2015

Feb DISC

@ WOCKHARDT BIO AG

5MG/5ML

A206456

001 Jun 16, 2015

Apr DISC

TABLET;ORAL

ROXYBOND

PROTEGA PHARMS

5MG

N209777

001 Apr 20, 2017

Mar CMFD

@

5MG

N209777

001 Apr 20, 2017

Feb CAHN

@

15MG

N209777

002 Apr 20, 2017

Mar CMFD

@

15MG

N209777

002 Apr 20, 2017

Feb CAHN

@

30MG

N209777

003 Apr 20, 2017

Mar CMFD

@

30MG

N209777

003 Apr 20, 2017

Feb CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP

GLAND PHARMA LTD

6MG/ML

A207326

001 Aug 23, 2016

Feb CTNA

PACRITINIB CITRATE

CAPSULE;ORAL

VONJO

+! CTI BIOPHARMA CORP

EQ 100MG BASE

N208712

001 Feb 28, 2022

Feb NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jan DISC
@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jan DISC

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

>A> AP	ASPIRO	EQ 40MG BASE/VIAL	A213778	001	May 18, 2022	May NEWA
>A> AP	BE PHARMS	EQ 40MG BASE/VIAL	A216171	001	May 18, 2022	May NEWA
>A> AP	GLAND PHARMA LTD	EQ 40MG BASE/VIAL	A204400	001	May 18, 2022	May NEWA
>A> AP	KNACK	EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	May NEWA

PARICALCITOL

SOLUTION; INTRAVENOUS

PARICALCITOL

@ RISING	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Mar DISC
----------	-------------------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

+ @ APOTEX	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
+ @	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
+ @	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
+ @	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION; ORAL

PAXIL

AB +! APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
--------------	------------------	---------	-----	--------------	----------

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB CHARTWELL RX	EQ 10MG BASE	A076618	001	Aug 15, 2005	Mar CAHN
AB	EQ 20MG BASE	A076618	002	Aug 15, 2005	Mar CAHN
AB	EQ 30MG BASE	A076618	003	Aug 15, 2005	Mar CAHN
AB	EQ 40MG BASE	A076618	004	Aug 15, 2005	Mar CAHN

PAXIL

AB + APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb CAHN
AB +	EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb CAHN
AB +	EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb CAHN
AB +!	EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb CAHN
AB @	EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

@ SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan DISC
@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan DISC
AB > A B	EQ 37.5MG BASE	A213612	003	May 26, 2022	May NEWA

PAXIL CR

AB + APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB +	EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB +!	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PEMETREXED

SOLUTION; INTRAVENOUS

PEMETREXED

>D> + @ ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	May CMFD
>A> +!	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	May CMFD
>D> + @	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	May CMFD
>A> +!	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	May CMFD
>D> + @	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	May CMFD
>A> +!	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	May CMFD

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

ALIMTA

>D> +! LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	May CFTG
>A> AP +!	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	May CFTG
>D> +!	EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	May CFTG
>A> AP +!	EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	May CFTG

POWDER; INTRAVENOUS

>A>	PEMETREXED DISODIUM						
>A> AP	ACCORD HLTHCARE	EQ 100MG BASE/VIAL	A203485	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A203485	002	May 25, 2022	May NFTG	
>A> AP		EQ 1GM BASE/VIAL	A203485	003	May 25, 2022	May NEWA	
>A> AP	APOTEX	EQ 100MG BASE/VIAL	A203774	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A203774	002	May 25, 2022	May NFTG	
>A> AP		EQ 750MG BASE/VIAL	A209851	001	May 25, 2022	May NEWA	
>A> AP		EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	May NEWA	
>A> AP	BIOCON PHARMA	EQ 1GM BASE/VIAL	A211090	001	May 25, 2022	May NEWA	
>A> AP	DR REDDYS	EQ 100MG BASE/VIAL	A202596	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A202596	002	May 25, 2022	May NFTG	
>A> AP		EQ 1GM BASE/VIAL	A202596	003	May 25, 2022	May NEWA	
>A> AP	EUGIA PHARMA	EQ 100MG BASE/VIAL	A214632	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A214632	002	May 25, 2022	May NFTG	
>A> AP		EQ 1GM BASE/VIAL	A214632	003	May 25, 2022	May NEWA	
>A> AP	FRESENIUS KABI USA	EQ 100MG BASE/VIAL	A090384	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A090384	002	May 25, 2022	May NFTG	
>A> AP	!	EQ 750MG BASE/VIAL	A090384	003	May 25, 2022	May NEWA	
>A> AP	!	EQ 1GM BASE/VIAL	A090384	004	May 25, 2022	May NEWA	
>A> AP	HOSPIRA	EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	May NFTG	
>A> AP		EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	May NEWA	
>A> AP	JIANGSU HANSOH PHARM	EQ 100MG BASE/VIAL	A208696	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A208696	002	May 25, 2022	May NFTG	
>A> AP	NANG KUANG PHARM CO	EQ 100MG BASE/VIAL	A207352	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A207352	002	May 25, 2022	May NFTG	
>A> AP	QILU PHARM HAINAN	EQ 100MG BASE/VIAL	A204890	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A204890	002	May 25, 2022	May NFTG	
>A> AP	WAVERLEY PHARMA INC	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	May NFTG	
>A> AP	ZYDUS PHARMS	EQ 100MG BASE/VIAL	A214073	001	May 25, 2022	May NFTG	
>A> AP		EQ 500MG BASE/VIAL	A214073	002	May 25, 2022	May NFTG	
>A> AP		EQ 1GM BASE/VIAL	A214073	003	May 25, 2022	May NEWA	

SOLUTION; INTRAVENOUSPEMETREXED

>A>	+! SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	May NEWA
>A>	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	May NEWA
>A>	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	May NEWA

PENTAMIDINE ISETHIONATEINJECTABLE; INJECTIONPENTAMIDINE ISETHIONATE

AP	XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022	Mar NEWA
----	-------------	------------	---------	-----	--------------	----------

PERPHENAZINETABLET; ORALPERPHENAZINE

>A> AB	APPCO	2MG	A210163	001	May 18, 2022	May NEWA
>A> AB		4MG	A210163	002	May 18, 2022	May NEWA
>A> AB		8MG	A210163	003	May 18, 2022	May NEWA
>A> AB		16MG	A210163	004	May 18, 2022	May NEWA
	@ MYLAN	2MG	A206691	001	Apr 14, 2017	Mar DISC
	@	4MG	A206691	002	Apr 14, 2017	Mar DISC
	@	8MG	A206691	003	Apr 14, 2017	Mar DISC
	@	16MG	A206691	004	Apr 14, 2017	Mar DISC

PHENDIMETRAZINE TARTRATETABLET; ORALPHENDIMETRAZINE TARTRATE

AA	CHARTWELL	35MG	A089452	001	Oct 30, 1991	Apr CAHN
----	-----------	------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDECAPSULE; ORALPHENTERMINE HYDROCHLORIDE

AA	+! SANDOZ	30MG	A087190	001		Feb CRLD
----	-----------	------	---------	-----	--	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Feb CMFD
AP1		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Feb CMFD
AP1		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Feb CMFD
@ PAR STERILE PRODUCTS		10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Jan DISC

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

AB	+! VIATRIS	125MG/5ML	N008762	001		Feb CAHN
	DILANTIN-30					
	@ VIATRIS	30MG/5ML	N008762	002		Feb CAHN
	PHENYTOIN					
AB	PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Apr CAHN
>A> AB	VISTAPHARM	125MG/5ML	A040342	002	Aug 18, 2005	May CMS1

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

+!	VIATRIS	30MG EXTENDED	A084349	001		Feb CAHN
AB	+!	100MG EXTENDED	A084349	002		Feb CAHN

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

AB2	! CIPLA	1MG/0.5ML	A212424	001	Apr 22, 2022	Apr NFTG
AB2		1MG/0.5ML	A214596	001	Apr 22, 2022	Apr NFTG
AB2	!	10MG/ML	A212424	002	Apr 22, 2022	Apr NFTG
AB2		10MG/ML	A214596	002	Apr 22, 2022	Apr NFTG
AB1	DR REDDYS	10MG/ML	A207719	001	May 22, 2019	Apr CTEC
	VITAMIN K1					
AB1	+! HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	Apr CTEC

PILOCARPINE HYDROCHLORIDESOLUTION; OPHTHALMIC  
ISOPTO CARPINE

>D> AT	+ NOVARTIS	1%	N200890	001	Jun 22, 2010	May CHRS
>A> AT	+!	1%	N200890	001	Jun 22, 2010	May CHRS
>D> AT	+	2%	N200890	002	Jun 22, 2010	May CHRS
>A> AT	+!	2%	N200890	002	Jun 22, 2010	May CHRS

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE; INJECTION  
PIPERACILLIN AND TAZOBACTAM

>D>	@ STERISCIENCE	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	May CMFD
>A> AP		EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	May CMFD
	@	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Feb CAHN
>D>	@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	May CMFD
>A> AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	May CMFD
	@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Feb CAHN
>D>	@	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	May CMFD
>A> AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	May CMFD
	@	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Feb CAHN

PIRFENIDONECAPSULE; ORAL  
PIRFENIDONE

AB	ACCORD HLTHCARE	267MG	A212731	001	Jan 20, 2022	Jan NEWA
>D>	@ AMNEAL	267MG	A212569	001	Jan 03, 2022	May CMFD
>A> AB		267MG	A212569	001	Jan 03, 2022	May CMFD
	@	267MG	A212569	001	Jan 03, 2022	Jan DISC

TABLET;ORAL  
ESBRIET

AB	+ GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan CFTG
AB	+! PIRFENIDONE	801MG	N208780	003	Jan 11, 2017	Jan CFTG
AB	ACCORD HLTHCARE	267MG	A212730	001	Jan 25, 2022	Jan NFTG
AB		801MG	A212730	002	Jan 25, 2022	Jan NFTG
>A> AB	ALEMBIC PHARMS LTD	267MG	A212708	001	May 20, 2022	May NEWA
>A> AB		801MG	A212708	002	May 20, 2022	May NEWA
AB	AMNEAL	267MG	A212570	001	Mar 25, 2022	Mar NEWA
AB		801MG	A212570	002	Mar 25, 2022	Mar NEWA
>A> AB	MICRO LABS	267MG	A212680	001	May 18, 2022	May NEWA
>A> AB		801MG	A212680	002	May 18, 2022	May NEWA
>A> AB	MSN	267MG	A212772	001	May 24, 2022	May NEWA
>A> AB		801MG	A212772	002	May 24, 2022	May NEWA
AB	SANDOZ INC	267MG	A212560	001	Apr 28, 2022	Apr NEWA
AB		801MG	A212560	002	Apr 28, 2022	Apr NEWA
AB	TEVA PHARMS USA	267MG	A212759	001	Jan 25, 2022	Jan NFTG
AB		801MG	A212759	002	Jan 25, 2022	Jan NFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

## FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

@ NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090019	001	May 27, 2009	Feb DISC
------------------	---	---------	-----	--------------	----------

POMALIDOMIDE

## CAPSULE;ORAL

## POMALIDOMIDE

AB	@ MYLAN	1MG	A210275	001	Jan 26, 2022	Feb CAHN
AB	@	1MG	A210275	001	Jan 26, 2022	Feb DISC
AB	@	1MG	A210275	001	Jan 26, 2022	Jan NEWA
AB	@	2MG	A210275	002	Jan 26, 2022	Feb CAHN
AB	@	2MG	A210275	002	Jan 26, 2022	Feb DISC
AB	@	2MG	A210275	002	Jan 26, 2022	Jan NEWA
AB	@	3MG	A210275	003	Jan 26, 2022	Feb CAHN
AB	@	3MG	A210275	003	Jan 26, 2022	Feb DISC
AB	@	3MG	A210275	003	Jan 26, 2022	Jan NEWA
AB	@	4MG	A210275	004	Jan 26, 2022	Feb CAHN
AB	@	4MG	A210275	004	Jan 26, 2022	Feb DISC
AB	TEVA PHARMS USA	4MG	A210275	004	Jan 26, 2022	Jan NEWA
AB		1MG	A209956	001	May 04, 2022	Apr NEWA
AB		2MG	A209956	002	May 04, 2022	Apr NEWA
AB		3MG	A209956	003	May 04, 2022	Apr NEWA
AB		4MG	A209956	004	May 04, 2022	Apr NEWA
AB	POMALYST					
AB	+ CELGENE	1MG	N204026	001	Feb 08, 2013	Apr CTEC
AB	+	1MG	N204026	001	Feb 08, 2013	Feb CTEC
AB	+	1MG	N204026	001	Feb 08, 2013	Jan CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Apr CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Feb CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Jan CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Apr CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Feb CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Jan CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Apr CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Jan CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Apr CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Feb CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Jan CTEC

POSACONAZOLE

## FOR SUSPENSION, DELAYED RELEASE;ORAL

## NOXAFIL POWDERMIX KIT

	+ @ MSD MERCK CO	300MG	N214770	001	May 31, 2021	Jan DISC
	SOLUTION;INTRAVENOUS					
	NOXAFIL					
>D>	+! MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	May CFTG
>A> AP	+!	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	May CFTG
>A>	POSACONAZOLE					
>A> AP	PAR STERILE PRODUCTS	300MG/16.7ML (18MG/ML)	A208768	001	May 25, 2022	May NFTG
	TABLET, DELAYED RELEASE;ORAL					
	POSACONAZOLE					
AB	BIOCON PHARMA	100MG	A214476	001	Feb 04, 2022	Jan NEWA
AB	DR REDDYS	100MG	A212500	001	Apr 07, 2022	Apr NEWA

## TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

AB	SPECGX LLC	100MG	A212226	001	May 10, 2022	Apr NEWA
<u>POTASSIUM ACETATE</u>						
	INJECTABLE; INJECTION					
POTASSIUM ACETATE						
	@ EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Mar DISC
<u>POTASSIUM CHLORIDE</u>						
CAPSULE, EXTENDED RELEASE;ORAL						
POTASSIUM CHLORIDE						
>D> AB	@ LANNETT CO INC	8MEQ	A204210	001	Mar 28, 2016	Mar DISC
>A>	@	10MEQ	A204210	002	Mar 28, 2016	Mar DISC
>D> AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	May DISC
>A>	@	8MEQ	A201944	001	Mar 04, 2016	May DISC
>D> AB		10MEQ	A201944	002	Mar 04, 2016	May DISC
>A>	@	10MEQ	A201944	002	Mar 04, 2016	May DISC
FOR SOLUTION;ORAL						
POTASSIUM CHLORIDE						
AA	GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jan NEWA
AA	RUBICON	20MEQ	A214108	001	Mar 24, 2022	Mar NEWA
INJECTABLE; INJECTION						
POTASSIUM CHLORIDE						
+ @ FRESENIUS KABI USA	2MEQ/ML		A080225	001		Mar DISC
POTASSIUM CHLORIDE 10MEQ						
AP	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar CMFD
AP		746MG/100ML	A211087	002	Sep 09, 2020	Mar CMFD
POTASSIUM CHLORIDE 20MEQ						
AP	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar CMFD
AP		1.49GM/100ML	A211087	005	May 07, 2021	Mar CMFD
POTASSIUM CHLORIDE 40MEQ						
AP	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar CMFD
SOLUTION;ORAL						
POTASSIUM CHLORIDE						
AA	RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022	Jan NEWA
AA		40MEQ/15ML	A214656	002	Jan 13, 2022	Jan NEWA
AA	@ TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022	Apr DISC
AA		20MEQ/15ML	A214076	001	Jan 26, 2022	Jan NEWA
AA	@	40MEQ/15ML	A214076	002	Jan 26, 2022	Apr DISC
AA		40MEQ/15ML	A214076	002	Jan 26, 2022	Jan NEWA
>A> AA	WES PHARMA INC	20MEQ/15ML	A213062	001	Jun 06, 2022	May NEWA
>A> AA		40MEQ/15ML	A213062	002	Jun 06, 2022	May NEWA
TABLET, EXTENDED RELEASE;ORAL						
K-TAB						
+ @ ABBVIE	8MEQ		N018279	002	Aug 01, 1988	Mar DISC
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>						
TABLET;ORAL						
MIRAPEX						
+ @ BOEHRINGER INGELHEIM	0.125MG		N020667	001	Jul 01, 1997	Mar DISC
+ @	0.25MG		N020667	002	Jul 01, 1997	Mar DISC
+ @	0.5MG		N020667	006	Feb 12, 1998	Mar DISC
+ @	0.75MG		N020667	007	Jul 30, 2007	Mar DISC
+ @	1MG		N020667	003	Jul 01, 1997	Mar DISC
+ @	1.5MG		N020667	005	Jul 01, 1997	Mar DISC
PRAMIPEXOLE DIHYDROCHLORIDE						
AB	! GLENMARK GENERICS	0.25MG	A090781	002	Oct 08, 2010	Mar CHRS
TABLET, EXTENDED RELEASE;ORAL						
PRAMIPEXOLE DIHYDROCHLORIDE						
AB	ALEMBIC PHARMS LTD	0.375MG	A204518	001	Jan 02, 2019	Apr CMFD
AB		0.75MG	A204518	002	Jan 02, 2019	Apr CMFD
AB		1.5MG	A204518	003	Jan 02, 2019	Apr CMFD
AB		2.25MG	A204518	004	Jan 02, 2019	Apr CMFD
AB		3MG	A204518	005	Jan 02, 2019	Apr CMFD
AB		3.75MG	A204518	006	Jan 02, 2019	Apr CMFD
AB		4.5MG	A204518	007	Jan 02, 2019	Apr CMFD
AB	NOVAST LABS	0.375MG	A213444	001	Feb 03, 2022	Jan NEWA
AB		0.75MG	A213444	002	Feb 03, 2022	Jan NEWA
AB		1.5MG	A213444	003	Feb 03, 2022	Jan NEWA
AB		2.25MG	A213444	004	Feb 03, 2022	Jan NEWA
AB		3MG	A213444	005	Feb 03, 2022	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

AB		3.75MG	A213444	006	Feb 03, 2022	Jan NEWA
AB		4.5MG	A213444	007	Feb 03, 2022	Jan NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL  
PRASUGREL  
@ USPHARMA WINDLAS EQ 5MG BASE  
@ EQ 10MG BASE

A205790	001	Oct 16, 2017	Apr DISC
A205790	002	Oct 16, 2017	Apr DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL  
PRAZOSIN HYDROCHLORIDE  
@ ANI PHARMS EQ 5MG BASE

A072577	003	May 16, 1989	Feb DISC
---------	-----	--------------	----------

PREDNISOLONE

TABLET;ORAL  
PREDNISOLONE  
+! WATSON LABS 5MG

A080354	001		Mar CRLD
---------	-----	--	----------

PREDNISONE

SOLUTION;ORAL  
PREDNISONE  
>D> ! HIKMA 5MG/5ML  
>A> +! 5MG/5ML  
TABLET;ORAL  
PREDNISONE  
AB AUROBINDO PHARMA LTD 2.5MG  
AB 5MG  
AB 10MG  
AB 20MG  
AB 50MG

A088703	001	Nov 08, 1984	May CRLD
A088703	001	Nov 08, 1984	May CRLD
A215672	001	Mar 28, 2022	Mar NEWA
A215672	002	Mar 28, 2022	Mar NEWA
A215672	003	Mar 28, 2022	Mar NEWA
A215672	004	Mar 28, 2022	Mar NEWA
A215672	005	Mar 28, 2022	Mar NEWA

PREGABALIN

CAPSULE;ORAL  
PREGABALIN  
AB ALLIED 50MG  
AB 75MG  
AB 100MG  
AB 150MG  
AB 200MG  
AB 300MG  
AB ESKAYEF 25MG  
AB 50MG  
AB 75MG  
AB 100MG  
AB 150MG  
AB 200MG  
AB 225MG  
AB 300MG  
AB LUPIN LTD 25MG  
AB 50MG  
AB 75MG  
AB 100MG  
AB 150MG  
AB 200MG  
AB 225MG  
AB 300MG

A210585	001	Dec 26, 2019	Feb CAHN
A210585	002	Dec 26, 2019	Feb CAHN
A210585	003	Dec 26, 2019	Feb CAHN
A210585	004	Dec 26, 2019	Feb CAHN
A210585	005	Dec 26, 2019	Feb CAHN
A210585	006	Dec 26, 2019	Feb CAHN
A212988	001	Mar 08, 2022	Feb NEWA
A212988	002	Mar 08, 2022	Feb NEWA
A212988	003	Mar 08, 2022	Feb NEWA
A212988	004	Mar 08, 2022	Feb NEWA
A212988	005	Mar 08, 2022	Feb NEWA
A212988	006	Mar 08, 2022	Feb NEWA
A212988	007	Mar 08, 2022	Feb NEWA
A212988	008	Mar 08, 2022	Feb NEWA
A091040	001	May 03, 2022	Apr NEWA
A091040	002	May 03, 2022	Apr NEWA
A091040	003	May 03, 2022	Apr NEWA
A091040	004	May 03, 2022	Apr NEWA
A091040	005	May 03, 2022	Apr NEWA
A091040	006	May 03, 2022	Apr NEWA
A091040	007	May 03, 2022	Apr NEWA
A091040	008	May 03, 2022	Apr NEWA

SOLUTION;ORAL  
PREGABALIN

AA	INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb NEWA
----	----------	---------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL  
PREGABALIN

AB	@ MYLAN	82.5MG	A211948	001	Apr 13, 2021	Mar DISC
AB	@	82.5MG	A211948	001	Apr 13, 2021	Mar CAHN
AB	RUBICON	165MG	A211967	001	Nov 04, 2021	Mar DISC
AB		82.5MG	A215249	001	Mar 22, 2022	Mar NEWA
AB		165MG	A215249	002	Mar 22, 2022	Mar NEWA
AB		330MG	A215249	003	Mar 22, 2022	Mar NEWA

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

@ ATLANTIDE	25MG/ML	A040785	001	Sep 26, 2008	Mar CAHN
@	50MG/ML	A040785	002	Sep 26, 2008	Mar CAHN
AP +! WEST-WARD PHARMS INT	25MG/ML	A083312	001		Apr CRLD
AP +!	50MG/ML	A083312	002		Apr CRLD

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

@ ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Feb DISC
@ CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000	Mar CAHN
AP ! HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	Feb CTEC
SOLUTION; ORAL					
PROPRANOLOL HYDROCHLORIDE					
@ PAI HOLDINGS PHARM	20MG/5ML	A071984	001	Mar 03, 1989	Apr CAHN
@	40MG/5ML	A071985	001	Mar 03, 1989	Apr CAHN
TABLET; ORAL					
PROPRANOLOL HYDROCHLORIDE					
@ CHARTWELL RX	10MG	A070663	001	Jun 13, 1986	Mar CAHN
@	20MG	A070664	001	Jun 13, 1986	Mar CAHN
@	40MG	A070665	001	Jun 13, 1986	Mar CAHN
@	60MG	A070666	001	Oct 10, 1986	Mar CAHN
@	80MG	A070667	001	Jun 13, 1986	Mar CAHN

PYRIDOSTIGMINE BROMIDE

SYRUP; ORAL

PYRIDOSTIGMINE BROMIDE

AA MILLA PHARMS	60MG/5ML	A212405	001	Apr 19, 2022	Apr NEWA
-----------------	----------	---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

AB PRINSTON INC	EQ 50MG BASE	A208781	001	Apr 26, 2022	Apr NEWA
AB	EQ 150MG BASE	A208781	002	Apr 26, 2022	Apr NEWA
AB	EQ 200MG BASE	A208781	003	Apr 26, 2022	Apr NEWA
AB	EQ 300MG BASE	A208781	004	Apr 26, 2022	Apr NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@ CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Mar CAHN
@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Mar CAHN
@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Mar CAHN
@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Mar CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

@ EYWA	324MG	A212589	001	Sep 17, 2021	Mar DISC
! SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Mar CTEC

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ CHARTWELL RX	1.25MG	A077514	001	Jun 18, 2008	Mar CAHN
@	2.5MG	A077514	002	Jun 18, 2008	Mar CAHN
@	5MG	A077514	003	Jun 18, 2008	Mar CAHN
@	10MG	A077514	004	Jun 18, 2008	Mar CAHN

RANOLAZINE

GRANULES, EXTENDED RELEASE; ORAL

ASPRUZYO SPRINKLE

+ SPIL	500MG	N216018	001	Feb 28, 2022	Mar CAHN
+!	1GM	N216018	002	Feb 28, 2022	Mar CAHN
+ SUN PHARMA GLOBAL	500MG	N216018	001	Feb 28, 2022	Feb NEWA
+!	1GM	N216018	002	Feb 28, 2022	Feb NEWA

## TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB	HETERO LABS LTD III	500MG	A212788	001	May 05, 2022	Apr NEWA
AB		1GM	A212788	002	May 05, 2022	Apr NEWA
AB	I3 PHARMS	500MG	A213517	001	Apr 27, 2022	Apr NEWA
AB		1GM	A213517	002	Apr 27, 2022	Apr NEWA
AB	VKT PHARMA	500MG	A214035	001	Jan 19, 2022	Jan NEWA
AB		1GM	A214035	002	Jan 19, 2022	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@ DR REDDYS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Jan DISC
@	EQ 1MG BASE	A201942	002	Nov 18, 2021	Jan DISC

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

AP	+! ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008	Apr CFTG
AP	ACCORD HLTHCARE	0.4MG/5ML (0.08MG/ML)	A213236	001	Apr 11, 2022	Apr NFTG
AP	APOTEX	0.4MG/5ML (0.08MG/ML)	A207604	001	Apr 11, 2022	Apr NFTG
AP	DR REDDYS	0.4MG/5ML (0.08MG/ML)	A213210	001	Apr 11, 2022	Apr NFTG
AP	HONG KONG	0.4MG/5ML (0.08MG/ML)	A212806	001	Apr 11, 2022	Apr NFTG
>A> AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	May CMS1

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

@ ATLANTIDE	1MGM/ML	A078744	001	Oct 08, 2009	Apr CAHN
>A> @ CHARTWELL MOLECULAR	1MGM/ML	A202386	001	Jan 12, 2015	May CAHN
>D> AA LANNETT CO INC	1MGM/ML	A079158	001	Dec 03, 2010	May CAHN
>A> AA	1MGM/ML	A079158	001	Dec 03, 2010	May CAHN
>D> @	1MGM/ML	A202386	001	Jan 12, 2015	May CAHN

RITONAVIR

TABLET;ORAL

RITONAVIR

AB	CIPPLA	100MG	A202573	001	Jan 15, 2015	Mar CAHN
AB		100MG	A203759	001	May 10, 2022	Apr NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

>A> AB CREEKWOOD PHARMS	EQ 5MG BASE	A202047	001	Dec 31, 2012	May CAHN
>A> AB	EQ 10MG BASE	A202047	002	Dec 31, 2012	May CAHN
>D> AB JUBILANT GENERICS	EQ 5MG BASE	A203252	001	Dec 31, 2014	May DISC
>A> @	EQ 5MG BASE	A203252	001	Dec 31, 2014	May DISC
>D> AB	EQ 10MG BASE	A203252	002	Dec 31, 2014	May DISC
>A> @	EQ 10MG BASE	A203252	002	Dec 31, 2014	May DISC
>D> AB PHARMA LIFE	EQ 5MG BASE	A202047	001	Dec 31, 2012	May CAHN
>D> AB	EQ 10MG BASE	A202047	002	Dec 31, 2012	May CAHN

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

>A> AP PRINSTON INC	50MG/5ML (10MG/ML)	A212668	001	May 26, 2022	May NEWA
>A> AP	100MG/10ML (10MG/ML)	A212668	002	May 26, 2022	May NEWA

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB	PRINSTON INC	500MCG	A208299	001	May 10, 2022	Apr NEWA
AB	ZYDUS PHARMS	500MCG	A208303	001	Feb 10, 2022	Feb NEWA

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	PRINSTON INC	EQ 2MG BASE	A204413	001	May 11, 2022	Apr NEWA
AB		EQ 4MG BASE	A204413	002	May 11, 2022	Apr NEWA
AB		EQ 6MG BASE	A204413	003	May 11, 2022	Apr NEWA
AB		EQ 8MG BASE	A204413	004	May 11, 2022	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL  
ROPINIROLE HYDROCHLORIDE

AB EQ 12MG BASE A204413 005 May 11, 2022 Apr NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

@ STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan CAHN
@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan CAHN
@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan CAHN
@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan CAHN
@ ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar CAHN
@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Mar CAHN
@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Mar CAHN
@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Mar CAHN

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

© LUPIN LTD 40MG/ML A213457 001 Dec 18, 2020 Apr DISC

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE;INJECTION

QUADRAMET

+ © LANTHEUS MEDICAL 50mCi/ML N020570 001 Mar 28, 1997 Jan DISC

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE

>A> AB DR REDDYS 500MG/PACKET A215798 001 May 13, 2022 May NEWA

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

© BOSCOGEN 5MG A074912 001 Apr 30, 1998 Apr DISC

SELINEXOR

TABLET;ORAL

XPOVIO

+ KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Mar CHRS
+!	60MG	N212306	004	Apr 15, 2021	Mar CHRS

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

+! NOVO 8MG/3ML (2.68MG/ML) N209637 003 Mar 28, 2022 Apr NEWA

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

ZOLOFT

AA +! VIATRIS EQ 20MG BASE/ML N020990 001 Dec 07, 1999 Jan CAHN

TABLET;ORAL

ZOLOFT

AB + VIATRIS EQ 25MG BASE N019839 005 Mar 06, 1996 Jan CAHN

AB + EQ 50MG BASE N019839 001 Dec 30, 1991 Jan CAHN

AB +! EQ 100MG BASE N019839 002 Dec 30, 1991 Jan CAHN

+ @ EQ 150MG BASE N019839 003 Dec 30, 1991 Jan CAHN

+ @ EQ 200MG BASE N019839 004 Dec 30, 1991 Jan CAHN

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

>D> AB LUPIN LTD 800MG A204600 001 Jan 14, 2021 May DISC

>A> @ 800MG A204600 001 Jan 14, 2021 May DISC

AB MICRO LABS 800MG A215537 001 Feb 07, 2022 Jan NEWA

© STRIDES PHARMA 800MG A201069 001 Aug 05, 2020 Jan CAHN

SILDENAFIL CITRATEFOR SUSPENSION;ORAL  
REVATIO

AB	+! VIATRIS	EQ 10MG BASE/ML	N 203109	001	Aug 30, 2012	Feb CAHN
AB	LUPIN LTD	EQ 10MG BASE/ML	A 211638	001	Mar 23, 2022	Mar NEWA
AB	MSN	EQ 10MG BASE/ML	A 214641	001	Feb 08, 2022	Jan NEWA
	@ TRIS PHARMA INC	EQ 10MG BASE/ML	A 212312	001	Nov 17, 2021	Apr DISC
	SOLUTION;INTRAVENOUS REVATIO					
AP	+! VIATRIS	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N 022473	001	Nov 18, 2009	Feb CAHN
	TABLET;ORAL REVATIO					
AB	+! VIATRIS	EQ 20MG BASE	N 021845	001	Jun 03, 2005	Feb CAHN
	VIAGRA					
AB	+ VIATRIS	EQ 25MG BASE	N 020895	001	Mar 27, 1998	Feb CAHN
AB	+	EQ 50MG BASE	N 020895	002	Mar 27, 1998	Feb CAHN
AB	+!	EQ 100MG BASE	N 020895	003	Mar 27, 1998	Feb CAHN

SILODOSINCAPSULE;ORAL  
SILODOSIN

@ UPSHER SMITH LABS	4MG	A 213230	001	Jan 03, 2022	Feb DISC
@	8MG	A 213230	002	Jan 03, 2022	Feb DISC

SIMVASTATINTABLET;ORAL  
SIMVASTATIN

@ CHARTWELL RX	5MG	A 077766	001	Dec 20, 2006	Mar CAHN
@	10MG	A 077766	002	Dec 20, 2006	Mar CAHN
@	20MG	A 077766	003	Dec 20, 2006	Mar CAHN
@	40MG	A 077766	004	Dec 20, 2006	Mar CAHN
@	80MG	A 077766	005	Dec 20, 2006	Mar CAHN

SIROLIMUSGEL;TOPICAL  
HYFTOR

+! NOBELPHARMA	0.2%	N 213478	001	Mar 22, 2022	Mar NEWA
----------------	------	----------	-----	--------------	----------

SODIUM BICARBONATEINJECTABLE;INJECTION  
SODIUM BICARBONATE

AP ! HOSPIRA INC	0.5MEQ/ML	A 202981	001	Mar 04, 2016	Apr CHRS
------------------	-----------	----------	-----	--------------	----------

SODIUM CHLORIDESOLUTION;INTRAVENOUS  
SODIUM CHLORIDE 23.4%

AP FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A 212070	003	Feb 14, 2022	Feb NFTG
AP +! HOSPIRA	400MEQ/100ML (4MEQ/ML)	N 018897	003	Jun 18, 2020	Feb CFTG

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS  
SODIUM FLUORIDE F 18  
+ @ NIH NCI DCTD

10-200mCi/ML

N 022494 001 Jan 26, 2011 Mar CRLD

SODIUM NITROPRUSSIDEINJECTABLE;INJECTION  
SODIUM NITROPRUSSIDE

AP BE PHARMS	25MG/ML	A 214971	001	Jul 12, 2021	Apr CMFD
@	25MG/ML	A 214971	001	Jul 12, 2021	Jan DISC
AP CAPLIN	25MG/ML	A 211016	001	Nov 29, 2019	Mar CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE;INJECTION  
SODIUM PHOSPHATES

AP FRESENIUS KABI USA	142MG/ML;276MG/ML	A 209997	001	Mar 30, 2022	Mar NFTG
	SODIUM PHOSPHATES IN PLASTIC CONTAINER				
AP +! HOSPIRA	142MG/ML;276MG/ML	N 018892	001	May 10, 1983	Mar CFTG

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL  
SODIUM POLYSTYRENE SULFONATE  
+ @ PAI HOLDINGS PHARM 453.6GM/BOT  
SUSPENSION;ORAL, RECTAL  
KIONEX  
AA ANI PHARMS 15GM/60ML A040028 001 Sep 17, 2007 Mar CMFD  
AA +! CMP PHARMA INC 15GM/60ML A087859 001 Dec 08, 1982 Mar CTEC

SOFOSBUVIR

TABLET;ORAL  
SOFOSBUVIR  
AB TEVA PHARMS USA INC 400MG A211353 001 Jan 27, 2022 Jan NFTG  
SOVALDI  
AB +! GILEAD SCIENCES INC 400MG N204671 001 Dec 06, 2013 Jan CFTG

SOLIFENACIN SUCCINATE

TABLET;ORAL  
SOLIFENACIN SUCCINATE  
@ AMNEAL PHARMS CO 5MG A209719 001 May 20, 2019 Jan DISC  
@ 10MG A209719 002 May 20, 2019 Jan DISC

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL  
SUNOSI  
>A> + AXSOME MALTA EQ 75MG BASE N211230 001 Jun 17, 2019 May CAHN  
>A> +! EQ 150MG BASE N211230 002 Jun 17, 2019 May CAHN  
>D> + JAZZ EQ 75MG BASE N211230 001 Jun 17, 2019 May CAHN  
>D> +! EQ 150MG BASE N211230 002 Jun 17, 2019 May CAHN

SONIDEGIB PHOSPHATE

CAPSULE;ORAL  
ODOMZO  
+! SUN PHARM EQ 200MG BASE N205266 001 Jul 24, 2015 Feb CAHN

SORAFENIB TOSYLATE

TABLET;ORAL  
NEXAVAR  
AB +! BAYER HLTHCARE EQ 200MG BASE N021923 001 Dec 20, 2005 Apr CTEC  
SORAFENIB TOSYLATE  
>A> AB DR REDDYS EQ 200MG BASE A216073 001 Jun 07, 2022 May NEWA  
AB MYLAN EQ 200MG BASE A207012 001 Sep 10, 2020 Apr CMFD

SOTALOL HYDROCHLORIDE

SOLUTION;ORAL  
SOTYLIZE  
+! AZURITY 5MG/ML (5MG/ML) N205108 001 Oct 22, 2014 Mar CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A  
STERILE WATER FOR INJECTION  
AP ! MEDEFIL INC 100% (5ML) A211188 004 Dec 02, 2019 Feb CTEC  
AP NEPHRON 100% (5ML) A211222 001 Feb 10, 2021 Feb CMFD

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION  
SUCCINYLCHOLINE CHLORIDE  
AP BE PHARMS 20MG/ML A216003 001 Feb 07, 2022 Jan NEWA  
AP MEITHEAL 20MG/ML A214514 001 Oct 19, 2021 Mar CAHN

SUCRALFATE

SUSPENSION;ORAL  
SUCRALFATE  
AB VISTAPHARM 1GM/10ML A211884 001 Mar 15, 2022 Mar NEWA  
TABLET;ORAL  
SUCRALFATE  
AB AMNEAL PHARMS 1GM A215576 001 Apr 15, 2022 Apr NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	AB	LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021	May DISC
>A>	@		200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021	May DISC
AB		NOVITIUM PHARMA	200MG/5ML;40MG/5ML	A214330	001	Feb 08, 2022	Jan NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

@	STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CAHN
@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB	DR REDDYS	EQ 12.5MG BASE	A215843	001	Apr 11, 2022	Apr NEWA
AB		EQ 25MG BASE	A215843	002	Apr 11, 2022	Apr NEWA
AB		EQ 37.5MG BASE	A215843	003	Apr 11, 2022	Apr NEWA
AB		EQ 50MG BASE	A215843	004	Apr 11, 2022	Apr NEWA

TADALAFIL

TABLET;ORAL

TADALAFIL

AB1	AUSTARPHARMA	2.5MG	A208824	001	Oct 27, 2020	Mar CAHN
AB1		5MG	A208824	002	Oct 27, 2020	Mar CAHN
AB1		10MG	A208824	003	Oct 27, 2020	Mar CAHN
AB1		20MG	A208824	004	Oct 27, 2020	Mar CAHN
>A>	@ CHARTWELL RX	2.5MG	A210716	001	Dec 29, 2020	May CAHN
>A>	@	5MG	A210716	002	Dec 29, 2020	May CAHN
>A>	@	10MG	A210716	003	Dec 29, 2020	May CAHN
>A>	@	20MG	A210716	004	Dec 29, 2020	May CAHN
>D>	@ GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29, 2020	May CAHN
>D>	@	5MG	A210716	002	Dec 29, 2020	May CAHN
>D>	@	10MG	A210716	003	Dec 29, 2020	May CAHN
>D>	@	20MG	A210716	004	Dec 29, 2020	May CAHN

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

AT	SANDOZ INC	0.0015%	A209040	001	Jan 28, 2022	Jan NEWA
AT	ZIOPTAN		N202514	001	Feb 10, 2012	Apr CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB	ACME LABS	0.4MG	A214730	001	May 04, 2022	Apr NEWA
----	-----------	-------	---------	-----	--------------	----------

&gt;A&gt; TAPINAROF

&gt;A&gt; CREAM;TOPICAL

&gt;A&gt; VTAMA

>A>	+! DERMAVANT SCI	1%	N215272	001	May 23, 2022	May NEWA
-----	------------------	----	---------	-----	--------------	----------

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

AB	CHARTWELL RX	5%	A211963	001	Feb 03, 2021	Mar CAHN
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Mar CMFD

TAZAROTENE

LOTION;TOPICAL

ARAZLO

>D>	+! BAUSCH	0.045%	N211882	001	Dec 18, 2019	May CAHN
>A>	+!	0.045%	N211882	001	Dec 18, 2019	May CAHN

TECHNETIUM TC-99M SUCCIMER

POWDER; INTRAVENOUS  
NEPHROSCAN  
+! THERAGNOSTICS N/A N214993 001 Feb 18, 2022 Mar CAIN

TECHNETIUM TC-99M SUCCIMER KIT

POWDER; INTRAVENOUS  
NEPHROSCAN  
+! THERAGNOSTICS N/A N214993 001 Feb 18, 2022 Feb NEWA

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION  
MYOVIEW  
+! GE HEALTHCARE N/A N020372 001 Feb 09, 1996 Feb CMFD

TECOVIRIMAT

>A> SOLUTION; INTRAVENOUS  
>A> TPOXX  
>A> +! SIGA TECHNOLOGIES 200MG/20ML (10MG/ML) N214518 001 May 18, 2022 May NEWA

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS  
GATTEX KIT  
+! TAKEDA PHARMS USA 5MG/VIAL N203441 001 Dec 21, 2012 Apr CAHN

TEMOZOLOMIDE

CAPSULE; ORAL TEMOZOLOMIDE @ ANI PHARMS	250MG	A203490 006 Jul 13, 2016	Mar DISC
AB HERITAGE	5MG	A078879 001 Mar 01, 2010	Jan CMFD
AB	20MG	A078879 002 Mar 01, 2010	Jan CMFD
AB	100MG	A078879 003 Mar 01, 2010	Jan CMFD
AB	140MG	A078879 005 Mar 01, 2010	Jan CMFD
AB	180MG	A078879 006 Mar 01, 2010	Jan CMFD
AB	250MG	A078879 004 Mar 01, 2010	Jan CMFD

TENAPANOR HYDROCHLORIDE

TABLET; ORAL  
IBSRELA  
+! ARDELYX INC EQ 50MG BASE N211801 001 Sep 12, 2019 Feb CMFD

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL  
TERBINAFINE HYDROCHLORIDE  
AB CHARTWELL EQ 250MG BASE A078199 001 Jul 02, 2007 Mar CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION  
TERBUTALINE SULFATE  
AP ! CHARTWELL INJECTABLE 1MG/ML A076770 001 Apr 23, 2004 Mar CAHN

TESTOSTERONE

GEL; TRANSDERMAL ANDROGEL + @ ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309 002 Sep 07, 2012	Jan DISC
+ @	1.62% (40.5MG/2.5GM PACKET)	N022309 003 Sep 07, 2012	Jan DISC
+ @	25MG/2.5GM PACKET	N021015 001 Feb 28, 2000	Jan DISC
+ @	50MG/5GM PACKET	N021015 002 Feb 28, 2000	Jan DISC
AB1 ! ACTAVIS LABS UT INC	50MG/5GM PACKET	A076737 002 Jan 27, 2006	Jan CHRS
AB2 ! PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)	A205781 002 Jul 12, 2017	Jan CHRS

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL  
TLANDO  
+! ANTARES PHARMA INC 112.5MG N208088 001 Mar 28, 2022 Mar NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

@ HIKMA 12.5MG  
@ 25MGA209739 001 Apr 08, 2019 Feb DISC  
A209739 002 Apr 08, 2019 Feb DISCTHIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP EUGIA PHARMA 100MG/ML

A208703 001 Apr 20, 2022 Apr NEWA

THIOGUANINE

TABLET;ORAL

THIOGUANINE

+! WOODWARD SPECL 40MG

N012429 001 Apr CAHN

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB AMNEAL 1MG  
AB 2MG  
AB 5MG  
AB 10MGA215456 001 Feb 28, 2022 Feb NEWA  
A215456 002 Feb 28, 2022 Feb NEWA  
A215456 003 Feb 28, 2022 Feb NEWA  
A215456 004 Feb 28, 2022 Feb NEWATICAGRELOR

TABLET;ORAL

BRILINTA

+ ASTRAZENECA 60MG  
TICAGRELOR  
@ MYLAN 60MG  
@ 90MGN022433 002 Sep 03, 2015 Feb CTEC  
A208597 001 Jul 09, 2021 Feb DISC  
A208597 002 Jul 09, 2021 Feb DISCTIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

AT +! THEA PHARMA EQ 0.25% BASE  
AT +! EQ 0.5% BASEN020439 001 Mar 31, 1995 Apr CAHN  
N020439 002 Mar 31, 1995 Apr CAHNTIMOLOL MALEATESOLUTION, GEL FORMING/DROPS;OPHTHALMIC  
TIMOPTIC-XEAB + BAUSCH EQ 0.25% BASE  
AB + EQ 0.5% BASE  
SOLUTION/DROPS;OPHTHALMIC  
TIMOPTIC  
AT1 + BAUSCH EQ 0.25% BASE  
AT1 + EQ 0.5% BASE  
TIMOPTIC IN OCUDOSE  
AT3 +! BAUSCH AND LOMB INC EQ 0.25% BASE  
AT3 +! EQ 0.5% BASEN020330 001 Nov 04, 1993 Apr CAHN  
N020330 002 Nov 04, 1993 Apr CAHN  
N018086 001 Apr CAHN  
N018086 002 Apr CAHN  
N019463 001 Nov 05, 1986 Feb CAHN  
N019463 002 Nov 05, 1986 Feb CAHNTIOPRONIN

TABLET;ORAL

TIOPRONIN

&gt;A&gt; AB PAR PHARM INC 100MG

A216198 001 Jun 02, 2022 May NEWA

TIRZEPATIDE

&gt;A&gt; SOLUTION;SUBCUTANEOUS

&gt;A&gt; MOUNJARO

>A> +! ELI LILLY AND CO 2.5MG/0.5ML (2.5MG/0.5ML)  
>A> +! 5MG/0.5ML (5MG/0.5ML)  
>A> +! 7.5MG/0.5ML (7.5MG/0.5ML)  
>A> +! 10MG/0.5ML (10MG/0.5ML)  
>A> +! 12.5MG/0.5ML (12.5MG/0.5ML)  
>A> +! 15MG/0.5ML (15MG/0.5ML)N215866 001 May 13, 2022 May NEWA  
N215866 002 May 13, 2022 May NEWA  
N215866 003 May 13, 2022 May NEWA  
N215866 004 May 13, 2022 May NEWA  
N215866 005 May 13, 2022 May NEWA  
N215866 006 May 13, 2022 May NEWA

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB

© ZYDUS PHARMS

EQ 11MG BASE

A214264 001 Aug 19, 2021

Jan DISC

©

EQ 22MG BASE

A214264 002 Aug 19, 2021

Jan DISC

XELJANZ XR

+ PFIZER

EQ 11MG BASE

N208246 001 Feb 23, 2016

Jan CTEC

+!

EQ 22MG BASE

N208246 002 Dec 12, 2019

Jan CTEC

TOLVAPTAN

TABLET;ORAL

SAMSCA

AB	+ OTSUKA TOLVAPTAN	15MG	N022275 001 May 19, 2009	Feb CFTG
AB	PAR PHARM INC	15MG	A206119 001 Feb 15, 2022	Feb NFTG
AB		30MG	A206119 002 Feb 15, 2022	Feb NEWA

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

© ATLANTIDE

25MG

A090353 001 Sep 01, 2010

Apr CAHN

©

50MG

A090353 002 Sep 01, 2010

Apr CAHN

©

100MG

A090353 003 Sep 01, 2010

Apr CAHN

©

200MG

A090353 004 Sep 01, 2010

Apr CAHN

© UPSHER SMITH LABS

25MG

A078499 001 Jan 07, 2010

Mar DISC

©

50MG

A078499 002 Jan 07, 2010

Mar DISC

©

100MG

A078499 003 Jan 07, 2010

Mar DISC

©

200MG

A078499 004 Jan 07, 2010

Mar DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	TEYRO LABS SOLUTION; INTRAVENOUS TOPOTECAN HYDROCHLORIDE	EQ 4MG BASE/VIAL	A091199 001 Dec 01, 2010	Apr CAHN
	© MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074 001 Nov 24, 2017	Mar DISC

TREPROSTINIL

&gt;A&gt; POWDER; INHALATION

&gt;A&gt; TYVASO DPI

&gt;A&gt; + UNITED THERAP

0.016MG/INH

N214324 001 May 23, 2022

May NEWA

&gt;A&gt; +

0.032MG/INH

N214324 002 May 23, 2022

May NEWA

&gt;A&gt; +

0.048MG/INH

N214324 003 May 23, 2022

May NEWA

&gt;A&gt; +!

0.064MG/INH

N214324 004 May 23, 2022

May NEWA

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL

NASACORT

© CHATTEM SANOFI

0.055MG/INH

N019798 001 Jul 11, 1991

Jan CAHN

©

0.055MG/INH

N019798 001 Jul 11, 1991

Jan CAHN

FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR

ZILRETTA

+! PACIRA PHARMS INC

32MG/VIAL

N208845 001 Oct 06, 2017

Feb CAHN

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

AB	CUSTOPHARM INC	40MG/ML	A213543 001 Jan 19, 2022	Jan NEWA
AB	LONG GROVE PHARMS	40MG/ML	A213543 001 Jan 19, 2022	Jan CAHN
	SPRAY, METERED; NASAL			
	TRIAMCINOLONE ACETONIDE			
	© PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104 001 Jul 30, 2009	Jan CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

© LUPIN LTD

250MG

A211637 001 May 21, 2020

Apr DISC

TRIENTINE TETRAHYDROCHLORIDE

TABLET;ORAL  
CUVRIOR  
+! ORPHALAN 300MG N215760 001 Apr 28, 2022 Apr NEWA

TROSPiUM CHLORIDE

TABLET;ORAL  
TROSPiUM CHLORIDE  
>D> AB AMICI 20MG A215781 001 Feb 16, 2022 May CAHN  
AB 20MG A215781 001 Feb 16, 2022 Feb NEWA  
>A> AB ENALTEC 20MG A215781 001 Feb 16, 2022 May CAHN

UPADACITINiB

TABLET, EXTENDED RELEASE;ORAL  
RINVOQ  
+ ABBVIE INC 15MG N211675 001 Aug 16, 2019 Jan CHRS  
+ 30MG N211675 002 Jan 14, 2022 Apr CHRS  
+! 30MG N211675 002 Jan 14, 2022 Jan NEWA  
+! 45MG N211675 003 Mar 16, 2022 Mar NEWA

URSODiOL

CAPSULE;ORAL  
ACTIGALL  
@ TEVA BRANDED PHARM 150MG N019594 001 Dec 31, 1987 Apr CAHN  
AB +! 300MG N019594 002 Dec 31, 1987 Apr CAHN  
URSODiOL  
@ VGYAAN 300MG A214329 001 Jul 28, 2021 Feb DISC

VALGANCiCLOViR HYDROCHLORIDE

FOR SOLUTION;ORAL  
VALGANCiCLOViR HYDROCHLORIDE  
AB AIRIS PHARMA PVT LTD 50MG/ML A210169 001 Feb 17, 2022 Feb NEWA  
TABLET;ORAL  
VALGANCiCLOViR HYDROCHLORIDE  
AB @ MYLAN EQ 450MG BASE A205151 001 Mar 03, 2021 Mar DISC  
EQ 450MG BASE A205151 001 Mar 03, 2021 Mar CAHN

VALPROATE SODiUM

INJECTABLE;INJECTION  
VALPROATE SODiUM  
>D> AP MYLAN EQ 100MG BASE/ML A208120 001 Dec 22, 2021 May DISC  
>A> @ EQ 100MG BASE/ML A208120 001 Dec 22, 2021 May DISC

VALPROiC ACiD

SYRUP;ORAL  
VALPROiC ACiD  
@ WOCKHARDT BIO AG 250MG/5ML A070868 001 Jul 01, 1986 Mar DISC

VANCOMYCiN HYDROCHLORiDE

INJECTABLE;INJECTION  
VANCOCiN HYDROCHLORiDE  
@ STERiSCiENCE EQ 500MG BASE/VIAL A060180 001 Jan CAHN  
@ EQ 500MG BASE/VIAL A062476 001 Mar 15, 1984 Jan CAHN  
@ EQ 500MG BASE/VIAL A062716 001 Mar 13, 1987 Jan CAHN  
@ EQ 500MG BASE/VIAL A062812 001 Nov 17, 1987 Jan CAHN  
@ EQ 1GM BASE/VIAL A060180 002 Mar 21, 1986 Jan CAHN  
@ EQ 1GM BASE/VIAL A062476 002 Mar 21, 1986 Jan CAHN  
@ EQ 1GM BASE/VIAL A062716 002 Mar 13, 1987 Jan CAHN  
@ EQ 1GM BASE/VIAL A062812 002 Nov 17, 1987 Jan CAHN  
@ EQ 10GM BASE/VIAL A062812 003 Nov 17, 1987 Jan CAHN  
VANCOMYCiN HYDROCHLORiDE  
AP KNACK EQ 500MG BASE/VIAL A213059 001 Feb 15, 2022 Feb NEWA  
AP EQ 750MG BASE/VIAL A213059 002 Feb 15, 2022 Feb NEWA  
AP EQ 1GM BASE/VIAL A213059 003 Feb 15, 2022 Feb NEWA

POWDER;INTRAVENOUS  
VANCOMYCiN HYDROCHLORiDE  
+ @ MYLAN LABS LTD EQ 250MG BASE/VIAL N209481 001 Jul 10, 2018 Feb DISC

VARDENAFIL HYDROCHLORIDE

	TABLET;ORAL LEVITRA						
+ @	BAYER HLTHCARE	EQ 20MG BASE	N021400	004	Aug 19, 2003	Feb	DISC
	VARDENAFIL HYDROCHLORIDE						
AB	! ZYDUS PHARMS	EQ 20MG BASE	A208960	004	Oct 31, 2018	Feb	CHRS
	TABLET, ORALLY DISINTEGRATING;ORAL STAXYN						
>D> AB	+ ! BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	May	DISC
>A>	+ @	10MG	N200179	001	Jun 17, 2010	May	DISC
	VARDENAFIL HYDROCHLORIDE						
>D> AB	ALEMBIC PHARMS LTD	10MG	A208324	001	Nov 16, 2018	May	CHRS
>A> AB	!	10MG	A208324	001	Nov 16, 2018	May	CHRS

VARENICLINE TARTRATE

	TABLET;ORAL CHANTIX						
+ @	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Apr	DISC
+ @		EQ 1MG BASE	N021928	002	May 10, 2006	Apr	DISC
AB	+	EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CHRS
	VARENICLINE TARTRATE						
	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Apr	CTEC
	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Apr	CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Feb	CHRS

VENLAFAKINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL VENLAFAKINE HYDROCHLORIDE						
@	YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jan	DISC
@		EQ 75MG BASE	A214654	002	Aug 06, 2021	Jan	DISC
@		EQ 150MG BASE	A214654	003	Aug 06, 2021	Jan	DISC

VERAPAMIL HYDROCHLORIDE

	INJECTABLE; INJECTION VERAPAMIL HYDROCHLORIDE						
AP	ACIC PHARMS	2.5MG/ML	A215829	001	Mar 17, 2022	Mar	NEWA
	TABLET;ORAL VERAPAMIL HYDROCHLORIDE						
	@ CHARTWELL RX	40MG	A073168	001	Jul 31, 1992	Mar	CAHN
	@	80MG	A071423	001	May 24, 1988	Mar	CAHN
	@	120MG	A071424	001	May 25, 1988	Mar	CAHN

VIGABATRIN

	FOR SOLUTION;ORAL VIGABATRIN						
AA	LUPIN LTD	500MG/PACKET	A211790	001	Mar 10, 2022	Mar	NEWA
	TABLET;ORAL VIGABATRIN						
AB	AUROBINDO PHARMA LTD	500MG	A215601	001	May 10, 2022	Apr	NEWA
AB	ZYDUS	500MG	A215707	001	Jan 19, 2022	Jan	NEWA

VILAZODONE HYDROCHLORIDE

	TABLET;ORAL VILAZODONE HYDROCHLORIDE						
>D>	@ TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	May	CMFD
>A> AB		10MG	A208212	001	Sep 30, 2019	May	CMFD
>D>	@	20MG	A208212	002	Sep 30, 2019	May	CMFD
>A> AB		20MG	A208212	002	Sep 30, 2019	May	CMFD
>D>	@	40MG	A208212	003	Sep 30, 2019	May	CMFD
>A> AB		40MG	A208212	003	Sep 30, 2019	May	CMFD

VINORELBINE TARTRATE

	INJECTABLE; INJECTION VINORELBINE TARTRATE						
AP	! JIANGSU HANSOH PHARM	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012	Apr	CHRS

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VORICONAZOLE

AP HONG KONG 200MG/VIAL A214516 001 May 09, 2022 Apr NEWA

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+ TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Mar CTEC
+ ZYDUS PHARMS	EQ 10MG BASE	N204447	002	Sep 30, 2013	Mar CTEC
+! VORTIOXETINE HYDROBROMIDE	EQ 20MG BASE	N204447	004	Sep 30, 2013	Mar CTEC
@ ZYDUS PHARMS	EQ 5MG BASE	A211146	001	Sep 17, 2021	Mar DISC
@	EQ 10MG BASE	A211146	002	Sep 17, 2021	Mar DISC
@	EQ 20MG BASE	A211146	003	Sep 17, 2021	Mar DISC

ZALEPLON

CAPSULE; ORAL

ZALEPLON

AB CHARTWELL MOLECULAR 5MG A077505 001 Jun 20, 2008 Mar CAHN  
AB 10MG A077505 002 Jun 20, 2008 Mar CAHNZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE

@ EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb DISC
ZINC CHLORIDE IN PLASTIC CONTAINER					
+! HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb CTEC

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AP +! AM REGENT EQ 25MG BASE/5ML (EQ 5MG BASE/ML) N209377 002 Jul 18, 2019 Apr CFTG  
AP +! EQ 30MG BASE/10ML (EQ 3MG BASE/ML) N209377 001 Jul 18, 2019 Apr CFTG  
AP GLAND PHARMA LTD EQ 25MG BASE/5ML (EQ 5MG BASE/ML) A216249 001 May 03, 2022 Apr NFTG  
AP EQ 30MG BASE/10ML (EQ 3MG BASE/ML) A216249 002 May 03, 2022 Apr NFTGZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB +! VIATRIS EQ 20MG BASE N020825 001 Feb 05, 2001 Jan CAHN  
AB + EQ 40MG BASE N020825 002 Feb 05, 2001 Jan CAHN  
AB + EQ 60MG BASE N020825 003 Feb 05, 2001 Jan CAHN  
AB + EQ 80MG BASE N020825 004 Feb 05, 2001 Jan CAHNZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

AP +! VIATRIS EQ 20MG BASE/VIAL N020919 001 Jun 21, 2002 Feb CPOT  
AP +! ZIPRASIDONE MESYLATE EQ 20MG BASE/ML N020919 001 Jun 21, 2002 Jan CAHN  
AP GLAND PHARMA LTD EQ 20MG BASE/VIAL A211908 001 Dec 26, 2019 Feb CPOT  
POWDER; INTRAMUSCULAR  
GEODON  
AP +! VIATRIS ZIPRASIDONE MESYLATE EQ 20MG BASE/VIAL N020919 001 Jun 21, 2002 Feb CDFR  
AP GLAND PHARMA LTD EQ 20MG BASE/VIAL A211908 001 Dec 26, 2019 Feb CDFRZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

>A> AP AMNEAL EQ 4MG BASE/100ML A210174 001 Oct 27, 2017 May CAHN  
>D> AP PUNISKA EQ 4MG BASE/100ML A210174 001 Oct 27, 2017 May CAHNZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB CHARTWELL MOLECULAR 5MG A077388 001 Jul 30, 2012 Mar CAHN  
AB 10MG A077388 002 Jul 30, 2012 Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

AUROBINDO PHARMA LTD 250MG;250MG;65MG

A211695 001 Feb 02, 2022 Jan NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

TARO PHARMS 0.1%

A215940 001 Jan 14, 2022 Jan NEWA

>D> ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

&gt;D&gt; TABLET, CHEWABLE;ORAL

&gt;D&gt; GAVISCON

&gt;D&gt; + CHATTEM SANOFI 80MG;20MG

N018685 001 Dec 09, 1983 May DISC

&gt;A&gt; + @ 80MG;20MG

N018685 001 Dec 09, 1983 May DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ CHARTWELL RX 5MG/5ML

A090378 002 May 09, 2008 Mar CAHN

TRIS PHARMA INC 5MG/5ML

A090572 001 Nov 16, 2012 May DISC

@ 5MG/5ML

A090572 001 Nov 16, 2012 May DISC

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CHARTWELL RX 5MG/5ML

A090378 001 May 09, 2008 Mar CAHN

TRIS PHARMA INC 5MG/5ML

A090572 002 Nov 16, 2012 May DISC

@ 5MG/5ML

A090572 002 Nov 16, 2012 May DISC

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

&gt;A&gt; GLENMARK PHARMS INC 5MG

A078427 003 Dec 28, 2007 May CAHN

&gt;A&gt; 10MG

A078427 004 Dec 28, 2007 May CAHN

&gt;D&gt; WOCKHARDT 5MG

A078427 003 Dec 28, 2007 May CAHN

&gt;D&gt; 10MG

A078427 004 Dec 28, 2007 May CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AKORN 1%

A209484 001 Nov 21, 2018 Mar CMKT

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

&gt;A&gt; AUROBINDO PHARMA LTD 38MG;200MG

A216204 001 May 31, 2022 May NEWA

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

ALEOR DERMACEUTICALS 10%

A215839 001 May 03, 2022 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

+ @ DEXCEL PHARMA EQ 20MG BASE

N214278 001 Oct 20, 2020 Jan DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

&gt;A&gt; GLENMARK PHARMS INC 20MG

A090837 001 Aug 04, 2010 May CAHN

VKT PHARMA 10MG

A215822 001 Jan 28, 2022 Jan NEWA

20MG

A215822 002 Jan 28, 2022 Jan NEWA

&gt;D&gt; WOCKHARDT 20MG

A090837 001 Aug 04, 2010 May CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ATLANTIDE 30MG

A079112 002 Feb 08, 2012 Apr CAHN

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

ATLANTIDE 30MG

A079112 001 Feb 08, 2012 Apr CAHN

FEXOFENADINE HYDROCHLORIDE ALLERGY

ATLANTIDE 60MG

A079112 004 Feb 08, 2012 Apr CAHN

## TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

180MG

A079112 006 Feb 08, 2012 Apr CAHN

FEXOFENADINE HYDROCHLORIDE HIVES

ATLANTIDE

60MG

A079112 003 Feb 08, 2012 Apr CAHN

180MG

A079112 005 Feb 08, 2012 Apr CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI

60MG;120MG

N020786 002 Jan 24, 2011 Jan CAHN

+!

60MG;120MG

N020786 002 Jan 24, 2011 Jan CAHN

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI

180MG;240MG

N021704 002 Jan 24, 2011 Jan CAHN

+!

180MG;240MG

N021704 002 Jan 24, 2011 Jan CAHN

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

&gt;A&gt;

DR REDDYS

60MG;120MG

A215434 001 May 31, 2022 May NEWA

GUAIFENESIN

## TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

DR REDDYS

600MG

A215932 001 Mar 15, 2022 Mar NEWA

1.2GM

A215932 002 Mar 15, 2022 Mar NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

L PERRIGO CO

600MG;60MG

A214407 001 Feb 01, 2022 Jan NEWA

1.2GM;120MG

A214407 002 Feb 01, 2022 Jan NEWA

IVERMECTIN

## LOTION;TOPICAL

IVERMECTIN

TEVA PHARMS USA

0.5%

A212485 001 Mar 21, 2022 Mar NEWA

KETOTIFEN FUMARATE

## SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH

EQ 0.025% BASE

A208158 001 Sep 24, 2020 Mar CPOT

BAUSCH AND LOMB INC

EQ 0.025% BASE

A208158 001 Sep 24, 2020 Mar CAHN

CHILDREN'S ALAWAY

+ BAUSCH AND LOMB

EQ 0.025% BASE

N021996 002 Feb 11, 2015 Mar CPOT

+

EQ 0.035% BASE

N021996 002 Feb 11, 2015 Mar CTNA

LANSOPRAZOLE

## CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

&gt;A&gt;

GLENMARK PHARMS INC

15MG

A202727 001 May 18, 2012 May CAHN

&gt;D&gt;

WOCKHARDT LTD

15MG

A202727 001 May 18, 2012 May CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

## SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI

2.5MG/5ML

N209090 001 Jan 31, 2017 Jan CAHN

## TABLET;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI

5MG

N209089 001 Jan 31, 2017 Jan CAHN

LEVONORGESTREL

## TABLET;ORAL

LEVONORGESTREL

&gt;D&gt;

! L PERRIGO CO

0.75MG

A090740 001 Dec 30, 2010 May DISC

&gt;A&gt;

@

0.75MG

A090740 001 Dec 30, 2010 May DISC

LORATADINE

## TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC

5MG

N021891 001 Aug 23, 2006 Apr CHRS

CLARITIN

+! BAYER HEALTHCARE LLC

10MG

N021891 002 Nov 21, 2018 Apr CHRS

MINOXIDIL

AEROSOL, FOAM;TOPICAL  
MINOXIDIL  
PERRIGO PHARMA INTL 5% A091344 001 Apr 28, 2011 Jan CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL  
NASONEX 24HR ALLERGY  
+! PERRIGO PHARMA INTL 0.05MG/SPRAY N215712 001 Mar 17, 2022 Mar NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
ALEVE-D SINUS & COLD  
+ @ BAYER 220MG;120MG N021076 001 Nov 29, 1999 Jan DISC  
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE  
>A> AUROBINDO PHARMA LTD 220MG;120MG A211360 001 Jun 01, 2022 May NEWA  
! PERRIGO 220MG;120MG A076518 001 Mar 17, 2004 Jan CHRS

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL  
NICOTINE POLACRILEX  
>A> AUROBINDO PHARMA LTD EQ 2MG BASE A215357 001 May 13, 2022 May NEWA  
>A> EQ 4MG BASE A215357 002 May 13, 2022 May NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE  
>A> @ GLENMARK PHARMS INC EQ 0.1% BASE A200810 001 Jun 28, 2017 May CAHN  
>D> MYLAN EQ 0.2% BASE A204620 001 Jun 16, 2020 May DISC  
>A> @ EQ 0.2% BASE A204620 001 Jun 16, 2020 May DISC  
>D> @ WOCKHARDT LTD EQ 0.1% BASE A200810 001 Jun 28, 2017 May CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
OMEPRAZOLE  
+! DEXCEL PHARMA 20MG N209400 001 Jul 05, 2017 Feb CHRS

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL  
OMEPRAZOLE MAGNESIUM  
>A> L PERRIGO CO EQ 20MG BASE A216096 001 May 24, 2022 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL  
ZEGERID OTC  
+! RILEY CONSUMER 20MG;1.1GM N022281 001 Dec 01, 2009 Mar CAHN  
FOR SUSPENSION;ORAL  
ZEGERID OTC  
+! RILEY CONSUMER 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

POTASSIUM IODIDE

SOLUTION;ORAL  
POTASSIUM IODIDE  
+ @ ROXANE 1GM/ML N018551 001 Feb 19, 1982 Jan CRLD

RANITIDINE HYDROCHLORIDE

TABLET;ORAL  
ZANTAC 150  
+ @ CHATTEM SANOFI EQ 150MG BASE N021698 001 Aug 31, 2004 Jan CAHN  
+ @ EQ 150MG BASE N021698 002 Mar 13, 2007 Jan CAHN  
ZANTAC 75  
+ @ CHATTEM SANOFI EQ 75MG BASE N020520 001 Dec 19, 1995 Jan CAHN  
TABLET, EFFERVESCENT;ORAL  
ZANTAC 75  
+ @ CHATTEM SANOFI EQ 75MG BASE N020745 001 Feb 26, 1998 Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

NASACORT ALLERGY 24 HOUR

+! CHATTEM SANOFI 0.055MG/SPRAY

N020468 002 Oct 11, 2013 Jan CAHN

+! 0.055MG/SPRAY

N020468 002 Oct 11, 2013 Jan CAHN

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2022**

NO MAY 2022 APPROVALS

## **ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2022 APPROVALS

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11255842	Jan 10, 2040		U-3322		
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034		U-3195		
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034		U-3195		
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034		U-3195		
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 001	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
	8426586	Oct 10, 2029	DS		PED	Oct 15, 2023
	8426586*PED	Apr 10, 2030			PED	Jul 12, 2025
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026		U-1950		
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 002	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
	8426586	Oct 10, 2029	DS		PED	Oct 15, 2023
	8426586*PED	Apr 10, 2030			PED	Jul 12, 2025
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026		U-1950		
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 003	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	10004743*PED	Jan 05, 2031			ODE-230	Jan 12, 2025
	8426586	Oct 10, 2029	DS		PED	Oct 15, 2023
	8426586*PED	Apr 10, 2030			PED	Jul 12, 2025
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026		U-1950		
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>ALBUTEROL SULFATE - PROAIR DIGITALER</u>						
N 205636 002	11266796	Feb 22, 2041	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	>A> 8357713	Dec 22, 2029	DP U-2104			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>ALLOPURINOL; LESINURAD - DUZALLO</u></b>						
N 209203 002 >A> 8357713		Dec 22, 2029	DP U-2104			
<b><u>ALPELISIB - VIJOICE</u></b>						
N 215039 001 8227462 8476268		Sep 28, 2030 Sep 10, 2029	DS DP DS DP		>A> NCE	May 24, 2024
<b><u>ALPELISIB - VIJOICE</u></b>						
N 215039 002 8227462 8476268		Sep 28, 2030 Sep 10, 2029	DS DP DS DP		>A> NCE	May 24, 2024
<b><u>ALPELISIB - VIJOICE</u></b>						
N 215039 003 8227462 8476268		Sep 28, 2030 Sep 10, 2029	DS DP DS DP		>A> NCE	May 24, 2024
<b><u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u></b>						
N 208944 001 11197835		Dec 02, 2030	U-2106			
<b><u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u></b>						
N 208944 002 11197835		Dec 02, 2030	U-2106			
<b><u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u></b>						
N 208078 001 11268128 11274331 11274332		Jun 29, 2032 Jun 29, 2032 Jun 29, 2032	U-2956 U-2956 U-2956			
<b><u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u></b>						
N 208081 001 11235169		Oct 15, 2040	U-3303			
<b><u>AMISULPRIDE - BARHEMSYS</u></b>						
N 209510 002 10525033 9084765 9084765 9545426 9545426 9889118 9889118		Mar 10, 2031 Mar 10, 2031 Mar 10, 2031 Mar 10, 2031 Mar 10, 2031 Mar 10, 2031 Mar 10, 2031	DP U-1744 U-2754 U-1744 U-2754 U-1744 U-2754		NCE	Feb 26, 2025
<b><u>AMLODIPINE BESYLATE - NORLIOVA</u></b>						
N 214439 001 11253474 11253474 11253474		Feb 24, 2041 Feb 24, 2041 Feb 24, 2041	DP U-3309 DP U-3310 DP U-3311		>A> NCE >A> GAIN	May 03, 2027 May 03, 2032
<b><u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u></b>						
N 215152 001						
<b><u>AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK</u></b>						
N 215153 001					>A> NCE >A> GAIN	May 03, 2027 May 03, 2032
<b><u>AMPHOTERICIN B - AMPHOTERICIN B</u></b>						
A 212514 001				CGT		Aug 14, 2022
<b><u>ANGIOTENSIN II ACETATE - GIAPREZA</u></b>						
N 209360 003 10028995 10335451 10493124 10500247 10500247 10548943 10548943 11096983 11096983		Dec 18, 2034 Dec 16, 2029 Dec 18, 2034 Dec 16, 2029 Dec 16, 2029 Dec 16, 2029 Dec 16, 2029 Dec 18, 2034 Dec 18, 2034	U-2338 U-2581 U-2679 U-2680 U-2681 U-2739 U-2740 U-3211 U-3212			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>ANGIOTENSIN II ACETATE - GIAPREZA</b></u>						
N 209360 003	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u><b>APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE</b></u>						
A 212025 001				CGT		Aug 24, 2022
<u><b>APREMILAST - OTEZLA</b></u>						
N 205437 001	6962940	Mar 19, 2023	U-1504	I-884		Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u><b>APREMILAST - OTEZLA</b></u>						
N 205437 002	6962940	Mar 19, 2023	U-1504	I-884		Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u><b>APREMILAST - OTEZLA</b></u>						
N 205437 003	6962940	Mar 19, 2023	U-1504	I-884		Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>APREMILAST - OTEZLA</u></b>						
N 205437 003	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<b><u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u></b>						
N 207202 001	11229378	Jul 11, 2031	DP			
<b><u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u></b>						
N 207202 002	11229378	Jul 11, 2031	DP			
<b><u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u></b>						
N 207202 003	11229378	Jul 11, 2031	DP			
<b><u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u></b>						
N 207202 004	11229378	Jul 11, 2031	DP			
<b><u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u></b>						
N 207202 005	11229378	Jul 11, 2031	DP			
<b><u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u></b>						
N 207202 006	11229378	Jul 11, 2031	DP			
<b><u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u></b>						
N 207533 001	11273158	Apr 06, 2039	U-543			
<b><u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u></b>						
N 207533 002	11273158	Apr 06, 2039	U-543			
<b><u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u></b>						
N 207533 003	11273158	Apr 06, 2039	U-543			
<b><u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u></b>						
N 207533 004	11273158	Apr 06, 2039	U-543			
<b><u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u></b>						
N 209830 001	11273158	Apr 06, 2039	U-543			
<b><u>ASCIMINIB HYDROCHLORIDE - SCENBLIX</u></b>						
N 215358 001	8829195	May 13, 2033	DS	U-1374	ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<b><u>ASCIMINIB HYDROCHLORIDE - SCENBLIX</u></b>						
N 215358 002	8829195	May 13, 2033	DS	U-1374	ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<b><u>AVACOPAN - TAVNEOS</u></b>						
N 214487 001					ODE-377	Oct 07, 2028
<b><u>BACLOFEN - FLEQSUVY</u></b>						
N 215602 001	>A> 11324696	Sep 29, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BALOXAVIR MARBOXIL - XOFLUZA</u></b>						
N 210854 001	11261198	Sep 25, 2038	DP			
	>A> 11306106	Aug 09, 2037		U-2816		
	>A> 11306106	Aug 09, 2037		U-3000		
<b><u>BALOXAVIR MARBOXIL - XOFLUZA</u></b>						
N 210854 002	11261198	Sep 25, 2038	DP			
	>A> 11306106	Aug 09, 2037		U-2816		
	>A> 11306106	Aug 09, 2037		U-3000		
<b><u>BALOXAVIR MARBOXIL - XOFLUZA</u></b>						
N 210854 003	11261198	Sep 25, 2038	DP			
	>A> 11306106	Aug 09, 2037		U-2816		
	>A> 11306106	Aug 09, 2037		U-3000		
<b><u>BALOXAVIR MARBOXIL - XOFLUZA</u></b>						
N 214410 001	11261198	Sep 25, 2038	DP			
	>A> 11306106	Aug 09, 2037		U-2816		
	>A> 11306106	Aug 09, 2037		U-3000		
<b><u>BARICITINIB - OLUMIANT</u></b>						
N 207924 001	>A> 11045474	Nov 30, 2032		U-3372		
	>A> 9089574	Nov 30, 2032		U-3372		
<b><u>BARICITINIB - OLUMIANT</u></b>						
N 207924 002	>A> 11045474	Nov 30, 2032		U-3372		
	>A> 9089574	Nov 30, 2032		U-3372		
<b><u>BARICITINIB - OLUMIANT</u></b>						
N 207924 003	>A> 11045474	Nov 30, 2032		U-3372		
	>A> 8158616	Jun 08, 2030	DS DP		>A> NCE	
	>A> 9089574	Nov 30, 2032		U-3372		May 31, 2023
<b><u>BELUMOSUDIL MESYLATE - REZUROCK</u></b>						
N 214783 001	>A> 11311541	Apr 09, 2035		U-3369		
<b><u>BENZOYL PEROXIDE - EPSOLAY</u></b>						
N 214510 001	10933046	Feb 19, 2040	DP	U-3357		
	10945987	Feb 19, 2040		U-3356		
	9687465	Nov 27, 2032	DP	U-3356		
	9868103	Aug 08, 2028	DP	U-3356		
<b><u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u></b>						
N 214094 001	11230530	Mar 09, 2035		U-3300		
<b><u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u></b>						
N 214094 002	11230530	Mar 09, 2035		U-3300		
<b><u>BETAINE - BETAINE</u></b>						
A 214864 001					CGT	Aug 02, 2022
<b><u>BEXAROTENE - BEXAROTENE</u></b>						
A 215398 001					>A> CGT	Nov 13, 2022
<b><u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u></b>						
N 210251 002					NCE	Feb 07, 2023
					ODE-378	Oct 07, 2028
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 001	8618109	Apr 12, 2026		U-3281		
	8618109	Apr 12, 2026		U-543		
	9839637	Apr 12, 2026	DP	U-1529		
	9839637	Apr 12, 2026	DP	U-3281		
	9839637	Apr 12, 2026	DP	U-543		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 001	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 002	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 003	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 004	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 005	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 006	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<b><u>BRIGATINIB - ALUNBRIG</u></b>						
N 208772 001 >A> 9012462		Apr 28, 2031	DS			
<b><u>BRIGATINIB - ALUNBRIG</u></b>						
N 208772 002 >A> 9012462		Apr 28, 2031	DS			
<b><u>BRIGATINIB - ALUNBRIG</u></b>						
N 208772 003 >A> 9012462		Apr 28, 2031	DS			
<b><u>BUDESONIDE - TARPEYO</u></b>						
N 215935 001					NP	Dec 15, 2024
<b><u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u></b>						
N 021929 001 >A> 11311558		Jan 29, 2023	DP			
>A> 11311558*PED		Jul 29, 2023				
<b><u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u></b>						
N 021929 002 >A> 11311558		Jan 29, 2023	DP			
>A> 11311558*PED		Jul 29, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BUPIVACAINE - EXPAREL</u></b>						
N 022496 001	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
<b><u>BUPIVACAINE - EXPAREL</u></b>						
N 022496 002	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u></b>						
N 211988 001	11253504	Mar 13, 2034	U-3118			
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u></b>						
N 211988 002	11253504	Mar 13, 2034	U-3118			
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u></b>						
N 211988 003	11253504	Mar 13, 2034	U-3118			
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u></b>						
N 211988 004	11253504	Mar 13, 2034	U-3118			
<b><u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u></b>						
N 200063 001	11278544	Apr 21, 2024	U-1583			
>A>	11324741	May 29, 2029	U-1583			
<b><u>CABOTEGRAVIR - APRETUDE</u></b>						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
<b><u>CABOTEGRAVIR SODIUM - VOCABRIA</u></b>						
N 212887 001	>A> 8410103	Apr 28, 2026	DS DP U-3061		M-273	Jan 31, 2025
	>A> 8410103	Apr 28, 2026	DS DP U-3348		>A> NPP	Mar 29, 2025
<b><u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u></b>						
N 212888 001	>A> 11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	>A> 7125879	Apr 21, 2025	DS DP U-3348		>A> NPP	Mar 29, 2025
	>A> 8410103	Apr 28, 2026	DS DP U-3348			
<b><u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u></b>						
N 212888 002	>A> 11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	>A> 7125879	Apr 21, 2025	DS DP U-3348		>A> NPP	Mar 29, 2025
	>A> 8410103	Apr 28, 2026	DS DP U-3348			
<b><u>CABOZANTINIB S-MALATE - COMETRIO</u></b>						
N 203756 001	11298349	Feb 10, 2032	DP			
<b><u>CABOZANTINIB S-MALATE - COMETRIO</u></b>						
N 203756 002	11298349	Feb 10, 2032	DP			
<b><u>CABOZANTINIB S-MALATE - CABOMETYX</u></b>						
N 208692 001	11298349	Feb 10, 2032	DP			
<b><u>CABOZANTINIB S-MALATE - CABOMETYX</u></b>						
N 208692 002	11298349	Feb 10, 2032	DP			
<b><u>CABOZANTINIB S-MALATE - CABOMETYX</u></b>						
N 208692 003	11298349	Feb 10, 2032	DP			
<b><u>CALCIFEDIOL - RAYALDEE</u></b>						
N 208010 001	11253528	Mar 14, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11253494	Mar 15, 2033		U-3323		
	11253494	Mar 15, 2033		U-3324		
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11207292	Apr 26, 2039	DS	U-3235		
	11207292	Apr 26, 2039	DS	U-3236		
	11207292	Apr 26, 2039	DS	U-3277		
>A>	11311498	Jun 17, 2035		U-3375		
>A>	11311498	Jun 17, 2035		U-3376		
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11033521	Mar 28, 2039	DP	U-219		
	11033521	Mar 28, 2039	DP	U-3304		
	11033521	Mar 28, 2039	DP	U-3305		
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	RE48960	Jun 28, 2025	DS	DP U-3087		
	RE48960	Jun 28, 2025	DS	DP U-3088		
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	>A> 10420841	Mar 14, 2034		U-1672		
>A>	10420841	Mar 14, 2034		U-2631		
>A>	10420841	Mar 14, 2034		U-3360		
>A>	10420841	Mar 14, 2034		U-3361		
	11278622	Mar 14, 2034		U-3335		
	11278622	Mar 14, 2034		U-3336		
>A>	7129232	May 15, 2028	DS	DP U-1676		
>A>	7129232	May 15, 2028	DS	DP U-3360		
>A>	7129232	May 15, 2028	DS	DP U-3361		
>A>	7129232	May 15, 2028	DS	DP U-36		
>A>	8968753	Mar 14, 2034		U-1672		
>A>	8968753	Mar 14, 2034		U-1673		
>A>	8968753	Mar 14, 2034		U-3360		
>A>	8968753	Mar 14, 2034		U-3361		
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	11246863	Nov 27, 2038	DP			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2023	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11207332	Nov 20, 2028	DP	U-3280		
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	11129896	Sep 22, 2036		U-3293		
					NP	Dec 07, 2024
					GAIN	Dec 07, 2029
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - CLINDAMYCIN PHOSPHATE AND TRETINOIN</u>						
A 212845 001					CGT	Oct 09, 2022
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	8633219	Apr 30, 2030	DP	U-257		
	8633219*PED	Oct 30, 2030				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Apr 30, 2030	DP	U-257		
	8633219*PED	Oct 30, 2030				
<u>COBIMETINIB FUMARATE - COTELICIC</u>						
N 206192 001	11254649	Jun 30, 2036	DS	DP U-1776		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 003	10993952	Feb 15, 2036	DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DAPSONE - ACZONE</u>						
N 207154 001	11273132	Nov 18, 2033	DP			
<u>DAPTOMYCIN - DAPZURA RT</u>						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 001	10023560	Dec 02, 2034	U-620			
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 002	10023560	Dec 02, 2034	U-620			
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11168058	Feb 27, 2038	DS DP			
<u>DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001 >A> 8501238		Dec 19, 2028	DS DP U-1636			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11236328	Jun 22, 2032	U-3301			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Jun 19, 2031	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7728143	Jun 19, 2031	DS			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>DEXAMETHASONE - HEMADY</b></u>						
N 211379 001	11304961	Dec 18, 2037	DP U-3344			
<u><b>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</b></u>						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		>A> NP	Apr 05, 2025
<u><b>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</b></u>						
N 215390 002	10792246	Jun 26, 2039	DP U-3350		>A> NP	Apr 05, 2025
<u><b>DEXTROAMPHETAMINE - XELSTRYM</b></u>						
N 215401 001	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u><b>DEXTROAMPHETAMINE - XELSTRYM</b></u>						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u><b>DEXTROAMPHETAMINE - XELSTRYM</b></u>						
N 215401 003	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u><b>DEXTROAMPHETAMINE - XELSTRYM</b></u>						
N 215401 004	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u><b>DIAZEPAM - VALTOCO</b></u>						
N 211635 001	11241414	Mar 27, 2029	DP			
<u><b>DIAZEPAM - VALTOCO</b></u>						
N 211635 002	11241414	Mar 27, 2029	DP			
<u><b>DIAZEPAM - VALTOCO</b></u>						
N 211635 003	11241414	Mar 27, 2029	DP			
<u><b>DIGOXIN - DIGOXIN</b></u>						
A 214982 001					CGT	Aug 16, 2022
<u><b>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</b></u>						
N 213436 001	11266799	Nov 05, 2036	DP			
<u><b>DIMETHYL FUMARATE - TECFIDERA</b></u>						
N 204063 001	11246850	Nov 16, 2035	U-1384			
<u><b>DIMETHYL FUMARATE - TECFIDERA</b></u>						
N 204063 002	11246850	Nov 16, 2035	U-1384			
<u><b>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</b></u>						
N 211994 001	11234985	Jan 24, 2031	DP U-257			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>DONEPEZIL HYDROCHLORIDE - ADLARITY</b></u>						
N 212304 001	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u><b>DONEPEZIL HYDROCHLORIDE - ADLARITY</b></u>						
N 212304 002	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u><b>DORAVIRINE - PIFELTRO</b></u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394	>A> NPP		Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
<u><b>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</b></u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395	>A> NPP		Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
<u><b>DOXE PIN HYDROCHLORIDE - DOXE PIN HYDROCHLORIDE</b></u>						
A 213796 001				CGT		Oct 29, 2022
<u><b>DOXE PIN HYDROCHLORIDE - SILENOR</b></u>						
N 022036 001	11234954	Jan 18, 2028	U-620			
<u><b>DOXE PIN HYDROCHLORIDE - SILENOR</b></u>						
N 022036 002	11234954	Jan 18, 2028	U-620			
<u><b>DRONABINOL - SYNDROS</b></u>						
N 205525 001	11253472	Aug 06, 2028	DS DP			
<u><b>DROSPIRENONONE - SLYND</b></u>						
N 211367 001	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
>A>	11351122	Jun 28, 2031	DP			
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 001	11202772	Apr 13, 2037	DP			
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 002	11202772	Apr 13, 2037	DP			
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 003	11202772	Apr 13, 2037	DP			
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 004	11202772	Apr 13, 2037	DP			
<u><b>DUVELISIB - COPIKTRA</b></u>						
N 211155 001	>A> 11312718	Jan 10, 2032	DP			
<u><b>DUVELISIB - COPIKTRA</b></u>						
N 211155 002	>A> 11312718	Jan 10, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>EDARAVONE - RADICAVA ORS</b></u>						
N 215446 001	>A> 10987341	Nov 01, 2039	DP			
	>A> 11241416	Nov 01, 2039	DP			
<u><b>EFINACONAZOLE - JUBLIA</b></u>						
N 203567 001	11213519	Jan 03, 2028	U-2720			
<u><b>ELBASVIR; GRAZOPREVIR - ZEPATIER</b></u>						
N 208261 001					NPP	Dec 09, 2024
<u><b>ELTROMBOPAG OLAMINE - PROMACTA KIT</b></u>						
N 207027 001	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u><b>ELUXADOLINE - VIBERZI</b></u>						
N 206940 001	11229627	Mar 14, 2033	DP			
	>A> 11311516	Mar 14, 2033	DP			
<u><b>ELUXADOLINE - VIBERZI</b></u>						
N 206940 002	11229627	Mar 14, 2033	DP			
	>A> 11311516	Mar 14, 2033	DP			
<u><b>EMPAGLIFLOZIN - JARDIANCE</b></u>						
N 204629 001	9949997	May 17, 2034	U-2292		M-82	Feb 24, 2025
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
<u><b>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCovy</b></u>						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	8754065	Aug 15, 2032	DS DP U-1663			
	9296769	Aug 15, 2032	DS DP U-1663			
<u><b>ENALAPRIL MALEATE - EPANED</b></u>						
N 208686 001	11173141	Mar 25, 2036	DP			
<u><b>ENCORAFENIB - BRAFTOVI</b></u>						
N 210496 002	9474754	Aug 05, 2033	U-2802			
<u><b>ENTRECTINIB - ROZLYTREK</b></u>						
N 212725 001	11253515	Jul 18, 2038	DP			
<u><b>ENTRECTINIB - ROZLYTREK</b></u>						
N 212725 002	11253515	Jul 18, 2038	DP			
<u><b>EPHEDRINE SULFATE - EMERPHED</b></u>						
N 213407 001	11241400	May 16, 2040	U-3183			
<u><b>EPHEDRINE SULFATE - EPHEDRINE SULFATE</b></u>						
N 213994 002	>A> 10869845	Jan 22, 2040	DP			
<u><b>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</b></u>						
N 211109 001	10961190	Oct 19, 2037	DS			
<u><b>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</b></u>						
N 211109 002	10961190	Oct 19, 2037	DS			
<u><b>ERTUGLIFLOZIN - STEGLATRO</b></u>						
N 209803 001					M-275	Sep 17, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN - STEGLATRO</u> N 209803 002					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u> N 209806 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u> N 209806 002					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u> N 209806 003					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u> N 209806 004					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u> N 209805 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u> N 209805 002					M-275	Sep 17, 2024
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u> N 211243 001 >A> 11311500 Sep 10, 2035 U-3034 >A> 11311500 Sep 10, 2035 U-3035 >A> 11311500 Sep 10, 2035 U-3036 >A> 8785500 Mar 05, 2033 U-2502						
<u>ESTRADIOL - IMVEXXY</u> N 208564 001 11241445 Nov 21, 2032 U-2316 11241445 Nov 21, 2032 U-2317 11246875 Nov 21, 2032 U-2316 11246875 Nov 21, 2032 U-2317 11266661 Feb 02, 2034 U-2316 11266661 Feb 02, 2034 U-2317 11304959 Nov 21, 2032 DP >A> 11351182 Nov 21, 2032 U-2316 >A> 11351182 Nov 21, 2032 U-2317						
<u>ESTRADIOL - IMVEXXY</u> N 208564 002 11241445 Nov 21, 2032 U-2316 11241445 Nov 21, 2032 U-2317 11246875 Nov 21, 2032 U-2316 11246875 Nov 21, 2032 U-2317 11266661 Feb 02, 2034 U-2316 11266661 Feb 02, 2034 U-2317 11304959 Nov 21, 2032 DP >A> 11351182 Nov 21, 2032 U-2316 >A> 11351182 Nov 21, 2032 U-2317						
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u> N 210132 002 10052386 Nov 21, 2032 DP 10206932 Nov 21, 2032 U-2439 10675288 Nov 21, 2032 U-2439 11033626 Nov 21, 2032 DP U-2439 11166963 Nov 21, 2032 DP 8633178 Nov 21, 2032 DP 8846648 Nov 21, 2032 U-2439 8846649 Nov 21, 2032 DP U-2439 8933059 Nov 21, 2032 DP U-2439 8987237 Nov 21, 2032 DP 8993548 Nov 21, 2032 DP 8993549 Nov 21, 2032 DP 9114145 Nov 21, 2032 U-2439 9114146 Nov 21, 2032 DP U-2439 9301920 Nov 21, 2032 DP U-2439						

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>ESTRADIOL; PROGESTERONE - BIJUVA</u></b>						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
<b><u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u></b>						
N 212102 001	10452815	Jun 29, 2038	U-2859		I-887	Mar 25, 2025
	10452815*PED	Dec 29, 2038			NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
	10478441*PED	Nov 03, 2033			PED	Dec 25, 2023
	10478442	May 03, 2033	U-2860		PED	Sep 25, 2025
	10478442*PED	Nov 03, 2033			PED	Dec 25, 2027
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	10950331	Sep 28, 2035	U-3098			
	10950331*PED	Mar 28, 2036				
	11040018	Aug 02, 2037	U-2861			
	11040018	Aug 02, 2037	U-3347			
	11040018*PED	Feb 02, 2038				
	9549909	May 03, 2033	U-2858			
	9549909*PED	Nov 03, 2033				
	9603814	May 03, 2033	U-2858			
	9603814*PED	Nov 03, 2033				
	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			
	9610260*PED	Nov 03, 2033				
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
<b><u>FERRIC OXYHYDROXIDE - VELPHORO</u></b>						
N 205109 001	11234938	Nov 26, 2034	DP			
<b><u>FINAFLOXACIN - XTORO</u></b>						
N 206307 001	9993483	Jul 02, 2030	DP			
<b><u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u></b>						
N 207648 001				NPP		Mar 22, 2025
<b><u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u></b>						
N 207648 002				NPP		Mar 22, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 004					NPP	Mar 22, 2025
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11173259	Jul 06, 2040		DP		
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041		DP		
	11266796*PED	Aug 22, 2041				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11173259	Jul 06, 2040		DP		
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041		DP		
	11266796*PED	Aug 22, 2041				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11173259	Jul 06, 2040		DP		
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041		DP		
	11266796*PED	Aug 22, 2041				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	10022510	May 18, 2031		DP		
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031		DP		
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031		DP		
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032		DP		
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036		DP		
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025		DP		
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035		DP		
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038		DP		
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040		DP		
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041		DP		
	11266796*PED	Aug 22, 2041				
	7540282	May 06, 2023		DP		
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028		DP		
	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030		DP		
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032		DP		
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031		DP		
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025		DP		
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024		DP		
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031		DP		
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035		DP		
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035		DP		
	9782551*PED	Feb 28, 2036				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALHALER</u>						
N 208799 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALHALER</u>						
N 208799 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALHALER</u>						
N 208799 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001				>A> D-186		May 02, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	>A> 11312698	May 23, 2032	DS DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	>A> 11312698	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	RE48898	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	RE48898	Jan 19, 2026	DP			
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828 001				ODE-383		Aug 21, 2026
				W		Aug 21, 2026
<u>GALLIUM GA-68 GOZETOTIDE - ILLUCCIX</u>						
N 214032 001	11027031	Jul 28, 2035	U-3317			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	>A> 10603308	Aug 10, 2037	U-3374			
	>A> 7858609	Oct 03, 2027	DP			
	>A> 8022054	Nov 01, 2027	DP			
	>A> 8318714	Nov 28, 2026	DP			
	>A> 8367651	Nov 28, 2026	DP			
	>A> 8618087	Nov 28, 2026	U-3374			
	>A> 9029355	Nov 28, 2026	DP			
	>A> 9056116	Nov 28, 2026	U-3374			
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	11028392	Oct 03, 2034	DS DP U-2672			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	11246866	Jun 24, 2036	DP			
	11246866*PED	Dec 24, 2036				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	11278683	Aug 16, 2026	DP			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001				NPP		Aug 18, 2024
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	11235168	Jan 04, 2038	U-2250			
	>A> 11311620	Dec 19, 2036	U-2250			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE</u>						
A 215586 001				CGT		Oct 09, 2022
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	11304962	May 02, 2036	U-2236			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002 >A> 11318130		Dec 11, 2029	U-68			
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272			
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>INCLISIRAN SODIUM - LEOVIO</b></u>						
N 214012 001	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022		U-3272		
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036		U-3272		
	11078485	Nov 04, 2023	DS	U-3272		
	8106022	Dec 12, 2029	DS DP	U-3272		
	8222222	Dec 29, 2027		U-3272		
	8232383	Feb 20, 2023	DS DP			
	8546143	Apr 23, 2022	DS	U-3272		
	8809292	May 10, 2027	DS DP	U-3272		
	8828956	Dec 04, 2028	DS DP	U-3272		
	9074213	Mar 09, 2022	DS	U-3272		
	9370582	Dec 04, 2028	DS DP	U-3272		
	9708610	Jan 01, 2024	DS DP	U-3272		
	9708615	Mar 08, 2024	DS			
<u><b>ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE</b></u>						
A 211290 001					CGT	Jun 20, 2022
<u><b>IVACAFTOR - KALYDECO</b></u>						
N 207925 001	11147770	Feb 27, 2033		DP U-3339		
<u><b>IVACAFTOR - KALYDECO</b></u>						
N 207925 002	11147770	Feb 27, 2033		DP U-3339		
<u><b>IVACAFTOR - KALYDECO</b></u>						
N 207925 003	11147770	Feb 27, 2033		DP U-3339		
<u><b>IVACAFTOR; LUMACAFTOR - ORKAMBI</b></u>						
N 206038 001 >A> 8846718		Jul 02, 2029		U-1717		
>A> 8846718		Jul 02, 2029		U-1908		
<u><b>IVACAFTOR; LUMACAFTOR - ORKAMBI</b></u>						
N 206038 002 >A> 8846718		Jul 02, 2029		U-1908		
<u><b>IVACAFTOR; LUMACAFTOR - ORKAMBI</b></u>						
N 211358 001 >A> 8846718		Jul 02, 2029		U-2375		
<u><b>IVACAFTOR; LUMACAFTOR - ORKAMBI</b></u>						
N 211358 002 >A> 8846718		Jul 02, 2029		U-2375		
<u><b>KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN</b></u>						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			
<u><b>LACOSAMIDE - VIMPAT</b></u>						
N 022253 001					NPP	Oct 14, 2024
<u><b>LACOSAMIDE - VIMPAT</b></u>						
N 022253 002					NPP	Oct 14, 2024
<u><b>LACOSAMIDE - VIMPAT</b></u>						
N 022253 003					NPP	Oct 14, 2024
<u><b>LACOSAMIDE - VIMPAT</b></u>						
N 022253 004					NPP	Oct 14, 2024
<u><b>LACOSAMIDE - VIMPAT</b></u>						
N 022254 001					NPP	Oct 14, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u> N 022255 001					NPP	Oct 14, 2024
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 001					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 002					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 003					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 004					PC	Aug 30, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u> N 206947 001					M-272	Dec 19, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u> N 206947 002					M-272	Dec 19, 2024
<u>LESINURAD - ZURAMPIC</u> N 207988 001 >A> 8357713 >A> 8357713 >A> 8357713		Dec 22, 2029 Dec 22, 2029 Dec 22, 2029		DP U-1801 DP U-1802 DP U-1803		
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u> N 209935 001 >A> 8415355		Mar 13, 2031	DS DP		NPP	Dec 10, 2024
<u>LEVOKETOCONAZOLE - RECORLEV</u> N 214133 001 10098877 10517868 10835530 11020393 11278547 9918984		Jan 10, 2026 Jan 10, 2026 Jan 10, 2026 Mar 02, 2040 Mar 02, 2040 Jan 10, 2026		U-3283 U-3283 U-3283 U-3282 U-3282 U-3283		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 013 10537538		Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 014 10537538		Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 015 10537538		Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - ERMEZA</u> N 215809 001 >A> 9345772		Feb 27, 2035	DP			
<u>LIDOCAINE - ZTLIDO</u> N 207962 001 11278623		May 10, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u> N 206321 001 >A> 11311679		Jan 20, 2026	DP			
<u>LORAZEPAM - LOREEV XR</u> N 214826 004 8999393		Jan 08, 2034	DP U-3210			
<u>LORLATINIB - LORBRENA</u> N 210868 001 11299500		Oct 04, 2038	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>LORLATINIB - LORBRENA</b>						
N 210868 002	11299500	Oct 04, 2038	DS			
<b>LOTEPREDNOL ETABONATE - INVELTYS</b>						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
<b>LOTEPREDNOL ETABONATE - EYSUVIS</b>						
N 210933 001	11219596	May 03, 2033	U-2985			
<b>LUMASIRAN SODIUM - OXLUMO</b>						
N 214103 001	11261447	Nov 20, 2038	DS DP U-2995			
<b>LUMATEPERONE TOSYLATE - CAPLYTA</b>						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<b>LUMATEPERONE TOSYLATE - CAPLYTA</b>						
N 209500 002	>A> 10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	>A> 10464938	Mar 12, 2028	DP			
	>A> 10695345	Aug 30, 2039	DP U-814			
	>A> 11026951	Dec 03, 2034	U-3364			
	>A> 11052084	Aug 30, 2039	DP U-3362			
	>A> 11052084	Aug 30, 2039	DP U-3363			
	>A> 8648077	Dec 01, 2029	DS DP			
	>A> 9199995	Mar 12, 2029	U-2713			
	>A> 9616061	May 27, 2029	DP			
	>A> 9956227	Dec 03, 2034	U-2714			
	>A> RE48825	Feb 12, 2029	DS			
	>A> RE48839	Dec 28, 2029	U-3271			
	>A> RE48839	Dec 28, 2029	U-814			
<b>LUMATEPERONE TOSYLATE - CAPLYTA</b>						
N 209500 003	>A> 10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	>A> 10464938	Mar 12, 2028	DP			
	>A> 10695345	Aug 30, 2039	DP U-814			
	>A> 11026951	Dec 03, 2034	U-3364			
	>A> 11052084	Aug 30, 2039	DP U-3362			
	>A> 11052084	Aug 30, 2039	DP U-3363			
	>A> 8648077	Dec 01, 2029	DS DP			
	>A> 9199995	Mar 12, 2029	U-2713			
	>A> 9616061	May 27, 2029	DP			
	>A> 9956227	Dec 03, 2034	U-2714			
	>A> RE48825	Feb 12, 2029	DS			
	>A> RE48839	Dec 28, 2029	U-3271			
	>A> RE48839	Dec 28, 2029	U-814			
<b>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO</b>						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	>A> 11318121	Aug 15, 2028	DS DP U-3345			
<b>MARALIXIBAT CHLORIDE - LIVMARLI</b>						
N 214662 001	11229647	Feb 12, 2040	U-3290		ODE-379	Sep 29, 2028
	11260053	May 26, 2031	U-3290			
<b>MARAVIROC - MARAVIROC</b>						
A 203347 001				PC		Aug 06, 2022
<b>MARAVIROC - MARAVIROC</b>						
A 203347 002				PC		Aug 06, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					NCE	Nov 23, 2026
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	>A> 9181200 >A> 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373	>A>	NCE	Apr 28, 2027
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	>A> 9181200 >A> 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373	>A>	NCE	Apr 28, 2027
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	>A> 9181200 >A> 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373	>A>	NCE	Apr 28, 2027
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	>A> 9181200 >A> 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373	>A>	NCE	Apr 28, 2027
<u>MELOXICAM - ANJESO</u>						
N 210583 001	11253478	May 26, 2030	DP U-3318			
<u>MESALAMINE - MESALAMINE</u>						
A 214585 001				>A>	CGT	Nov 14, 2022
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001					NP	Jun 19, 2023
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	>A> 7973031	Oct 09, 2028	U-2007			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>MIGALASTAT HYDROCHLORIDE - GALAFOLD</b>						
N 208623 001	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
<b>MITAPIVAT SULFATE - PYRUKYND</b>						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<b>MITAPIVAT SULFATE - PYRUKYND</b>						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<b>MITAPIVAT SULFATE - PYRUKYND</b>						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<b>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</b>						
N 211746 001	10016443	Sep 04, 2034	U-3297		>A> NP	
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			
	9937189	Sep 04, 2034	DP			
<b>NALOXONE HYDROCHLORIDE - KLOXXADO</b>						
N 212045 001	11135155	Aug 26, 2034	DP			
<b>NALOXONE HYDROCHLORIDE - ZIMHI</b>						
N 212854 001	>A> 11027072	May 24, 2039	DP			
<b>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</b>						
N 215457 001	10143792	May 24, 2031	U-2476			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</b></u>						
N 215457 001	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			
<u><b>NAPROXEN SODIUM - NAPROXEN SODIUM</b></u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
<u><b>NILOTINIB HYDROCHLORIDE - TASIGNA</b></u>						
N 022068 001				ODE-380 PED	Sep 23, 2028 Mar 23, 2029	
<u><b>NILOTINIB HYDROCHLORIDE - TASIGNA</b></u>						
N 022068 002				ODE-380 PED	Sep 23, 2028 Mar 23, 2029	
<u><b>NILOTINIB HYDROCHLORIDE - TASIGNA</b></u>						
N 022068 003				ODE-380 PED	Sep 23, 2028 Mar 23, 2029	
<u><b>NIMODIPINE - NYMALIZE</b></u>						
N 203340 002	11207306	Apr 16, 2038	U-2804			
<u><b>NITRIC OXIDE - GENOSYL</b></u>						
N 202860 001 >A> 11291793		Aug 18, 2025	DP			
<u><b>OBETICHOOLIC ACID - OCALIVA</b></u>						
N 207999 001	RE48286	Feb 21, 2027	DS DP			
<u><b>OBETICHOOLIC ACID - OCALIVA</b></u>						
N 207999 002	RE48286	Feb 21, 2027	DS DP			
<u><b>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</b></u>						
N 213378 001	11241425	Aug 23, 2031	U-3137			
<u><b>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</b></u>						
N 213378 002	11241425	Aug 23, 2031	U-3137			
<u><b>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</b></u>						
N 213378 003	11241425	Aug 23, 2031	U-3137			
<u><b>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</b></u>						
N 213378 004	11241425	Aug 23, 2031	U-3137			
<u><b>OLAPARIB - LYNPARZA</b></u>						
N 208558 001	8071579	Aug 12, 2027	U-2101	I-885	Mar 11, 2025	
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>OLAPARIB - LYNPARZA</u></b>						
N 208558 001	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<b><u>OLAPARIB - LYNPARZA</u></b>						
N 208558 002	8071579	Aug 12, 2027	U-2101	I-885	Mar 11, 2025	
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>OLAPARIB - LYNPARZA</u></b>						
N 208558 002	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2716			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<b><u>OTESECONAZOLE - VIVJOA</u></b>						
N 215888 001	>A> 10414751	Mar 17, 2036	DS DP		>A> NCE	Apr 26, 2027
	>A> 11247981	May 09, 2033		U-3366	>A> GAIN	Apr 26, 2032
	>A> 8236962	Apr 22, 2031	DS DP			
	>A> 8754227	Apr 22, 2031		U-3366		
	>A> 9840492	Mar 17, 2036	DS DP			
<b><u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u></b>						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<b><u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u></b>						
N 022272 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<b><u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u></b>						
N 022272 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<b><u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u></b>						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039		U-2849		
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001	8153632	Jan 17, 2029	DS DP	U-3331		
	8153632	Jan 17, 2029	DS DP	U-3332		
	8980873	Mar 25, 2030	DS DP	U-3331		
	8980873	Mar 25, 2030	DS DP	U-3332		
	9573964	May 05, 2028		U-3331		
	9573964	May 05, 2028		U-3332		
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	10881747	Aug 26, 2033	DS DP	U-3291		
	9061057	Aug 26, 2033	DS DP	U-3291		
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP	U-3291		
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP	U-3291		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11304951	May 07, 2041		U-3349		
>A>	11324751	May 07, 2041		U-3359		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11304951	May 07, 2041		U-3349		
>A>	11324751	May 07, 2041		U-3359		
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11292815	Nov 15, 2033	DS DP	U-3124		
	11292815	Nov 15, 2033	DS DP	U-3354		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	>A> 6949571	Jun 08, 2023	DS DP	U-106		
	>A> 6949571	Jun 08, 2023	DS DP	U-2088		
	>A> 6949571	Jun 08, 2023	DS DP	U-2089		
	>A> 6949571	Jun 08, 2023	DS DP	U-2428		
	>A> 6949571	Jun 08, 2023	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	>A> 6949571	Jun 08, 2023	DS DP	U-106		
	>A> 6949571	Jun 08, 2023	DS DP	U-2088		
	>A> 6949571	Jun 08, 2023	DS DP	U-2089		
	>A> 6949571	Jun 08, 2023	DS DP	U-2428		
	>A> 6949571	Jun 08, 2023	DS DP	U-2429		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	>A> 6949571	Jun 08, 2023	DS DP U-106			
	>A> 6949571	Jun 08, 2023	DS DP U-2088			
	>A> 6949571	Jun 08, 2023	DS DP U-2089			
	>A> 6949571	Jun 08, 2023	DS DP U-2428			
	>A> 6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	>A> 6949571	Jun 08, 2023	DS DP U-106			
	>A> 6949571	Jun 08, 2023	DS DP U-2088			
	>A> 6949571	Jun 08, 2023	DS DP U-2089			
	>A> 6949571	Jun 08, 2023	DS DP U-2428			
	>A> 6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	>A> 6949571	Jun 08, 2023	DS DP U-106			
	>A> 6949571	Jun 08, 2023	DS DP U-2088			
	>A> 6949571	Jun 08, 2023	DS DP U-2089			
	>A> 6949571	Jun 08, 2023	DS DP U-2428			
	>A> 6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	>A> 6949571	Jun 08, 2023	DS DP U-106			
	>A> 6949571	Jun 08, 2023	DS DP U-2088			
	>A> 6949571	Jun 08, 2023	DS DP U-2089			
	>A> 6949571	Jun 08, 2023	DS DP U-2428			
	>A> 6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	>A> 6949571	Jun 08, 2023	DS DP U-106			
	>A> 6949571	Jun 08, 2023	DS DP U-2088			
	>A> 6949571	Jun 08, 2023	DS DP U-2089			
	>A> 6949571	Jun 08, 2023	DS DP U-2428			
	>A> 6949571	Jun 08, 2023	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11266750	Mar 16, 2037		U-665		
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11266750	Mar 16, 2037		U-665		
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 001					CGT	Oct 30, 2022
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 002					CGT	Oct 30, 2022
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	11285134	Apr 24, 2039		U-3252		
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	>A> 8383150	May 10, 2028		DP U-2361		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	>A> 8383150	May 10, 2028		DP U-2361		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	>A> 8383150	May 10, 2028		DP U-2361		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	>A> 8383150	May 10, 2028		DP U-2361		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>PLECANATIDE - TRULANCE</b></u>						
N 208745 001 >A> 11319346		Mar 01, 2032		DP		
<u><b>PONATINIB HYDROCHLORIDE - ICLUSIG</b></u>						
N 203469 001	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
<u><b>PONATINIB HYDROCHLORIDE - ICLUSIG</b></u>						
N 203469 002	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
<u><b>PONATINIB HYDROCHLORIDE - ICLUSIG</b></u>						
N 203469 003	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
<u><b>PONATINIB HYDROCHLORIDE - ICLUSIG</b></u>						
N 203469 004	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
<u><b>POSACONAZOLE - NOXAFIL</b></u>						
N 205053 001					I-881	Jun 17, 2024
<u><b>POSACONAZOLE - NOXAFIL</b></u>						
N 205596 001					I-881	Jun 17, 2024
<u><b>PRALSETINIB - GAVRETO</b></u>						
N 213721 001	11273160	Apr 03, 2039		U-2952		
<u><b>PRASTERONE - INTRAROSA</b></u>						
N 208470 001 >A> 8957054		Jan 08, 2030		U-1922		
<u><b>RANOLAZINE - ASPRUZYO SPRINKLE</b></u>						
N 216018 002	10898444	Jan 24, 2038		DP		
<u><b>REMDESIVIR - VEKLURY</b></u>						
N 214787 001 >A> 10695361		Sep 16, 2036	U-2984		D-183	Jan 21, 2025
>A> 10695361		Sep 16, 2036	U-3249		>A> NPP	Apr 25, 2025
>A> 10695361		Sep 16, 2036	U-3367			
>A> 10695361		Sep 16, 2036	U-3368			
>A> 11007208		Sep 16, 2036	U-2984			
>A> 11007208		Sep 16, 2036	U-3249			
>A> 11007208		Sep 16, 2036	U-3367			
>A> 11007208		Sep 16, 2036	U-3368			
>A> 11266681		Jul 10, 2038	U-2984			
>A> 11266681		Jul 10, 2038	U-3249			
>A> 11266681		Jul 10, 2038	U-3367			
>A> 11266681		Jul 10, 2038	U-3368			
<u><b>REMDESIVIR - VEKLURY</b></u>						
N 214787 002 >A> 10695361		Sep 16, 2036	U-2984		D-183	Jan 21, 2025
>A> 10695361		Sep 16, 2036	U-3249		>A> NPP	Apr 25, 2025
>A> 10695361		Sep 16, 2036	U-3367			
>A> 10695361		Sep 16, 2036	U-3368			
>A> 11007208		Sep 16, 2036	U-2984			
>A> 11007208		Sep 16, 2036	U-3249			
>A> 11007208		Sep 16, 2036	U-3367			
>A> 11007208		Sep 16, 2036	U-3368			
>A> 11266681		Jul 10, 2038	U-2984			
>A> 11266681		Jul 10, 2038	U-3249			
>A> 11266681		Jul 10, 2038	U-3367			
>A> 11266681		Jul 10, 2038	U-3368			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>REMDESIVIR - VEKLURY</u></b>						
N 214787 002	>A> 10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	>A> 10695361	Sep 16, 2036	U-3249	>A>	NPP	Apr 25, 2025
	>A> 10695361	Sep 16, 2036	U-3367			
	>A> 10695361	Sep 16, 2036	U-3368			
	>A> 11007208	Sep 16, 2036	U-2984			
	>A> 11007208	Sep 16, 2036	U-3249			
	>A> 11007208	Sep 16, 2036	U-3367			
	>A> 11007208	Sep 16, 2036	U-3368			
	>A> 11266681	Jul 10, 2038	U-2984			
	>A> 11266681	Jul 10, 2038	U-3249			
	>A> 11266681	Jul 10, 2038	U-3367			
	>A> 11266681	Jul 10, 2038	U-3368			
<b><u>REVEFENACIN - YUPELRI</u></b>						
N 210598 001	11247969	Mar 10, 2025	DP			
<b><u>RIBOCICLIB SUCCINATE - KISOALI</u></b>						
N 209092 001	>A> 8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
<b><u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u></b>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
<b><u>RIOCIGUAT - ADEMPAS</u></b>						
N 204819 001	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<b><u>RIOCIGUAT - ADEMPAS</u></b>						
N 204819 002	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<b><u>RIOCIGUAT - ADEMPAS</u></b>						
N 204819 003	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<b><u>RIOCIGUAT - ADEMPAS</u></b>						
N 204819 004	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<b><u>RIOCIGUAT - ADEMPAS</u></b>						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<b><u>RIPRETTINIB - QINLOCK</u></b>						
N 213973 001	11266635	Aug 12, 2040	U-3330			
<b><u>RIVAROXABAN - XARELTO</u></b>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
<b><u>RIVAROXABAN - XARELTO</u></b>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>RIVAROXABAN - XARELTO</b>						
N 022406 002	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-3289		
	9539218*PED	Aug 17, 2034				
<b>RIVAROXABAN - XARELTO</b>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-1954		
	9539218	Feb 17, 2034		U-1955		
	9539218	Feb 17, 2034		U-3285		
	9539218*PED	Aug 17, 2034				
<b>RIVAROXABAN - XARELTO</b>						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP PED	Dec 20, 2024 Jun 20, 2025
<b>RUXOLITINIB PHOSPHATE - OPZELURA</b>						
N 215309 001	11219624	May 20, 2031	DP U-3229			
<b>SECNIDAZOLE - SOLOSEC</b>						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10335390	Sep 04, 2035	DP U-3270			
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
>A>	11324721	Sep 04, 2035	DP U-2583			
>A>	11324721	Sep 04, 2035	DP U-3169			
>A>	11324721	Sep 04, 2035	DP U-3270			
>A>	11324721	Sep 04, 2035	DP U-3302			
<b>SEMAGLUTIDE - OZEMPIC</b>						
N 209637 001	>A> 11311679	Jan 20, 2026	DP			
<b>SEMAGLUTIDE - OZEMPIC</b>						
N 209637 002	>A> 11311679	Jan 20, 2026	DP			
<b>SEMAGLUTIDE - OZEMPIC</b>						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP		NCE	Dec 05, 2022
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
>A>	11311679	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>SEMAGLUTIDE - OZEMPIC</u></b>						
N 209637 003	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3355			
	8536122	Mar 20, 2026	DS DP U-3355			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<b><u>SIPONIMOD FUMARIC ACID - MAYZENT</u></b>						
N 209884 001				M-274		Mar 01, 2025
<b><u>SIPONIMOD FUMARIC ACID - MAYZENT</u></b>						
N 209884 002				M-274		Mar 01, 2025
<b><u>SIPONIMOD FUMARIC ACID - MAYZENT</u></b>						
N 209884 003				M-274		Mar 01, 2025
<b><u>SIROLIMUS - HYFTOR</u></b>						
N 213478 001				NP		Mar 22, 2025
<b><u>SODIUM OXYBATE - XYREM</u></b>						
N 021196 001	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
<b><u>SOFOSBUVIR - SOVALDI</u></b>						
N 212480 001				ODE*		Apr 07, 2024
				PED		Oct 07, 2024
<b><u>SOFOSBUVIR - SOVALDI</u></b>						
N 212480 002				ODE*		Apr 07, 2024
				PED		Oct 07, 2024
<b><u>SONIDEGIB PHOSPHATE - ODOMZO</u></b>						
N 205266 001 >A> 10266523		Mar 30, 2036	DS DP			
<b><u>SOTORASIB - LUMAKRAS</u></b>						
N 214665 001	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
<b><u>SPINOSAD - NATROBA</u></b>						
N 022408 001 >A> 9895388		Nov 25, 2033	U-3365			
<b><u>SUCRALFATE - SUCRALFATE</u></b>						
A 211884 001				CGT		Sep 11, 2022
<b><u>SUMATRIPTAN - TOSYMR</u></b>						
N 210884 001 >A> 11337962		Jun 16, 2030	DP U-1719			
<b><u>TASIMELTEON - HETLIOZ</u></b>						
N 205677 001	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			
<b><u>TASIMELTEON - HETLIOZ LO</u></b>						
N 214517 001	11285129	Jan 25, 2033	U-3342			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	11311482	May 11, 2038	U-2368			
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u>						
N 216318 001	>A> 11311554	Mar 25, 2039	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	>A> 11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	>A> 11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	>A> 11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
>A>	11311555	Nov 30, 2030	U-1500			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 001					CGT	Aug 25, 2022
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 002					CGT	Aug 25, 2022
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 001				>A> NCE		May 13, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u> N 215866 002				>A> NCE		May 13, 2027
<u>TIRZEPATIDE - MOUNJARO</u> N 215866 003				>A> NCE		May 13, 2027
<u>TIRZEPATIDE - MOUNJARO</u> N 215866 004				>A> NCE		May 13, 2027
<u>TIRZEPATIDE - MOUNJARO</u> N 215866 005				>A> NCE		May 13, 2027
<u>TIRZEPATIDE - MOUNJARO</u> N 215866 006				>A> NCE		May 13, 2027
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u> N 212904 001 6821987		Apr 26, 2023	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u> N 212904 002 6821987		Apr 26, 2023	DS DP U-3100			
<u>TOFACITINIB CITRATE - XELJANZ</u> N 203214 001				I-879		Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ</u> N 203214 002				I-879		Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ XR</u> N 208246 001 11253523	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
<u>TOFACITINIB CITRATE - XELJANZ XR</u> N 208246 002 11253523	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
<u>TOLVAPTAN - TOLVAPTAN</u> A 206119 001				PC		Sep 06, 2022
<u>TRETINOIN - ALTRENO</u> N 209353 001 >A> 11324710		Aug 22, 2038	U-2368			
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u> N 215760 001 >A> 10988436	>A> 11072577	May 03, 2039	DS	>A> NP		Apr 28, 2025
		May 03, 2039	U-3370			
<u>ULIPRISTAL ACETATE - ELLA</u> N 022474 001				M-271		Jun 24, 2024
<u>UMBRALISIB TOSYLATE - UKONIQ</u> N 213176 001 10981919	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			
<u>UPADACITINIB - RINVOQ</u> N 211675 001 10995095	10995095	Oct 17, 2036	U-3298	I-880		Dec 14, 2024
	>A> 8962629	Jan 15, 2031	DS	I-883		Jan 14, 2025
	>A> 8962629	Jan 15, 2031	DS	I-886		Mar 16, 2025
	>A> 8962629	Jan 15, 2031	DS	I-888		Apr 29, 2025
	>A> 8962629	Jan 15, 2031	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036		U-3298	I-886	Mar 16, 2025
	10730883	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS	U-3341		
	9951080	Oct 17, 2036	DS	DP		
	RE47221	Dec 01, 2030	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS	U-3341		
	9951080	Oct 17, 2036	DS	DP		
	RE47221	Dec 01, 2030	DS			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	>A> 11311532 >A> 8039627	Sep 18, 2038 Apr 11, 2031	DP DS DP	U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	>A> 11311532 >A> 8039627	Sep 18, 2038 Apr 11, 2031	DP DS DP	U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	>A> 11311532 >A> 8039627	Sep 18, 2038 Apr 11, 2031	DP DS DP	U-1995		
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11224598	Oct 19, 2035		U-1900		
<u>VASOPRESSIN - VASOPRESSIN</u>						
A 211538 001					PC	Jul 17, 2022
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	10010575 9919026 9925233 9925234 9962422 9968649 9974827 9981006	Jan 30, 2035 Jan 30, 2035	DP U-1857 U-1857 U-1857 U-1857 U-1857 U-1857 U-1857			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	>A> 11324753	Sep 04, 2029		U-727	>A> NPP	Apr 29, 2025
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	>A> 11324753	Sep 04, 2029		U-727	>A> NPP	Apr 29, 2025
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	>A> 11324753	Sep 04, 2029		U-727	>A> NPP	Apr 29, 2025
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	>A> 7304078	Dec 23, 2027	DS DP	U-1512		
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10017491 10034879 10722502	Dec 28, 2032 Dec 28, 2032 Feb 06, 2035	DP DS DP DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036		U-3133		
	11020382	Dec 02, 2036		U-3134		
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034		U-2676		
	9248199	Jan 29, 2034		U-2715		
	9447071	Feb 06, 2035	DS DP			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004					M-232	Jan 28, 2025

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42<sup>ND</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)